Availability
of Annual Report on Form 10-K
Accompanying
this Proxy Statement is a copy of the Company’s Annual Report on Form 10-K for 2019. Shareholders who would like additional
copies of the Annual Report on Form 10-K should direct their requests in writing to:
Oragenics,
Inc.
4902
Eisenhower Blvd., Suite 125
Tampa,
Florida 33634
Attention:
Michael Sullivan, Secretary.
Miscellaneous
Management
does not know of any matters to be brought before the Annual Meeting of Shareholders other than as described in this Proxy Statement.
Should any other matters properly come before the Annual Meeting of Shareholders, the persons designated as proxies will vote
in accordance with their best judgment on such matters.
BY
ORDER OF THE
|
|
BOARD
OF DIRECTORS
|
|
|
|
/s/
Michael Sullivan
|
|
Michael
Sullivan,
|
|
Secretary
|
|
|
|
Tampa,
Florida
|
|
July
13, 2020
|
|
APPENDIX
A
STOCK
PURCHASE AGREEMENT
between
JOSEPH
HERNANDEZ
as
Seller,
and
ORAGENICS,
INC.,
as
Buyer,
Dated
as of May 1, 2020
TABLE
OF CONTENTS
|
|
Page
|
|
|
|
Article
I DEFINITIONS
|
A-5
|
|
|
|
|
1.1
|
Certain
Defined Terms
|
A-5
|
|
1.2
|
Table
of Definitions
|
A-13
|
|
|
|
|
Article
II PURCHASE AND SALE
|
A-14
|
|
|
|
|
2.1
|
Purchase
and Sale of the Shares
|
A-14
|
|
2.2
|
Closing
|
A-14
|
|
2.3
|
Additional
Cash Consideration
|
A-15
|
|
2.4
|
Withholding
|
A-16
|
|
|
|
|
Article
III REPRESENTATIONS AND WARRANTIES Regarding THE SELLER and the company
|
A-16
|
|
|
|
|
3.1
|
Organization
and Qualification
|
A-16
|
|
3.2
|
Authority
|
A-16
|
|
3.3
|
No
Conflict; Required Filings and Consents
|
A-17
|
|
3.4
|
Shares
|
A-18
|
|
3.5
|
Capitalization
|
A-18
|
|
3.6
|
Equity
Interests
|
A-18
|
|
3.7
|
Financial
Statements; No Undisclosed Liabilities
|
A-18
|
|
3.8
|
Reserved
|
A-19
|
|
3.9
|
Absence
of Certain Changes or Events
|
A-19
|
|
3.10
|
Compliance
with Law; Permits
|
A-19
|
|
3.11
|
Litigation
|
A-20
|
|
3.12
|
Employee
Benefit Plans
|
A-20
|
|
3.13
|
Labor
and Employment Matters
|
A-21
|
|
3.14
|
Assets
|
A-22
|
|
3.15
|
Real
Property
|
A-23
|
|
3.16
|
Intellectual
Property
|
A-23
|
|
3.17
|
Taxes
|
A-26
|
|
3.18
|
Environmental
Matters
|
A-28
|
|
3.19
|
Material
Contracts
|
A-28
|
|
3.20
|
Affiliate
Interests and Transactions
|
A-29
|
|
3.21
|
Insurance
|
A-29
|
|
3.22
|
Bank
Accounts, Letters of Credit and Powers of Attorney
|
A-29
|
|
3.23
|
Brokers
|
A-30
|
|
3.24
|
Investment
Representations
|
A-30
|
Article
IV REPRESENTATIONS AND WARRANTIES OF THE
BUYER
|
A-32
|
|
|
|
|
4.1
|
Organization
|
A-32
|
|
4.2
|
Authority
|
A-32
|
|
4.3
|
No
Conflict; Required Filings and Consents
|
A-32
|
|
4.4
|
Brokers
|
A-33
|
|
4.5
|
Investment
Intent
|
A-33
|
|
4.6
|
SEC
Filings
|
A-33
|
|
4.7
|
Legal
Proceedings
|
A-34
|
|
4.8
|
Issuance
of Share Consideration
|
A-34
|
|
4.9
|
Material
Changes; Undisclosed Events, Liabilities or Developments
|
A-34
|
|
4.10
|
Sarbanes-Oxley;
Internal Accounting Controls
|
A-35
|
|
4.11
|
Investment
Company
|
A-35
|
|
4.12
|
Listing
and Maintenance Requirements
|
A-35
|
|
|
|
|
Article
V COVENANTS
|
A-36
|
|
|
|
|
5.1
|
Non-Competition;
Non-Solicitation
|
A-36
|
|
5.2
|
Release
of Obligations
|
A-37
|
|
5.3
|
Transfer
of Permits
|
A-38
|
|
5.4
|
Intercompany
Arrangements
|
A-38
|
|
5.5
|
Confidentiality
|
A-38
|
|
5.6
|
Consents
and Filings; Further Assurances
|
A-39
|
|
5.7
|
Registration
Rights
|
A-39
|
|
5.8
|
NYSE
American Required Shareholder Approval
|
A-41
|
|
5.9
|
Voting
|
A-42
|
|
5.10
|
Listing
of Common Stock
|
A-42
|
|
5.11
|
Form
D; Blue Sky Filings
|
A-42
|
|
5.12
|
Board
Appointment
|
A-42
|
|
5.13
|
Lock-Up
|
A-42
|
|
|
|
|
Article
VI TAX MATTERS
|
A-43
|
|
|
|
|
6.1
|
Allocation
of Taxes for a Straddle Period
|
A-43
|
|
6.2
|
Tax
Returns for Pre-Closing Tax Periods and Straddle Periods
|
A-43
|
|
6.3
|
Other
Tax Matters
|
A-44
|
|
6.4
|
Cooperation
on Tax Matters
|
A-44
|
|
6.5
|
Transfer
Taxes
|
A-44
|
|
6.6
|
Tax
Contests
|
A-45
|
|
|
|
|
Article
VII INDEMNIFICATION
|
A-45
|
|
|
|
|
7.1
|
Survival
|
A-45
|
|
7.2
|
Indemnification
by Seller
|
A-46
|
|
7.3
|
Indemnification
by Buyer
|
A-47
|
|
7.4
|
Procedures
|
A-47
|
|
7.5
|
Limits
on Indemnification
|
A-49
|
|
7.6
|
Remedies
Not Affected by Investigation, Disclosure or Knowledge
|
A-49
|
|
7.7
|
Tax
Matters
|
A-50
|
|
7.8
|
Right
of Set-off
|
A-50
|
|
7.9
|
Exclusive
Remedy
|
A-50
|
Article
VIII GENERAL PROVISIONS
|
A-50
|
|
|
|
|
8.1
|
Fees
and Expenses
|
A-50
|
|
8.2
|
Amendment
and Modification
|
A-51
|
|
8.3
|
Waiver
|
A-51
|
|
8.4
|
Notices
|
A-51
|
|
8.5
|
Interpretation
|
A-52
|
|
8.6
|
Entire
Agreement
|
A-52
|
|
8.7
|
No
Third-Party Beneficiaries
|
A-52
|
|
8.8
|
Governing
Law
|
A-52
|
|
8.9
|
Submission
to Jurisdiction
|
A-53
|
|
8.10
|
Assignment;
Successors
|
A-53
|
|
8.11
|
Enforcement
|
A-53
|
|
8.12
|
Currency;
Payments
|
A-53
|
|
8.13
|
Severability
|
A-53
|
|
8.14
|
Waiver
of Jury Trial
|
A-54
|
|
8.15
|
Counterparts
|
A-54
|
|
8.16
|
Facsimile
or .pdf Signature
|
A-54
|
|
8.17
|
Time
of Essence
|
A-54
|
|
8.18
|
No
Presumption Against Drafting Party
|
A-54
|
INDEX
OF EXHIBITS
Exhibit
|
|
Description
|
Exhibit
A
|
|
Form
of Warrant
|
Exhibit
B
|
|
List
of Additional Cash Consideration Warrants
|
Schedules
Disclosure
Schedules
STOCK
PURCHASE AGREEMENT
STOCK
PURCHASE AGREEMENT, dated as of May 1, 2020 (this “Agreement”), between Joseph Hernandez (“Seller”),
an individual residing in Florida, and Oragenics, Inc., a Florida corporation (the “Buyer”).
RECITALS
A.
Seller owns 100% of the issued and outstanding common stock (the “Shares”) of Noachis Terra, Inc., a Delaware
corporation (the “Company”);
B.
On March 23, 2020, the Company was granted a License Agreement (the “License”), effective as of March 18, 2020,
by the National Institutes of Allergy and Infectious Diseases (“NIAID”), License Number (L-121-2020-0); and
C.
Seller wishes to sell to Buyer, and Buyer wishes to purchase from Seller, all of the Stock, on the term set forth herein;
AGREEMENT
In
consideration of the foregoing and the mutual covenants and agreements herein contained, and intending to be legally bound hereby,
the parties agree as follows:
Article
I
DEFINITIONS
1.1
Certain Defined Terms. For purposes of this Agreement:
“Accounts
Payable” means accounts payable, notes payable and other payables generated in connection with the business of the Company.
“Accounts
Receivable” means accounts receivable, notes receivable and other receivables generated in connection with the business
of the Company.
“Action”
means any claim, action, suit, inquiry, proceeding, audit or investigation by or before any Governmental Authority, or any other
arbitration, mediation or similar proceeding.
“Affiliate”
means, with respect to any Person, any other Person that directly, or indirectly through one or more intermediaries, controls,
is controlled by, or is under common control with, such first Person.
“Ancillary
Agreements” means the Warrant and all other agreements, documents and instruments required to be delivered by any party
pursuant to this Agreement, and any other agreements, documents or instruments entered into at or prior to the Closing in connection
with this Agreement or the transactions contemplated.
“BARDA”
means the Biomedical Advanced Research Development Authority under the Health and Human Services HS Office of the Assistant Secretary
for Preparedness and Response,
“Business
Day” means any day that is not a Saturday, a Sunday or other day on which banks are required or authorized by Law to
be closed in the City of Florida.
“Buyer
Common Stock” means the common stock, $0.001 par value per share, of Buyer.
“Company
Intellectual Property” means any and all Technology and Intellectual Property Rights that are owned or purported to
be owned by or exclusively licensed to the Company.
“Competitive
Business” means any business enterprise involved in the research, development, manufacture, distribution, and/or sale
of products for SARS-CoV-2 immunization.
“Contract”
means any contract, agreement, arrangement or understanding, whether written or oral and whether express or implied.
“Control,”
including the terms “controlled by” and “under common control with,” means the possession,
directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through
the ownership of voting securities, as trustee or executor, as general partner or managing member, by Contract or otherwise, including
the ownership, directly or indirectly, of securities having the power to elect a majority of the board of directors or similar
body governing the affairs of such Person.
“Encumbrance”
means any charge, claim, limitation, condition, equitable interest, mortgage, lien, option, pledge, security interest, easement,
encroachment, right of first refusal, adverse claim or restriction of any kind, including any restriction on or transfer or other
assignment, as security or otherwise, of or relating to use, quiet enjoyment, voting, transfer, receipt of income or exercise
of any other attribute of ownership.
“Environmental
Laws” means all Laws relating to pollution or protection of the environment, exposure of any individual to Hazardous
Materials, and Laws which prohibit, regulate or control any Hazardous Material, including Laws relating to emissions, discharges,
releases or threatened releases of Hazardous Materials, or otherwise relating to the manufacture, processing, registration, distribution,
labeling, sale, or the exposure of others to, recycling, use, treatment, storage, disposal, transport, or handling of Hazardous
Materials or any product containing any Hazardous Material, and including related electronic waste, product content or product
take-back requirements.
“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder
“Fraud”
means a claim for common law fraud with the intent to deceive brought against a Person based on a representation or warranty contained
in this Agreement; provided, that (a) at the time of the applicable misrepresentation or omission, the Person making such
misrepresentation or omission had knowledge of the inaccuracy of such misrepresentation or omission and (b) another Person acted
in reliance on such misrepresentation or omission and suffered financial injury as a result of such inaccuracy.
“GAAP”
means United States generally accepted accounting principles and practices as in effect on the date hereof.
“Governmental
Authority” means any United States or non-United States federal, national, supranational, state, provincial, local or
similar government, governmental, regulatory or administrative authority, branch, agency or commission or any court, tribunal,
or arbitral or judicial body (including any grand jury).
“Hazardous
Materials” means any material, emission, or substance that has been designated by a Governmental Authority to be a pollutant,
contaminant, hazardous, toxic, radioactive or biological waste, or otherwise a danger to health, reproduction or the environment,
including asbestos-containing materials, mold, and petroleum and petroleum products or any fraction thereof.
“Hedging
Activities” means any forward sale, hedging or similar transaction involving any Securities, including any transaction
by which any economic risks and/or rewards or ownership of, or voting rights with respect to, any such Securities are Transferred
or affected.
“Immediate
Family” means, with respect to any specified Person, any other Person who is an “immediate family member”
of such first Person as defined in the general commentary to Section 303A.02(b) of the Listed Company Manual of the NYSE American.
“Indebtedness”
means, without duplication (but before taking into account the consummation of the transactions contemplated hereby), (i) the
unpaid principal amount, accrued interest, premiums, penalties and other fees, expenses (if any), and other payment obligations
and amounts due (including such amounts that would become due as a result of the consummation of the transactions contemplated
by this Agreement) that would be required to be paid by a borrower to a lender pursuant to a customary payoff letter, in each
case, in respect of (A) all indebtedness for borrowed money of the Company, (B) indebtedness evidenced by notes, debentures, bonds
or other similar instruments (including any note payable to a Seller or former equityholder), and (C) all obligations with respect
to interest-rate hedging, swaps or similar financial arrangements (valued at the termination value thereof and net of all payments
owed to the Company or its Affiliates thereunder); (ii) all obligations under capitalized leases with respect to which the Company
is liable, determined in accordance with GAAP; (iii) any amounts for the deferred purchase price of goods and services, including
any earn out liabilities associated with past acquisitions, but excluding trade payables; (iv) all liabilities with respect to
any current or former employee, officer, director or equityholder of the Company that arise before or on the Closing Date, including
all liabilities with respect to any Plan, all accrued salary, deferred compensation and vacation obligations, all workers’
compensation claims, any liability in respect of accrued but unpaid bonuses for the prior fiscal year and for the period commencing
on the first day of the current fiscal year and ending on the Closing Date, and any employment Taxes payable by the Company with
respect to the foregoing; (v) unpaid management fees; (vi) all Accounts Payable (including any accrued payables and any payments
owed under the License, inclusive of any royalty payment that may be due pursuant to Section 14.7 of the License) and all other
amounts payable to NIH, NIAID, any Consultant or any other third party arising or accruing on or prior to the date hereof, (vii)
all indebtedness created or arising under any conditional sale or other title retention agreement with respect to property acquired
by the Company; (viii) all unpaid Pre-Closing Taxes (except those described in clause (i) of the definition of Pre-Closing Taxes);
and (ix) all obligations of the type referred to in clauses (i) through (viii) of other Persons for the payment of which the Company
is responsible or liable, as obligor, guarantor, surety or otherwise, including any guarantee of such obligations.
“Intellectual
Property Rights” means worldwide common law and statutory rights associated with (i) patents and patent applications
of any kind, (ii) copyrights, copyright registrations and copyright applications, “moral”, “economic”
and mask work rights, (iii) the protection of trade and industrial secrets and confidential information, (iv) logos, trademarks,
trade names and service marks, (v) domain names and (vi) any other proprietary rights relating to Technology, including any analogous
rights to those set forth above.
“Knowledge,”
with respect to a party, means the knowledge of such party, in the case of an individual, or any officer or director of such party,
in the case of an entity, and, in each case, such knowledge as would be imputed to such Persons upon due inquiry.
“Law”
means any statute, law, ordinance, regulation, rule, code, executive order, injunction, judgment, decree or order of any Governmental
Authority.
“Leased
Real Property” means all real property leased, subleased or licensed to the Company or which the Company otherwise has
a right or option to use or occupy, together with all structures, facilities, fixtures, systems, improvements and items of property
previously or hereafter located thereon, or attached or appurtenant thereto, and all easements, rights and appurtenances relating
to the foregoing.
“Material
Adverse Effect” means any event, change, circumstance, occurrence, effect, result or state of facts that, individually
or in the aggregate, (i) is or would reasonably be expected to be materially adverse to the business, assets, liabilities, financial
condition or results of operations of the Company, as applicable, or (ii) materially impairs the ability of Seller, on the one
hand, or Buyer, on the other hand, as applicable, to consummate the transactions contemplated by this Agreement or the Ancillary
Agreements or would reasonably be expected to do so; provided, however, that, solely with respect to the foregoing
clause (i), any event, change, circumstance, occurrence, effect, result or state of facts shall not be taken into account in determining
if a Material Adverse Effect exists or has occurred to the extent such event, change, circumstance, occurrence, effect, result
or state of facts, directly or indirectly, arises out of or is attributable to: (A) changes, conditions or effects in the United
States or foreign economies or securities or financial markets in general; (B) changes, conditions or effects that affect the
industries in which the Company, as appropriate, operates; (C) changes in applicable Laws or accounting rules, including GAAP,
first proposed after the date hereof; (D) the public announcement of this Agreement or the transactions contemplated hereby, include
losses of employees, customers, suppliers, distributors or others having relationships with the Company (provided, that
this shall not limit any representation, warranty or covenant made herein); (E) any failure by the Company to meet any internal
or published projections, forecasts or revenue or earnings predictions (provided, that the underlying causes of such failures
(subject to the other provisions of this definition) shall not be excluded); or (F) conditions caused by acts of terrorism or
war (whether or not declared) or any natural or man-made disaster or acts of God; provided, however, that, with
respect to the foregoing clauses (A), (B), (C) and (F), any such event, change, occurrence, circumstance, effect condition or
state of facts may be taken into account in determining whether there has been or is a Material Adverse Effect to the extent it
disproportionately impacts the business, assets, liabilities, financial condition or results of operations of the Company, as
applicable, in comparison to other participants of similar size in the same industry in which the Company, as applicable, operate.
“NIH”
means the U.S. National Institutes of Health.
“Open
Source” means all software and other material that is distributed as “freeware,” “free software,”
“open source software” or under a similar licensing or distribution model. Open Source includes any software and other
material that is distributed under any license listed or that is substantially similar to any license listed at http://www.opensource.org/licenses.
“Person”
means an individual, corporation, partnership, limited liability company, limited liability partnership, syndicate, person, trust,
association, organization or other entity, including any Governmental Authority, and including any successor, by merger or otherwise,
of any of the foregoing.
“Pre-Closing
Tax Period” means all taxable periods ending on or before the Closing Date.
“Pre-Closing
Taxes” means, without duplication, (i) all Taxes (or the non-payment thereof) of, or imposed on, the Company for each
Pre-Closing Tax Period and the portion through the end of the Closing Date for any Straddle Period, (ii) all Taxes of any member
of an affiliated group of which the Company (or any predecessor of any of the foregoing) is or was a member on or before the Closing
Date, including pursuant to Treasury Regulations Section 1.1502-6 or any analogous or similar U.S. state or local, or non-U.S.
Law, (iii) Taxes arising from the transactions contemplated by this Agreement, and (iv) any and all Taxes of any Person (other
than the Company) imposed on the Company as a transferee or successor, by contract or pursuant to any Law, which Taxes relate
to an event or transaction occurring on or before the Closing.
“Registered
Intellectual Property Rights” means any and all Intellectual Property Rights that have been registered, applied for,
filed, certified or otherwise perfected, issued, or recorded with or by any state, government or other public or quasi-public
legal authority.
“Registrable
Securities” means the Share Consideration, the Warrants and the Warrant Shares (and any securities issued in exchange
or upon exercise of the Share Consideration and Warrants, and any securities issued or issuable with respect to any securities
described in this definition above by way of a dividend or stock split or in connection with a combination of stock, recapitalization,
merger, consolidation or other reorganization); provided, however, that, as to any particular Registrable Security,
such securities shall cease to be Registrable Securities when (i) an Seller ceases to hold such securities, (ii) a Registration
Statement covering the resale of such securities has been declared effective by the SEC and such securities have been disposed
of pursuant to such effective Registration Statement, (iii) such securities shall be eligible to be transferred by an Seller pursuant
to Rule 144 (or any successor provision) under the Securities Act without any time or volume limitations, or (iv) such securities
cease to be outstanding.
“Related
Party,” with respect to any specified Person, means: (i) any Affiliate of such specified Person, or any director, executive
officer, general partner or managing member of such Affiliate; (ii) any Person who serves or since the Company’s inception
has served as a director, executive officer, partner, member or in a similar capacity of such specified Person; (iii) any Immediate
Family member of a Person described in clause (ii); or (iv) any other Person who holds, individually or together with any Affiliate
of such other Person and any member(s) of such Person’s Immediate Family, more than 5% of the outstanding equity or ownership
interests of such specified Person.
“Representatives”
means, with respect to any Person, the officers, directors, principals, employees, agents, auditors, advisors, bankers and other
representatives of such Person.
“SEC”
means the United States Securities and Exchange Commission.
“Securities”
means the Share Consideration, the Warrants and the Warrant Shares.
“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
“Shareholder
Approval” means such approval as may be required by the applicable rules and regulations of the Trading Market from
the shareholders of Buyer with respect to the transactions contemplated by the Ancillary Agreements, including approval of the
exercisability of the Warrants for Buyer Common Stock as required by NYSE American rules.
“Short
Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include locating and/or borrowing shares of Common Stock).
“Software”
means any and all computer programs, software (in object and source code), firmware, middleware, applications, API’s, web
widgets, code and related algorithms, models and methodologies, files, documentation and all other tangible embodiments thereof.
“Straddle
Period” means any taxable period that includes (but does not end on) the Closing Date.
“Subsidiary”
means, with respect to any Person, any other Person controlled by such first Person, directly or indirectly, through one or more
intermediaries.
“Systems”
means servers, hardware systems, databases, circuits, networks and other computer and telecommunications assets and equipment.
“Tax
Return” means any return, declaration, report, claim for refund, estimate, information report, return statement or filing
relating to Taxes, including any schedule or attachment thereto and including any amendment thereof, including any return, declaration,
report or other statement provided or required to be provided to any Person for compliance with Code Sections 1471-1474 (including
any intergovernmental agreements thereunder and any Treasury Regulations or other official interpretations with respect thereof).
“Taxes”
means: (i) all federal, state, local, foreign and other net income, gross income, gross receipts, sales, use, ad valorem, transfer,
franchise, profits, registration, license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp,
occupation, premium, property, windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatsoever
(including any amounts resulting from the failure to file any Tax Return), together with any interest and any penalties, additions
to tax or additional amounts with respect thereto; (ii) any liability for payment of amounts described in clause (i) whether as
a result of transferee liability, of being a member of an affiliated, consolidated, combined or unitary group for any period or
otherwise through operation of law; and (iii) any liability for the payment of amounts described in clauses (i) or (ii) as a result
of any tax sharing, tax receivable, tax indemnity or tax allocation agreement or any other express or implied agreement to indemnify
any other Person.
“Taxing
Authority” means any Governmental Authority responsible for the administration, imposition or collection of any Tax.
“Technology”
means any or all of the following: (i) works of authorship including computer programs, source code, and executable code, whether
embodied in software, firmware or otherwise, architecture, documentation, designs, files, and records, (ii) inventions (whether
or not patentable), discoveries, and improvements, (iii) proprietary and confidential information, trade secrets and know how,
(iv) databases, data compilations and collections and technical data, (v) domain names, web addresses and Websites, (vi) tools,
methods and processes, and (vii) any and all instantiations or embodiments of the foregoing in any form and embodied in any media.
“Trading
Day” means a day on which the principal Trading Market is open for trading.
“Trading
Market” means any of the following markets or exchanges on which the Buyer Common Stock is listed or quoted for trading
on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market,
the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).
“Transfer”
shall mean any offer, direct or indirect sale, assignment, Encumbrance, option, pledge, hypothecation, disposition, loan or other
transfer, whether directly or indirectly, or entry into any Contract with respect to any offer, sale, assignment, Encumbrance,
option, right to purchase, pledge, hypothecation, disposition, loan or other transfer, whether directly or indirectly, or any
public announcement of any intention to effect any of the foregoing, excluding entry into this Agreement and the consummation
of the transactions contemplated hereby and thereby.
“Transaction
Expenses” means the aggregate amount of any and all fees and expenses incurred by or on behalf of, or paid or to be
paid directly by, Seller or the Company or any Person that Seller or the Company pays or reimburses or is otherwise legally obligated
to pay or reimburse (including any such fees and expenses incurred by or on behalf of Seller) in connection with the process of
selling the Company or the negotiation, preparation or execution of this Agreement or the Ancillary Agreements or the performance
or consummation of the transactions contemplated hereby or thereby, including (i) all fees and expenses of counsel, advisors,
consultants, investment bankers, accountants, auditors and any other experts in connection with the transactions contemplated
hereby; (ii) any fees and expenses associated with obtaining necessary or appropriate waivers, consents, or approvals of any Governmental
Authority or third parties on behalf of the Company in connection with the transactions contemplated hereby; (iii) any fees or
expenses associated with obtaining the release and termination of any Encumbrances in connection with the transactions contemplated
hereby; (iv) all brokers’, finders’ or similar fees in connection with the transactions contemplated hereby; and (v)
any change of control payments, bonuses, severance, termination, or retention obligations or similar amounts payable in the future
or due by Seller or the Company in connection with the transactions contemplated hereby, including any Taxes payable in connection
with any of the foregoing, and, in each of the cases above, including any fee payable in connection with the License (including
any fee payable to NIAID or NIH related to the change of control of the Company).
“Transfer
Agent” means Continental Stock Transfer & Trust Co, the current Transfer Agent of the Company, with a mailing address
of One State Street Plaza, 30th Floor, New York, NY 10004-1561 and any successor Transfer Agent of the Company.
“Transfer
Taxes” means all transfer, documentary, sales, use, stamp, registration and other such Taxes and fees (including any
penalties and interest) incurred in connection with this Agreement, including any Taxes required to be withheld with respect to
any indirect share transfer.
“Warrants”
means warrants to purchase Buyer Common Stock in the form attached hereto as Exhibit A, the exercisability of which will
be subject to Shareholder Approval, the terms of which will provide for (a) an exercise price equal to $1.25, subject to adjustment
as contained in the Warrant, (b) an exercise date commencing on the earlier of: (i) receipt of notification that BARDA is willing
to fund the development program for SARS-CoV-2 vaccine, (ii) phase 1 clinical data demonstrating activity (by definition this
requires evidence of SARS-COV-2 antibody appearance in blood/serum in phase 1 subjects who had tested negative for SARS-Cov-2
antibodies prior to receipt of the vaccine), or (iii) one year from the date of issuance, and (c) a five-year expiration date.
“Websites”
means all Internet websites, including content, text, graphics, images, audio, video, data, databases, Software and related items
included on or used in the operation of and maintenance thereof, and all documentation, ASP, HTML, DHTML, SHTML, and XML files,
cgi and other scripts, subscriber data, archives, and server and traffic logs and all other tangible embodiments related to any
of the foregoing.
1.2
Table of Definitions . The following terms have the meanings set forth in the Sections referenced below:
Definition
|
|
Location
|
|
|
|
Additional
Cash Consideration
|
|
2.3
|
Agreement
|
|
Preamble
|
Balance
Sheet
|
|
3.7(b)
|
Basket
|
|
7.5(a)
|
Buyer
|
|
Preamble
|
Cash
Consideration
|
|
2.1(a)
|
Claim
Notice
|
|
7.4(a)
|
Closing
|
|
2.2(a)
|
Closing
Date
|
|
2.2(a)
|
Code
|
|
3.11(b)
|
Company
|
|
Preamble
|
Company
Group Employees
|
|
5.1(a)(ii)
|
Company
Registered Intellectual Property Rights
|
|
3.15(a)
|
Company
Source Code
|
|
3.15(s)
|
Company
Unregistered Intellectual Property Rights
|
|
3.15(c)
|
Competitive
Business
|
|
5.1(a)(i)
|
Confidential
Information
|
|
5.5(a)
|
Consultants
|
|
3.12(f)
|
Contest
|
|
6.6(a)
|
Customer
|
|
5.1(a)(iii)
|
Direct
Claim
|
|
7.4(c)
|
Disclosure
Schedules
|
|
Article
III
|
Disqualification
Event
|
|
3.23(i)
|
ERISA
|
|
3.11(a)(i)
|
Evaluation
Date
|
|
4.10
|
Exchange
Act
|
|
4.6(a)
|
Financial
Statements
|
|
3.7(a)
|
Fundamental
Representations
|
|
7.1(a)(i)
|
General
Cap
|
|
7.5(b)
|
Indemnified
Party
|
|
7.4(a)
|
Indemnifying
Party
|
|
7.4(a)
|
Issuance
Limit
|
|
5.8
|
License
|
|
Preamble
|
Losses
|
|
7.2
|
Material
Contracts
|
|
3.18(a)
|
NIAID
|
|
Preamble
|
Permits
|
|
3.9(b)
|
Permitted
Encumbrances
|
|
3.13(a)
|
Plans
|
|
3.11(a)(ii)
|
PTO
|
|
3.15(a)
|
Purchase
Price
|
|
2.1
|
Purchase
Price Allocation
|
|
6.8
|
Registration
Statement
|
|
5.7(a)
|
Restricted
Period
|
|
5.1(a)
|
SEC
Documents
|
|
4.6(a)
|
Securities
Act
|
|
4.5
|
Seller
|
|
Preamble
|
Set-off
Amount
|
|
7.8
|
Set-off
Notice
|
|
7.8
|
Share
Consideration
|
|
2.1(c)
|
Shares
|
|
Preamble
|
Tax
Consideration
|
|
6.8
|
Territory
|
|
5.1(a)(i)
|
Third
Party Claim
|
|
7.4(a)
|
Valid
Business Reason
|
|
5.7(c)
|
Warrant
Shares
|
|
2.1(d)
|
Article
II
PURCHASE AND SALE
2.1
Purchase and Sale of the Shares. Upon the terms and subject to the conditions of this Agreement, at the Closing, Seller
shall sell, assign, transfer, convey and deliver the Shares to Buyer free and clear of all Encumbrances, and Buyer, in reliance
on the representations, warranties and covenants of Seller contained herein, shall purchase the Shares from Seller, representing,
in the aggregate, 100% of the issued and outstanding capital stock of the Company, for an aggregate purchase price (the “Purchase
Price”) equal to:
(a)
$1,925,000 in cash (the “Cash Consideration”), minus the Indebtedness and minus the Transaction
Expenses (including any Accounts Payable and any payments owed under the License or that have accrued on or prior to the date
hereof, inclusive of any royalty payment that may be due pursuant to Section 14.7 of the License);
(b)
the Additional Cash Compensation;
(c)
9,200,000 shares of the Buyer Common Stock (“Share Consideration”); and
(d)
a Warrant to purchase up to 9,200,000 shares of Buyer Common Stock at an exercise price of $1.25, subject to adjustment in accordance
with the Warrant (the “Warrant Shares.”)
2.2
Closing.
(a)
The sale and purchase of the Shares shall take place concurrently with the execution and delivery of this Agreement (the “Closing”)
to be held at the offices of Shumaker, Loop & Kendrick, LLP, 101 East Kennedy Boulevard, Suite 2800, Tampa FL 33602, or at
such other place or at such other time or on such other date as Seller and Buyer mutually may agree in writing. The day on which
the Closing actually takes place is referred to as the “Closing Date.”
(b)
At or prior to the Closing, Seller shall deliver or cause to be delivered to Buyer:
(i)
an instrument of assignment duly endorsed by Seller transferring and assigning the Shares to Buyer;
(ii)
the authorization, approval, order, permit or consent of all Governmental Authorities disclosed on Schedule 3.3(b) of the
Disclosure Schedules, including the consent from the NIH to the transactions contemplated by this Agreement including the Company’s
ownership change, in form and substance reasonably acceptable to Buyer;
(iii)
a general release of all claims, as further contemplated by Section 5.2, executed by Seller, Erin Henderson, David Zarley, Gary
Ascani and all Consultants;
(iv)
a list of all Persons owed Indebtedness and/or Transaction Expenses;
(v)
a bad actor questionnaire, in form and substance reasonably acceptable to Buyer, establishing that Seller is not subject to any
Disqualification Event, duly executed by Seller; and
(vi)
a properly completed and duly executed IRS Form W-9 from Seller.
(c)
At the Closing, Buyer shall deliver or cause to be delivered:
(i)
to Seller, the Cash Consideration, minus the Indebtedness and Transaction Expenses, by wire transfer of immediately available
funds in United States dollars to the account(s) designated in writing by Seller to Buyer;
(ii)
to Seller, evidence of the issuance of the Share Consideration;
(iii)
to Seller, Warrants to purchase up to 9,200,000 Warrant Shares, in the aggregate;
(iv)
on behalf of the Company, the amount payable to each counterparty or holder of Indebtedness identified on Schedule 3.7(c)
of the Disclosure Schedules; and
(v)
on behalf of the Company, the amount payable to each Person who is owed Transaction Expenses identified on Schedule 3.7(c).
2.3
Additional Cash Consideration. Subject to Section 7.8, if any of the warrants to purchase Buyer Common Stock issued and
outstanding as of the date hereof and listed in Exhibit B that provide for an exercise price of $0.75 or $0.90 per share
are timely exercised, for cash, in accordance with the terms of such warrants, Buyer shall pay to Seller twenty percent (20%)
of the net cash proceeds received by the Company from such exercises, promptly after the receipt of the cash exercise price related
thereto, and if any of the warrants to purchase Buyer Common Stock issued and outstanding as of the date hereof and listed in
Exhibit B that provide for an exercise price of $1.00 per share are timely exercised, for cash, in accordance with the
terms of such warrants, Buyer shall pay to Seller forty five percent (45%) of the net cash proceeds received by the Company from
such exercises, promptly after the receipt of the cash exercise price related thereto (collectively, the “Additional
Cash Consideration”).
2.4
Withholding. Buyer shall be entitled to deduct and withhold (or cause to be deducted and withheld) any amount from the
Purchase Price otherwise payable to Seller pursuant to this Agreement that are required to be withheld therefrom or with respect
thereto under the Code, Treasury Regulation or other applicable Law. To the extent that amounts are so deducted or withheld, such
amounts shall be treated for all purposes of this Agreement as having been paid to Seller in respect of which such deduction and
withholding was made.
Article
III
REPRESENTATIONS AND WARRANTIES Regarding THE SELLER and the company
Except
as set forth in the corresponding sections or subsections of the Disclosure Schedules attached hereto (collectively, the “Disclosure
Schedules”) (each of which shall qualify the specifically identified Sections or subsections hereof to which such Disclosure
Schedule relates and those other Sections and subsections for which the relevance or applicability of such disclosure is reasonably
apparent on the face of such disclosure), Seller hereby represents and warrants to Buyer as follows:
3.1
Organization and Qualification.
(a)
The Company is (i) a corporation duly organized, validly existing and in good standing under the Laws of Delaware and has full
power and authority to own, lease and operate its properties and assets and to carry on its business as now conducted and as currently
proposed to be conducted and (ii) duly qualified or licensed as a foreign company to do business, and is in good standing, in
each jurisdiction where the character of the properties and assets occupied, owned, leased or operated by it or the nature of
its business makes such qualification or licensing necessary, except for any such failures to be so qualified or licensed and
in good standing that, individually or in the aggregate, have not had and would not reasonably be expected to have a Material
Adverse Effect.
(b)
Seller has heretofore furnished to Buyer a complete and correct copy of the articles of incorporation and bylaws, each as amended
to date, of the Company. Such articles of incorporation and bylaws are in full force and effect. The Company is not in violation
of any of the provisions of its articles of incorporation or bylaws. The transfer books and minute books of the Company have been
made available for inspection by Buyer prior to the date hereof and are true and complete.
3.2
Authority. Seller has full power and authority and, if Seller is a natural Person, capacity, to execute and deliver this
Agreement and each of the Ancillary Agreements to which Seller is a party, to perform his, her or its obligations hereunder and
thereunder and to consummate the transactions contemplated hereby and thereby. The execution, delivery and performance by Seller
of this Agreement and each of the Ancillary Agreements to which Seller is a party and the consummation by Seller of the transactions
contemplated hereby and thereby have been duly and validly authorized by all necessary corporate and individual action. This Agreement
has been, and upon their execution each of the Ancillary Agreements to which Seller is a party will have been, duly executed and
delivered by Seller and, assuming due execution and delivery by each of the other parties hereto and thereto, this Agreement constitutes,
and upon their execution each of the Ancillary Agreements to which Seller is be a party will constitute, the legal, valid and
binding obligations of Seller, enforceable against Seller in accordance with their respective terms, except as enforcement may
be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights
generally and by general principles of equity (regardless of whether considered in a proceeding in equity or at law).
3.3
No Conflict; Required Filings and Consents.
(a)
The execution, delivery and performance by Seller of this Agreement and each of the Ancillary Agreements to which a Seller will
be a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not:
(i)
conflict with or violate the articles of incorporation, bylaws or equivalent organizational documents of Seller (if applicable)
or the Company;
(ii)
conflict with or violate any Law applicable to Seller or the Company or by which any property or asset of Seller or the Company
is bound or affected; or
(iii)
result in any breach of, constitute a default (or an event that, with notice or lapse of time or both, would become a default)
under, require any consent of or notice to any Person pursuant to, give to others any right of termination, amendment, modification,
acceleration or cancellation of, allow the imposition of any fees or penalties, require the offering or making of any payment
or redemption, give rise to any increased, guaranteed, accelerated or additional rights or entitlements of any Person or otherwise
adversely affect any rights of Seller or the Company under, or result in the creation of any Encumbrance on any property, asset
or right of Seller or the Company pursuant to, any note, bond, mortgage, indenture, agreement, lease, license, permit, franchise,
instrument, obligation or other Contract to which Seller or the Company is a party or by which Seller or the Company or any of
their respective properties, assets or rights are bound or affected.
(b)
Except as set forth on Schedule 3.3(b) of the Disclosure Schedules, neither the Seller or the Company is required to file,
seek or obtain any notice, authorization, approval, order, permit or consent of or with any Governmental Authority in connection
with the execution, delivery and performance by Seller of this Agreement and each of the Ancillary Agreements to which Seller
will be a party or the consummation of the transactions contemplated hereby or thereby or in order to prevent the termination
of any right, privilege, license or qualification of the Company.
(c)
No “fair price,” “interested shareholder,” “business combination” or similar provision of
any state takeover Law is applicable to the transactions contemplated by this Agreement or the Ancillary Agreements.
3.4
Shares. Seller has the sole right, authority and power to sell, assign and transfer the Shares to Buyer. Upon Buyer’s
payment of the portion of the Purchase Price payable at the Closing, Buyer shall (i) acquire good, valid and marketable title
to such Shares, free and clear of any Encumbrance other than Encumbrances created by Buyer, (ii) be the sole record and beneficial
owner of all outstanding capital stock of the Company and (iii) be the sole shareholder of the Company.
3.5
Capitalization. The authorized capital stock of the Company consists of ten million (10,000,000) shares of Common Stock,
with a par value of $0.01 per share, of which ten thousand (10,000) shares of Common Stock, constituting the Shares, are issued
and outstanding, and Seller collectively owns, beneficially and of record, all of the Shares free and clear of any Encumbrance.
Except for such Shares, the Company has not issued or agreed to issue any: (a) capital stock or other equity or ownership interest;
(b) option, warrant or interest convertible into or exchangeable or exercisable for the purchase of any capital stock or other
ownership interests; (c) stock appreciation right, phantom stock, interest in the ownership or earnings of the Company or other
equity equivalent or equity-based award or right; or (d) bond, debenture or other Indebtedness having the right to vote or convertible
or exchangeable for securities having the right to vote. Each outstanding Share is duly authorized, validly issued, fully paid
and nonassessable. All of the Shares have been offered, sold and delivered by the Company in compliance with all applicable federal
and state securities laws. Except for rights granted to Buyer under this Agreement, there are no outstanding obligations of Seller
or the Company to issue, sell or transfer or repurchase, redeem or otherwise acquire, or that with respect to the Company and/or
Seller, relate to the holding, voting or disposition of or that restrict the transfer of, the issued or unissued capital stock
or other equity or ownership interests of the Company. No capital stock or other equity or ownership interests of the Company
have been issued in violation of any rights, agreements, arrangements or commitments under any provision of applicable Law, articles
of incorporation or bylaws of the Company or any Contract to which the Company is a party or by which the Company is bound. There
are no voting trusts, proxies, or other agreements or understandings with respect to the equity securities of the Company. There
are no agreements relating to the registration, sale or transfer (including agreements relating to rights of first refusal, first
offer, preemptive rights, co-sale rights or “drag-along” rights) of any capital stock in the Company.
3.6
Equity Interests. The Company does not own and has not owned, directly or indirectly, any equity, partnership, membership
or similar interest in, or any interest convertible into, exercisable for the purchase of or exchangeable for any such equity,
partnership, membership or similar interest in any Person. The Company is not under any current or prospective obligation to form
or participate in, provide funds to, make any loan, capital contribution or other investment in or assume any liability or obligation
of, any Person.
3.7
Financial Statements; No Undisclosed Liabilities.
(a)
True and complete copies of the balance sheet of the Company as at March 31, 2020, and the related statements of income, cash
flows and changes in shareholders’ equity of the Company (collectively referred to as the “Financial Statements”),
are attached hereto as Schedule 3.7(a) of the Disclosure Schedules. The Financial Statements (i) are correct and complete
in all material respects and have been prepared in accordance with the books and records of the Company, (ii) have been prepared
in accordance with GAAP applied on a consistent basis throughout the periods indicated (except as may be indicated in the notes
thereto) and (iii) fairly present, in all material respects, the financial position, results of operations and cash flows of the
Company as at the respective dates thereof and for the respective periods indicated therein, except as otherwise noted therein
and subject to normal and recurring year-end adjustments that will not, individually or in the aggregate, be material.
(b)
Except as and to the extent adequately accrued or reserved against in the balance sheet of the Company as at March 31, 2020 (such
balance sheet, together with all related notes and schedules thereto, the “Balance Sheet”), the Company does
not have any liability or obligation of any nature, whether accrued, absolute, contingent or otherwise, whether known or unknown
and whether or not required by GAAP to be reflected in a balance sheet of the Company or disclosed in the notes thereto, except
for liabilities and obligations, incurred in the ordinary course of business consistent with past practice since the date of the
Balance Sheet, that are not, individually or in the aggregate, material to the Company.
(c)
As of the date hereof, the Company does not have any Indebtedness or Transaction Expenses (including any Accounts Payable and
any payments owed under the License or that have accrued on or prior to the date hereof, inclusive of any royalty payment that
may be due pursuant to Section 14.7 of the License), other than as set forth in Schedule 3.7(c).
(d)
The books of account and financial records of the Company are true and correct in all material respects and have been prepared
and are maintained in accordance with sound accounting practice. To the Company’s knowledge, the Company maintains proper
and adequate internal accounting controls, and, as of the date of this Agreement, there are no significant deficiencies in the
design or operation of the Company’s internal controls over financial reporting which could adversely affect in any material
respect the Company’s ability to record, process, summarize and report financial data or material weaknesses in internal
controls over financial reporting. There has been no fraud, whether or not material, that involved management or other employees
of the Company who have a significant role in the Company’s internal control over financial reporting.
(e)
The Company does not have any Accounts Receivable. Except as set forth on Schedule 3.7(c) of the Disclosure Schedules,
the Company does not have any Accounts Payable to any Person.
3.8
Reserved
3.9
Absence of Certain Changes or Events. Since the date of the Balance Sheet: (a) the Company has conducted its business in
the ordinary course consistent with past practice in all material respects; (b) there has not been any change, event or development
or prospective change, event or development that, individually or in the aggregate, has had or is reasonably likely to have a
Material Adverse Effect; and (c) the Company has not suffered any material loss, damage, destruction or other casualty affecting
any of its properties or assets, whether or not covered by insurance.
3.10
Compliance with Law; Permits.
(a)
The Company is and has been in compliance in all material respects with all Laws applicable to it. None of the Company or any
of its executive officers has received, since the Company’s inception, nor is there any basis for, any notice, order, complaint
or other communication from any Governmental Authority or any other Person that the Company is not in compliance in any material
respect with any Law applicable to it.
(b)
Schedule 3.9 of the Disclosure Schedules sets forth a true and complete list of all permits, licenses, franchises, approvals,
certificates, consents, waivers, concessions, exemptions, orders, registrations, notices or other authorizations of any Governmental
Authority necessary for the Company to own, lease and operate its properties and to carry on its business in all material respects
as currently conducted (the “Permits”). The Company is and has been in compliance in all material respects
with all such Permits. No suspension, cancellation, modification, revocation or nonrenewal of any Permit is pending or, to the
knowledge of the Company, threatened. The Company will continue to have the use and benefit of all Permits following consummation
of the transactions contemplated hereby. No Permit is held in the name of any employee, officer, director, equityholder, agent
or otherwise on behalf of the Company. The Permits are in full force and effect and constitute all Permits required to permit
the Company to operate or conduct its business or hold any interest in its properties or assets.
3.11
Litigation. There is no Action pending or, to the knowledge of the Company, threatened against the Company, or any material
property or asset of the Company, or any of the officers of the Company in regard to their actions as such, nor is there any basis
for any such Action. There is no Action pending or, to the knowledge of the Company, threatened seeking to prevent, hinder, modify,
delay or challenge the transactions contemplated by this Agreement or the Ancillary Agreements. There is no outstanding order,
writ, judgment, injunction, decree, determination or award of, or pending or, to the knowledge of the Company, threatened investigation
by, any Governmental Authority relating to any Seller, the Company, any of their respective properties or assets, any of their
respective officers or directors, or the transactions contemplated by this Agreement or the Ancillary Agreements. There is no
Action by the Company pending, or which the Company has commenced preparations to initiate, against any other Person.
3.12
Employee Benefit Plans.
(a)
The Company does not have and has never had or maintained any (i) employee benefit plans (as defined in Section 3(3) of the Employee
Retirement Income Security Act of 1974, as amended (“ERISA”)) (whether or not subject to ERISA), (ii) bonus,
commission, stock option, stock purchase, restricted stock, incentive, deferred compensation, retiree medical or life insurance,
supplemental retirement, 401(k), severance or other benefit plans, programs or arrangements or (iii) employment, termination,
change in control, severance or other similar contracts or agreements or any other Contracts between the Company and any current
or former employee, officer or director of the Company, including any Contracts relating in any way to a change in control or
sale of the Company or any material portion of its assets, including any Contracts providing for any severance, golden parachute
benefits, change in control benefits, tax gross-ups, and/or equity acceleration or other waiver or modification of equity vesting
criteria (collectively, the “Plans”).
(b)
The Company does not have any express or implied commitment (A) to create, incur liability with respect to or cause to exist any
other plan, program, arrangement, agreement or contract that would fall within the definition of a Plan at its inception, (B)
to enter into any Contract to provide compensation or benefits to any individual or (C) to modify, change or terminate any Plan,
other than with respect to a modification, change or termination required by ERISA or the Internal Revenue Code of 1986, as amended
(the “Code”).
(c)
The Company and its Affiliates are not obligated to make any payments, including under any Plan, that reasonably could be expected
to be “excess parachute payments” pursuant to Section 280G of the Code.
3.13
Labor and Employment Matters.
(a)
The Company does not has and never had any employees and is not, and have never been, a part to any employment agreement or any
other agreement that (i) restricts the Company’s right to terminate the employment of any Person or (ii) obligates the Company
to pay severance to any Person upon termination of such Person’s employment. The Company is and since its inception has
been in compliance in all material respects with all applicable Laws, agreements, contracts, policies, plans and programs respecting
employment, including equal opportunity, affirmative action, discrimination or harassment in employment, terms and conditions
of employment, termination of employment, wages, overtime classification, hours, meals and rest breaks, disability rights and
benefits, vacation pay, sick pay, unemployment insurance, workers’ compensation, occupational safety and health, employee
whistle-blowing, background checks, immigration, employee privacy, employment practices and classification of employees, consultants
and independent contractors. The Company has withheld and paid to the appropriate Governmental Authority or is holding for payment
not yet due to such Governmental Authority all amounts required to be withheld from employees of the Company and is not liable
for any arrears of wages, taxes, penalties or other sums for failure to comply with any applicable Laws relating to the employment
of labor.
(b)
Schedule 3.12(b) of the Disclosure Schedules sets forth a true and complete list of all present and former independent
contractors, consultants, interns and service providers (the “Consultants”) of the Company, and includes each
Consultant’s name, engaging entity, date of commencement, scope of engagement, prior notice entitlement and rate of all
regular compensation, benefits, bonus or any other compensation payable. Except as set forth on Schedule 3.12(b) of the
Disclosure Schedules, all Consultants of the Company can be terminated on notice of 30 days or less to the Consultant. All former
and current Consultants of the Company signed consultancy agreements, which contain provisions which state that no employer-employee
relations exist between the Consultant and the Company, copies of which Seller has delivered to Buyer. All former and current
Consultants (including any interns) of the Company were and are rightly classified as independent contractors and would not reasonably
be expected to be reclassified by any Governmental Authority as employees of the Company, for any purpose whatsoever. According
to the consultancy agreements with the Company, no Consultant is entitled to any rights under the applicable labor Laws. All current
and former Consultants have received all their rights to which they are and were entitled to according to any applicable Law or
Contract with the Company. The Company does not engage any personnel through manpower agencies or any employee or Consultant,
whose employment or engagement requires special licenses or permits.
(c)
The Company has no unsatisfied obligations of any nature to any of its former employees or Consultants, and their termination
was in compliance with all material applicable Laws and Contracts.
(d)
All past and present Consultants of the Company have executed the Company’s restrictive covenants agreement substantially
in the standard form of the Company as in effect from time to time and made available to Buyer. No current or former Consultant
of the Company is or was engaged by the Company without a written contract or failed to execute an agreement concerning Intellectual
Property Rights (including inventions), confidentiality and non-competition.
(e)
There has not been, and the Company does not anticipate or have any reason to believe that there will be, any adverse change in
relations with Consultants as a result of the announcement of the transactions contemplated by this Agreement. To the knowledge
of the Company, no current Consultant or officer of the Company intends, or is expected, to terminate his or her relationship
with the Company following the consummation of the transactions contemplated hereby. Neither the execution and delivery of this
Agreement nor the consummation of the transactions contemplated by this Agreement will, either alone or in conjunction with any
other event, (A) result in any material payment or benefit becoming due or payable, or required to be provided, to any Consultant,
(B) increase the amount or value of any benefit or compensation otherwise payable or required to be provided to any such individual,
or (C) result in the acceleration of the time of payment, vesting, exercisability or funding of any such benefit or compensation.
(f)
All Consultants of the Company are legally entitled to work in the United States and, to the knowledge of the Company, all Persons
engaged by the Company since its inception were at the time of their engagement, legally entitled to work in the United States.
(g)
To the knowledge of the Company, no former or current Consultant of the Company is bound by any contract (other than with the
Company) that restricts or limits the scope or type of work in which such Consultant may be engaged or requires such Person to
transfer, assign or disclose information concerning such Consultant’s work to any Person other than the Company.
3.14
Assets.
(a)
The Company has good and valid title to or a valid leasehold interest in all of its assets, including all of the assets reflected
on the Balance Sheet or acquired in the ordinary course of business since the date of the Balance Sheet, except those sold or
otherwise disposed of for fair value since the date of the Balance Sheet in the ordinary course of business consistent with past
practice. None of the assets owned or leased by the Company is subject to any Encumbrance, other than (i) liens for Taxes not
yet due and payable and for which adequate reserves have been established in accordance with GAAP and (ii) mechanics’, workmen’s,
repairmen’s, warehousemen’s and carriers’ liens arising in the ordinary course of business of the Company consistent
with past practice (collectively, “Permitted Encumbrances”).
(b)
All tangible assets owned or leased by the Company have been maintained in all material respects in accordance with generally
accepted industry practice, are in all material respects in good operating condition and repair, ordinary wear and tear excepted,
and are adequate for the uses to which they are being put.
3.15
Real Property.
(a)
The Company does not own any real property, nor has the Company ever owned any real property. Schedule 3.14(a) of the Disclosure
Schedules sets forth a true and complete list of all Leased Real Property. The Company has good and marketable leasehold title
to all Leased Real Property, in each case, free and clear of all Encumbrances except Permitted Encumbrances. No parcel of Leased
Real Property is subject to any governmental decree or order to be sold or is being condemned, expropriated, re-zoned or otherwise
taken by any public authority with or without payment of compensation therefore, nor, to the knowledge of the Company, has any
such condemnation, expropriation or taking been proposed. All leases of Leased Real Property and all amendments and modifications
thereto are in full force and effect, and there exists no default under any such lease by the Company or any other party thereto,
nor any event which, with notice or lapse of time or both, would constitute a default thereunder by the Company or any other party
thereto. All leases of Leased Real Property shall remain valid and binding in accordance with their terms following the Closing.
(b)
There are no contractual or legal restrictions that preclude or restrict the ability to use any Leased Real Property by the Company
or for the current or contemplated use of such real property. There are no material latent defects or material adverse physical
conditions affecting the Leased Real Property. All plants, warehouses, distribution centers, structures and other buildings on
the Leased Real Property are adequately maintained and are in good operating condition and repair for the requirements of the
business of the Company as currently conducted.
3.16
Intellectual Property.
(a)
Schedule 3.15(a) of the Disclosure Schedules lists all Registered Intellectual Property Rights owned by, or filed in the
name of, the Company (the “Company Registered Intellectual Property Rights”), the applicable owner of the Company
Registered Intellectual Property Rights, and any material proceedings or actions before any court, tribunal (including the United
States Patent and Trademark Office (the “PTO”) or equivalent authority anywhere in the world) related to any
of the Company Registered Intellectual Property Rights or Company Intellectual Property.
(b)
Each item of Company Registered Intellectual Property Rights is valid and subsisting, and all necessary registration, maintenance
and renewal fees in connection with such Company Registered Intellectual Property Rights have been paid and all necessary documents
and certificates in connection with such Company Registered Intellectual Property Rights have been filed with the relevant patent,
copyright, trademark or other authorities in the United States or foreign jurisdictions, as the case may be, for the purposes
of maintaining such Registered Intellectual Property Rights. There are no actions that must be taken by the Company within 100
days following the date of this Agreement, including the payment of any registration, maintenance or renewal fees or the filing
of any documents, applications or certificates for the purposes of maintaining, perfecting or preserving or renewing any Registered
Intellectual Property Rights. In each case in which the Company has acquired any Registered Intellectual Property Rights from
any Person, the Company has obtained a valid and enforceable assignment sufficient to irrevocably transfer all rights in Registered
Intellectual Property Rights (including the right to seek past and future damages with respect thereto) to the Company, and, to
the maximum extent provided for by, and in accordance with, applicable Laws, the Company has recorded each such assignment with
the relevant governmental authorities, including the PTO, the U.S. Copyright Office, or their respective equivalents in any relevant
foreign jurisdiction, as the case may be.
(c)
Schedule 3.15(c) of the Disclosure Schedules lists all material unregistered trademarks and service marks owned by the
Company (the “Company Unregistered Intellectual Property Rights”).
(d)
All Company Intellectual Property is fully transferable and licensable by the Company, and following the Closing will be fully
transferable and licensable by the Company, without restriction and without payment of any kind to any third party.
(e)
Each item of Company Intellectual Property, including all Company Registered Intellectual Property Rights and Company Unregistered
Intellectual Property Rights, and all Technology and Intellectual Property Rights licensed to the Company, is free and clear of
any Encumbrances. The Company is the exclusive owner or exclusive licensee of all Company Intellectual Property.
(f)
To the extent that any Technology or Intellectual Property Rights have been developed or created independently or jointly by any
Person other than the Company, including by any consultant or service providers for or on behalf of the Company or for which the
Company has, directly or indirectly, provided consideration for such development or creation, the Company has a written non-disclosure
and intellectual property assignment agreement with such Person with respect thereto, and the Company thereby has obtained ownership
of, and is the exclusive owner of, all such Technology and associated Intellectual Property Rights by operation of law or by valid
assignment, and has required the waiver of all non-assignable rights (including moral rights) and of all claims and demands that
may be associated with such Intellectual Property Rights.
(g)
The Company has not (i) transferred ownership of, or granted any exclusive license of or exclusive right to use, or authorized
the retention of any exclusive rights to use or joint ownership of, any Technology or Intellectual Property Rights that are or
were Company Intellectual Property, to any other Person or (ii) permitted the Company’s rights in any Company Intellectual
Property to enter into the public domain.
(h)
Except for the Technology licensed to the Company pursuant to the in-bound licenses listed in Schedule 3.15(t) of the Disclosure
Schedules and off-the-shelf computer software that is generally and commercially available, all Technology used in or necessary
to the conduct of the business of the Company as presently conducted or currently contemplated to be conducted by the Company
was written and created solely by either (i) employees of the Company acting within the scope of their employment who have validly
and irrevocably assigned all of their rights, including all Intellectual Property Rights therein, to the Company and waived their
right to sue for any moral rights that they may have in any Company Intellectual Property or (ii) by third parties who have validly
and irrevocably assigned all of their rights, including all Intellectual Property Rights therein, to the Company, and no third
party owns or has any rights to any of the Company Intellectual Property and waived any and all claims that they may have in connection
with any non-assignable Intellectual Property Rights, including any moral rights.
(i)
The Company will own or possess sufficient rights to all Technology and Intellectual Property Rights immediately following the
Closing Date that are used in or necessary to the operation of the business of the Company as it currently is conducted or planned
by the Company to be conducted and without infringing on the Intellectual Property Rights of any Person.
(j)
None of the contracts, licenses and agreements pursuant to which the Company licenses any Technology or Intellectual Property
Rights will terminate, or may be terminated by a third party, solely by the passage of time or at the election of a third party
within 120 days after the Closing Date.
(k)
No third party that has licensed Technology or Intellectual Property Rights to the Company has ownership rights or license rights
to improvements or derivative works made by the Company in such Technology or Intellectual Property Rights that have been licensed
to the Company.
(l)
There are no contracts, licenses or agreements between the Company and any other Person with respect to Company Intellectual Property
or other Technology or Intellectual Property Rights used in and/or necessary to the conduct of the business as it is currently
conducted or planned by the Company to be conducted under which there is any dispute regarding the scope of such agreement, or
performance under such agreement including with respect to any payments to be made or received by the Company thereunder.
(m)
The operation of the business of the Company as it has been conducted, is currently conducted and is currently contemplated by
the Company to be conducted has not infringed or misappropriated, does not infringe or misappropriate, and will not infringe or
misappropriate when conducted by the Company following the Closing in the manner currently planned to be conducted, any Intellectual
Property Rights of any Person, violate any right of any Person (including any right to privacy or publicity), or constitute unfair
competition or trade practices under the Laws of any jurisdiction. The Company has not received notice from any Person claiming
that such operation, or any act or Technology of the Company, infringes or misappropriates any Intellectual Property Rights of
any Person or constitutes unfair competition or trade practices under the Laws of any jurisdiction (nor does the Company have
knowledge of any basis therefor).
(n)
Neither this Agreement nor the transactions contemplated by this Agreement, including the assignment to Company by operation of
law or otherwise of any contracts or agreements to which the Company is a party, will result in: (i) the Company granting to any
third party any right to or with respect to any Intellectual Property Rights owned by, or licensed to the Company, (ii) the Company,
being bound by or subject to, any exclusivity obligations, non-compete or other restriction on the operation or scope of its business,
or (iii) the Company being obligated to pay any royalties or other material amounts to any third party in excess of those payable
by any of them, respectively, in the absence of this Agreement or the transactions contemplated hereby.
(o)
To the knowledge of the Company, no Person is infringing or misappropriating or, since the Company’s inception, has infringed
or misappropriated, any Company Intellectual Property.
(p)
The Company has taken all reasonable steps that are required or necessary to protect the Company’s rights in confidential
information and trade secrets of the Company or provided by any other Person to the Company. Without limiting the foregoing, the
Company has, and enforces, a policy requiring each current and former employee, consultant, intern, service provider and contractor
to execute proprietary information, confidentiality and assignment agreements substantially in the Company’s standard forms,
and all current and former employees, consultants, interns, service providers and contractors of the Company have executed such
an agreement in substantially the Company’s standard form.
(q)
No Company Intellectual Property is subject to any proceeding or outstanding decree, order, judgment or settlement agreement or
stipulation that restricts in any manner the use, transfer or licensing thereof by the Company or may affect the validity, use
or enforceability of such Company Intellectual Property.
(r)
No (i) publication of the Company, (ii) material published or distributed by the Company, or (iii) conduct or statement of the
Company constitutes obscene material, a defamatory statement or material, false advertising or otherwise violates any Law.
(s)
Neither the Company nor any Person acting on the Company’s behalf has disclosed, delivered or licensed to any Person, agreed
to disclose, deliver or license to any Person, or permitted the disclosure or delivery to any escrow agent or other Person of
any source code (or any proprietary or confidential information or algorithms related to the source code) owned by the Company
or used in its business (“Company Source Code”). No event has occurred, and no circumstance or condition exists,
that (with or without notice or lapse of time or both) will, or would reasonably be expected to, result in the disclosure or delivery
by or on behalf of the Company of any Company Source Code.
(t)
The Company’s use and distribution of each component of Open Source (including incorporated Open Source) complies with all
provisions of all applicable Open Source license agreements, including all notice and attribution requirements, and in no case
does such use or distribution give rise under such license agreement to any rights in any third parties under any Company Intellectual
Property or obligations for the Company with respect to any Company Intellectual Property, including any obligation to disclose
or distribute any such Technology in source code form, to license any such Technology for the purpose of making derivative works,
or to distribute any such Technology without charge.
3.17
Taxes.
(a)
The Company has duly and timely filed all Tax Returns required to be filed by or with respect to it under applicable Laws, and
all such Tax Returns are true, complete and correct in all material respects and have been prepared in compliance with all applicable
Laws. Seller has made available to Buyer correct and complete copies of all Tax Returns for all Tax periods with respect to which
the statute of limitations has not expired.
(b)
The Company has timely paid all Taxes, including all installments on account of Taxes for the current year, due and owing by it
(whether or not such Taxes are related to, shown on or required to be shown on any Tax Return), and has timely withheld or deducted
and paid over to the appropriate Governmental Authority all Taxes that it is required to withhold or deduct from amounts paid
or owing or deemed paid or owing or benefits given to any employee, equityholder, creditor or other third party.
(c)
No Tax audits or assessments or administrative or judicial proceedings are pending or are threatened in writing with respect to
the Company, and there are no matters under discussion, audit or appeal with any Governmental Authority with respect to Taxes
of the Company.
(d)
There are no liens, other than Permitted Encumbrances, on any of the assets of the Company that arose in connection with any failure
(or alleged failure) to pay any Tax.
(e)
No claim has ever been made by a Governmental Authority in a jurisdiction where the Company does not file Tax Returns that the
Company is or may be subject to taxation by that jurisdiction, which claim has not been resolved. To the knowledge of the Company
and Seller, the Company is not and has not been a resident for Tax purposes in any jurisdiction other than Florida, and is not
and has not had, any branch, agency, permanent establishment or other taxable presence in any such jurisdiction.
(f)
The Company (i) has not been a member of an affiliated group, (ii) does not have any liability for the Taxes of any Person other
than itself under Section 1.1502-6 of the Treasury Regulations (or any similar provision of U.S. state or local or non-U.S. Law),
as a transferee or successor, by contract or otherwise, (iii) is not party to or bound by and does not have any obligations under
any Tax allocation, Tax sharing, Tax indemnification, Tax receivable or other similar contract (other than any such contract entered
into in the ordinary course and the principal purpose of which is not the allocation or sharing of Taxes), and no charge to Tax
will arise to the Company as a result of the Company ceasing to be a member of any affiliated group in connection with this Agreement,
and (iv) is not party to any contract or arrangement to pay, indemnify or make any payment with respect to any Tax liabilities
of any equityholder, member, manager, director, officer or other employee or contractor of the Company.
(g)
The Pre-Closing Taxes of the Company (i) did not, as of the date of the Balance Sheet, exceed the accrued liability for Taxes
(other than any accrued liability for deferred Taxes established solely to reflect timing differences between income for financial
statement purposes and income for Tax purposes) set forth on the face of the Balance Sheet (rather than in any notes thereto)
and (ii) will not exceed that accrued liability as adjusted for operations and transactions (other than the transactions contemplated
by this Agreement) through the Closing Date in accordance with the past custom and practice of the Company in filing its Tax Returns.
(h)
The Company will not be required to include any item of income in, or exclude any item of deduction from, taxable income for any
taxable period (or portion thereof) ending after the Closing Date, including as a result of any (i) change in method of accounting
for a taxable period ending on or prior to the Closing Date, (ii) “closing agreement” as described in Code section
7121 (or any corresponding or similar provision of state, local or non-U.S. income Tax Law) executed on or prior to the Closing
Date, (iii) intercompany transactions or any excess loss account described in Treasury Regulations under Code section 1502 (or
any corresponding or similar provision of state, local or non-U.S. income Tax Law), (iv) installment sale or open transaction
disposition made on or prior to the Closing Date or (v) prepaid amount received on or prior to the Closing Date.
(i)
At all times since formation until the date hereof, the Company was a validly electing C corporation for U.S. federal income tax
purposes.
(j)
The Company has duly and timely collected all amounts on account of any sales, use, or transfer taxes, including goods and services,
harmonized sales and state, provincial or territorial sales taxes, required by applicable Laws to be collected by it and has duly
and timely remitted to the appropriate Governmental Authority any such amounts required by Law to be remitted by it.
3.18
Environmental Matters. The Company (i) has complied in all material respects with all Environmental Laws; (ii) has not
received any written notice of any alleged claim, complaint, violation of, or liability under any Environmental Law (including
any claim or complaint from any employee alleging exposure to Hazardous Materials); (iii) has not disposed of, emitted, discharged,
handled, stored, transported, used or released any Hazardous Materials, arranged for the disposal, discharge, storage or release
of any Hazardous Materials; (iv) has not entered into any agreement that may require it to guarantee, reimburse, pledge, defend,
hold harmless or indemnify any other party with respect to liabilities arising out of Environmental Laws or the Hazardous Materials
related activities of the Company; and (v) has delivered to Buyer or made available for inspection by Buyer and its agents, representatives
and employees all records in the possession or control of the Company concerning the Hazardous Materials activities of the Company
and all environmental audits and environmental assessments of any facility owned, leased or used at any time by the Company conducted
at the request of, or otherwise in the possession or control of the Company. There are no Hazardous Materials in, on, or under
any properties owned, leased or used at any time by the Company which could give rise to any material liability or corrective
or remedial obligation of the Company under any Environmental Laws.
3.19
Material Contracts. The Company is not a party to or bound by any Contract other than those set forth in Schedule 3.18
(such Contracts as are required to be set forth in Schedule 3.18 of the Disclosure Schedules being “Material
Contracts”). Each Material Contract is a legal, valid, binding and enforceable agreement and is in full force and effect
and will continue to be in full force and effect on identical terms immediately following the Closing Date. None of the Company
or, to the knowledge of the Company, any other party is in breach or violation of, or (with or without notice or lapse of time
or both) default under, any Material Contract, nor has the Company received any claim of any such breach, violation or default.
Seller has delivered or made available to Buyer true and complete copies of all Material Contracts, including any amendments thereto.
3.20
Affiliate Interests and Transactions.
(a)
No Related Party of a Seller or the Company: (i) owns or, since the Company’s inception, has owned, directly or indirectly,
any equity or other financial or voting interest in any competitor, supplier, licensor, lessor, distributor, independent contractor
or customer of the Company or its business; (ii) owns or, since the Company’s inception, has owned, directly or indirectly,
or has or has had any interest in any property (real or personal, tangible or intangible) that the Company uses or has used in
or pertaining to the business of the Company; (iii) has or, since the Company’s inception, has had any business dealings
or a financial interest in any transaction with the Company or involving any assets or property of the Company, other than business
dealings or transactions conducted in the ordinary course of business at prevailing market prices and on prevailing market terms;
or (iv) is or, since the Company’s inception, has been employed by the Company.
(b)
Except for this Agreement and certain of the Ancillary Agreements, there are no Contracts by and between the Company, on the one
hand, and any Related Party of a Seller or the Company, on the other hand, pursuant to which such Related Party provides or receives
any information, assets, properties, support or other services to or from the Company (including Contracts relating to billing,
financial, tax, accounting, data processing, human resources, administration, legal services, information technology and other
corporate overhead matters). Immediately subsequent to the Closing, the Company will own or have a valid lease or license to all
assets, properties and rights currently used in the conduct or operation of its business.
(c)
Except as set forth on Schedule 3.19(c) of the Disclosure Schedules, there are no outstanding notes payable to, accounts
receivable from or advances by the Company to, and the Company is not otherwise a debtor or creditor of, and does not have any
liability or other obligation of any nature to, any Related Party of a Seller or the Company. Since the date of the Balance Sheet,
the Company has not incurred any obligation or liability to, or entered into or agreed to enter into any transaction with or for
the benefit of, any Related Party of a Seller or the Company, other than the transactions contemplated by this Agreement and the
Ancillary Agreements.
3.21
Insurance. Schedule 3.20 of the Disclosure Schedules sets forth a true and complete list of all casualty, directors
and officers liability, general liability, product liability and all other types of insurance policies maintained with respect
to the Company, together with the carriers and liability limits for each such policy. All such policies are in full force and
effect and no application therefor included a material misstatement or omission. All premiums with respect thereto have been paid
to the extent due. No Seller has received notice of, nor to the knowledge of the Company is there threatened, any cancellation,
termination, reduction of coverage or material premium increases with respect to any such policy. No claim currently is pending
under any such policy. All material insurable risks in respect of the business and assets of the Company are covered by such insurance
policies and the types and amounts of coverage provided therein are usual and customary in the context of the business and operations
in which the Company is engaged. The activities and operations of the Company have been conducted in a manner so as to conform
in all material respects to all applicable provisions of such insurance policies. The consummation of the transactions contemplated
by this Agreement and the Ancillary Agreements will not cause a cancellation or reduction in the coverage of such policies.
3.22
Bank Accounts, Letters of Credit and Powers of Attorney. Schedule 3.21 of the Disclosure Schedules lists (a) all
bank accounts, lock boxes and safe deposit boxes relating to the business and operations of the Company (including the name of
the bank or other institution where such account or box is located and the name of each authorized signatory thereto), (b) all
outstanding letters of credit issued by financial institutions for the account of the Company (setting forth, in each case, the
financial institution issuing such letter of credit, the maximum amount available under such letter of credit, the terms (including
the expiration date) of such letter of credit and the party or parties in whose favor such letter of credit was issued), and (c)
the name and address of each Person who has a power of attorney to act on behalf of the Company. The Company has heretofore delivered
to Buyer true, correct and complete copies of each letter of credit and each power of attorney described in Schedule 3.21
of the Disclosure Schedules.
3.23
Brokers. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission
in connection with the transactions contemplated hereby based upon arrangements made by or on behalf of any Seller or the Company.
3.24
Investment Representations.
(a)
The Share Consideration, Warrants and, upon exercise of the Warrants, the Warrant Shares, are being obtained by Seller for its
own account for investment purposes, and not with a view to any distribution thereof in violation of any applicable securities
Laws (this representation and warranty not limiting Seller’s right to sell any securities pursuant to the Registration Statement
or otherwise in compliance with applicable federal and state securities laws). Seller is fully capable of understanding and evaluating
the risks associated with the ownership of the Share Consideration, Warrants. Seller understands and acknowledges that the securities
comprising the Share Consideration, Warrants and Warrants Shares to be received hereunder are “restricted securities”
under the United States federal securities Laws inasmuch as they are being acquired from Company in a transaction not involving
a public offering and that, under such Laws and applicable regulations, such securities may be resold without registration under
the applicable United States securities Laws only in certain limited circumstances.
(b)
Neither Seller nor the Company own any shares of the Buyer Common Stock immediately prior to the Closing.
(c)
At the time Seller began to negotiate this Agreement it was, and as of the date hereof it is, and on each date on which it exercises
any Warrants, it will be, an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8)
under the Securities Act.
(d)
Seller, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial
matters so as to be capable of evaluating the merits and risks of the prospective investment in the Share Consideration, Warrants
and Warrant Shares, and has so evaluated the merits and risks of such investment. Seller is able to bear the economic risk of
an investment in the Share Consideration, Warrants and Warrant Shares and, at the present time, is able to afford a complete loss
of such investment.
(e)
Seller acknowledges that it has had the opportunity to review the this Agreement and the Ancillary Agreements (including all exhibits
and schedules thereto) and the SEC Documents and has been afforded, (i) the opportunity to ask such questions as it has deemed
necessary of, and to receive answers from, representatives of Buyer concerning the terms and conditions of the offering of the
Share Consideration, Warrants and Warrant Shares and the merits and risks of investing in the Share Consideration, Warrants and
Warrant Shares; (ii) access to information about Buyer and its financial condition, results of operations, business, properties,
management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional
information that Buyer possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment
decision with respect to the investment. Seller acknowledges and agrees that neither Buyer nor any Affiliate of Buyer has provided
Seller with any information or advice with respect to the Share Consideration, Warrants and Warrant Shares nor is such information
or advice necessary or desired. Neither Buyer nor any of its Affiliates has made or makes any representation as to Buyer or the
quality of the securities constituting the Share Consideration, Warrants and Warrant Shares.
(f)
Other than consummating the transactions contemplated hereunder, Seller has not, nor has any Person acting on behalf of or pursuant
to any understanding with Seller, directly or indirectly executed any purchases or sales, including Short Sales, of the securities
of Buyer during the period commencing as of the time that Seller first received a term sheet (written or oral) from Buyer or any
other Person representing Buyer setting forth the material terms of the transactions contemplated hereunder and ending immediately
prior to the execution hereof. Other than to other Persons party to this Agreement or to Seller’s representatives, including
its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, Seller has maintained the confidentiality
of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude
any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.
(g)
Seller is not purchasing the Share Consideration, Warrants or Warrant Shares as a result of any advertisement, article, notice
or other communication regarding such securities or Buyer published in any newspaper, magazine or similar media or broadcast over
television or radio or presented at any seminar or, to the knowledge of Seller, any other general solicitation or general advertisement.
(h)
Seller acknowledges and agrees that neither Buyer nor its Affiliates or their respective Representatives have made and is not
making any representations or warranties whatsoever regarding the subject matter of this Agreement or its business or the Share
Consideration, Warrants or Warrants Shares, express or implied, except those specifically contained in Article IV below, and Seller
hereby represents and warrants to Buyer that Seller is not relying and has not relied on any representations or warranties whatsoever
regarding the subject matter of this Agreement or its business or the Share Consideration, Warrants or Warrants Shares, express
or implied, except those specifically contained in Article IV below. Seller further understands and acknowledges that Buyer is
in possession of information about Buyer and its securities (which may include material non-public information) that may or may
not be material or superior to information available to Seller, and Seller has specifically requested that it not be provided
with any such information. Seller acknowledges that it is entering this Agreement and, if it exercises any Warrants, it is doing
so without any reliance on Buyer. Seller and Buyer understand and acknowledge that neither party would enter into this Agreement
in the absence of the representations and warranties set forth in this paragraph, and that these representations and warranties
are a fundamental inducement to the parties in entering into this Agreement. Seller hereby waives any claim, or potential claim,
it has or may have against Buyer relating to Buyer’s possession of material non-public information. Seller has independently
participated in the negotiation of this Agreement and has been represented by separate counsel. In connection with Seller’s
entry into this Agreement, neither Buyer nor its counsel is advising Seller on any aspects of law, including compliance with Sections
13 and 16 under the Exchange Act or Section 5 of the Securities Act and the exemptions thereunder.
(i)
Neither the Company nor Seller is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i)
to (viii) under the Securities Act (a “Disqualification Event”).
Article
IV
REPRESENTATIONS AND WARRANTIES OF THE BUYER
Buyer
hereby represents and warrants to Seller as follows:
4.1
Organization. Buyer is a corporation duly organized, validly existing and in good standing under the Laws of the State
of Florida and has full corporate power and authority to own, lease and operate its properties and to carry on its business as
it is now being conducted.
4.2
Authority. Buyer has full corporate power and authority to execute and deliver this Agreement and each of the Ancillary
Agreements to which it will be a party, to perform its obligations hereunder and thereunder and to consummate the transactions
contemplated hereby and thereby. The execution, delivery and performance by Buyer of this Agreement and each of the Ancillary
Agreements to which it will be a party and the consummation by Buyer of the transactions contemplated hereby and thereby have
been duly and validly authorized by all necessary corporate action. This Agreement has been, and upon their execution each of
the Ancillary Agreements to which Buyer will be a party will have been, duly executed and delivered by Buyer and, assuming due
execution and delivery by each of the other parties hereto and thereto, this Agreement constitutes, and upon their execution each
of the Ancillary Agreements to which Buyer will be a party will constitute, the legal, valid and binding obligations of Buyer,
enforceable against Buyer in accordance with their respective terms, except as enforcement may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general principles of
equity (regardless of whether considered in a proceeding in equity or at law).
4.3
No Conflict; Required Filings and Consents.
(a)
The execution, delivery and performance by Buyer of this Agreement and each of the Ancillary Agreements to which Buyer will be
a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not:
(i)
conflict with or violate the certificate of incorporation or bylaws of Buyer;
(ii)
conflict with or violate any Law applicable to Buyer; or
(iii)
result in any breach of, constitute a default (or an event that, with notice or lapse of time or both, would become a default)
under or require any consent of any Person pursuant to, any note, bond, mortgage, indenture, agreement, lease, license, permit,
franchise, instrument, obligation or other Contract to which Buyer is a party;
except
for any such conflicts, violations, breaches, defaults or other occurrences that, individually or in the aggregate, are not expected
to have a Material Adverse Effect on Buyer.
(b)
Other than with regard to obtaining Shareholder Approval and the filing of Registration Statement as contemplated by this Agreement,
Buyer is not required to file, seek or obtain any notice, authorization, approval, order, permit or consent of or with any Governmental
Authority in connection with the execution, delivery and performance by Buyer of this Agreement and each of the Ancillary Agreements
to which it will be party or the consummation of the transactions contemplated hereby or thereby, except for such filings as may
be required by any applicable federal or state securities or “blue sky” Laws.
4.4
Brokers. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission
in connection with the transactions contemplated hereby based upon arrangements made by or on behalf of Buyer.
4.5
Investment Intent. Buyer is acquiring the Shares for its own account for investment purposes only and not with a view to
any public distribution thereof or with any intention of selling, distributing or otherwise disposing of the Shares in a manner
that would violate the registration requirements of the Securities Act. Buyer acknowledges that the Shares are not registered
under the Securities Act or any state securities laws, and that the Shares may not be transferred or sold except pursuant to the
registration provisions of the Securities Act or pursuant to an applicable exemption therefrom and subject to state securities
laws and regulations, as applicable.
4.6
SEC Filings.
(a)
All reports, schedules, forms, registration statements and other documents required to be filed by Buyer with the SEC pursuant
to the Exchange Act since January 1, 2019, as amended prior to the date of this Agreement (together with any documents furnished
during such period by Buyer to the SEC on a voluntary basis on Current Reports on Form 8-K and any reports, schedules, forms and
other documents filed with the SEC pursuant to the Exchange Act subsequent to the date hereof, collectively, the “SEC
Documents”), have been filed and complied in all material respects with, to the extent in effect at the time of filing,
the requirements of the Exchange Act applicable to such SEC Documents. The SEC Documents, when read together, do not contain and
will not contain, any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances under which they were made, not misleading. As of the date
of this Agreement, there are no outstanding or unresolved comments received from the SEC or its staff with respect to the SEC
Documents.
(b)
The financial statements of Buyer included or incorporated by reference in the SEC Documents comply, as of their respective dates
and, if amended, as of the date of the last such amendment, in all material respects with applicable accounting requirements and
the published rules and regulations of the SEC with respect thereto, have been prepared in accordance with GAAP applied on a consistent
basis during the periods involved (except as may be indicated in the notes thereto) and fairly present, in all material respects,
the consolidated financial position of Buyer and its Subsidiaries as of the dates thereof and the consolidated results of their
operations and cash flows for the periods then ended (subject, in the case of unaudited quarterly statements, to normal year-end
audit adjustments, the absence of notes and other adjustments described therein).
(c)
Buyer does not have pending before the SEC any request for confidential treatment of information.
(d)
Buyer has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Buyer Common Stock under the Exchange Act nor has Buyer received any notification that the SEC is contemplating terminating
such registration.
(e)
As of the date hereof, Buyer is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance
in all material respects with all listing and maintenance requirements for any trading market on which the Buyer Common Stock
is listed or quoted (including the NYSE American).
4.7
Legal Proceedings. There are no actions, suits, claims, investigations or other legal proceedings pending or, to Buyer’s
knowledge, threatened against or by Buyer or any Affiliate of Buyer that would materially impair the ability of Buyer to consummate
the transactions contemplated by this Agreement.
4.8
Issuance of Share Consideration. The Share Consideration is, and upon exercise of the Warrant Shares when issued in accordance
with the terms of the Warrants and this Agreement, the Warrant Shares will be, duly authorized and validly issued, fully paid,
nonassessable and owned of record and beneficially by Seller. At the Closing, with regard to the Share Consideration, and upon
exercise of the Warrants and the payment of the exercise price set forth therein, with regard to the Warrants Shares, Seller shall
acquire good, valid and marketable title to the Share Consideration and Warrant Shares, as applicable, free and clear of any Encumbrance
other than Encumbrances created by Seller or Seller. Subject to Seller’s representations and warranties contained herein,
the Share Consideration, the Warrants and the Warrant Shares will be issued in compliance with all applicable federal and state
securities Laws, other than Laws imposed on Seller. Subject to restrictions provided under applicable Law and as created by or
imposed by Seller, Seller will receive the Share Consideration and Warrants free of any adverse claim, assuming Seller do not
have notice of any adverse claim to the Share Consideration or Warrants. The Company has reserved from its duly authorized capital
stock the maximum number of shares of Buyer Common Stock issuable pursuant to this Agreement and the Warrants.
4.9
Material Changes; Undisclosed Events, Liabilities or Developments. Other than as set forth in the SEC Documents filed by
the Company with the SEC, (i) there has been no event, occurrence or development that has had or that could reasonably be expected
to result in a Material Adverse Effect, (ii) Buyer has not incurred any liabilities (contingent or otherwise) other than (A) trade
payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not
required to be reflected in Buyer’s financial statements pursuant to GAAP or disclosed in filings made with the SEC, (iii)
Buyer has not altered its method of accounting and (iv) Buyer has not declared or made any dividend or distribution of cash or
other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital
stock. The Company does not have pending before the SEC any request for confidential treatment of information.
4.10
Sarbanes-Oxley; Internal Accounting Controls. Buyer and the Subsidiaries are in compliance with any and all applicable
requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and
regulations promulgated by the SEC thereunder that are effective as of the date hereof and as of the Closing Date. Buyer and the
Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions
are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary
to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets
is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability
for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.
Buyer and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) for Buyer and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required
to be disclosed by Buyer in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported,
within the time periods specified in the SEC’s rules and forms. Buyer’s certifying officers have evaluated the effectiveness
of the disclosure controls and procedures of Buyer and the Subsidiaries as of the end of the period covered by the most recently
filed periodic report under the Exchange Act (such date, the “Evaluation Date”) . Buyer presented in its most recently
filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure
controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes
in the internal control over financial reporting (as such term is defined in the Exchange Act) of Buyer and its Subsidiaries that
have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of Buyer
and its Subsidiaries.
4.11
Investment Company. Buyer is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940,
as amended. Buyer shall conduct its business in a manner so that it will not become an “investment company” subject
to registration under the Investment Company Act of 1940, as amended.
4.12
Listing and Maintenance Requirements. The Buyer Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange
Act, and Buyer has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Buyer Common Stock under the Exchange Act nor has Buyer received any notification that the SEC is contemplating terminating
such registration. Buyer has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which
the Buyer Common Stock is or has been listed or quoted to the effect that Buyer is not in compliance with the listing or maintenance
requirements of such Trading Market. Buyer is. The Common Stock is currently eligible for electronic transfer through the Depository
Trust Company or another established clearing corporation and Buyer is current in payment of the fees to the Depository Trust
Company (or such other established clearing corporation) in connection with such electronic transfer.
Article
V
COVENANTS
5.1
Non-Competition; Non-Solicitation.
(a)
For a period of five years following the Closing (the “Restricted Period”), Seller shall not, and he shall
cause his Affiliates not to, directly or indirectly through any Person or contractual arrangement:
(i)
(A) serve as a partner, principal, licensor, licensee, employee, consultant, officer, director, manager, agent, representative,
advisor, promoter, associate, or investor for, (B) directly or indirectly, own, purchase, organize, or take preparatory steps
for the organization of, or (C) build, design, finance, acquire, lease, operate, manage, control, invest in, work or consult for
or otherwise join, participate in or affiliate himself/herself with, any business whose business, products or operations are in
any respect competitive with any Competitive Business; provided, that the foregoing covenant shall cover Seller’s
activities in every part of the Territory and “Territory” shall mean (x) all counties in the State of Florida;
(y) all states, districts, and territories of the United States of America; and (z) all other countries of the world;
(ii)
solicit, recruit or hire any person who at any time on or after the date of this Agreement is a Company Group Employee (as hereinafter
defined); provided, that the foregoing shall not prohibit (A) a general solicitation to the public of general advertising
or similar methods of solicitation by search firms not specifically directed at Company Group Employees or (B) Seller or any of
their Affiliates from soliciting, recruiting or hiring any Company Group Employee who has ceased to be employed or retained by
the Company, Buyer or any of their respective Affiliates for at least 12 months (provided, that such Company Group Employee
is not otherwise prohibited from being employed by Seller or its Affiliates). For purposes of this Section 5.1, “Company
Group Employees” means, collectively, officers, directors and employees of the Company, Buyer and their respective Affiliates
and persons acting under any management, service, consulting, distribution, dealer or similar contract with respect to the Company
or Buyer;
(iii)
approach or seek Business from any Customer (as hereinafter defined), refer Business from any Customer to any Person or be paid
commissions based on Business sales received from any Customer by any Person other than on behalf of Buyer or any of its Affiliates.
For purposes of this Section 5.1(a)(iii), the term “Customer” means any Person to which Seller, the Company,
Buyer or any of the Affiliates of Seller or the Company provided products or services during the 12-month period prior to the
time at which any determination shall be made that any such Person is a Customer; provided, that the foregoing shall not
prohibit any referral of Business by Seller, or the Company to Buyer or its Affiliates;
(iv)
other than on behalf of Buyer or any of its Affiliates, solicit, encourage, or induce, or cause to be solicited, encouraged or
induced, directly or indirectly, any franchisee, joint venture, supplier, vendor or contractor who conducted business with the
Company at any time during the one-year period preceding the Closing Date to terminate or adversely modify any business relationship
with the Company or Buyer, or not to proceed with, or enter into, any business relationship with the Company or Buyer, nor shall
Seller otherwise interfere with any business relationship between the Company, Buyer, and any such franchisee, joint venture,
supplier, vendor or contractor; or
(v)
disparage Buyer or any of its Affiliates in any way that could adversely affect the goodwill, reputation or business relationships
of Buyer or any of its Affiliates with the public generally, or with any of their customers, suppliers or employees.
(b)
Seller acknowledge that the covenants of Seller set forth in this Section 5.1 are an essential element of this Agreement and that
any breach by Seller of any provision of this Section 5.1 will result in irreparable injury to Buyer. Seller acknowledge that
in the event of such a breach, in addition to all other remedies available at law, Buyer shall be entitled to equitable relief,
including injunctive relief, and an equitable accounting of all earnings, profits or other benefits arising therefrom, as well
as such other damages as may be appropriate. Seller have independently consulted with their counsel and after such consultation
each agrees that the covenants set forth in this Section 5.1 are reasonable and proper to protect the legitimate interest of Buyer.
(c)
If a court of competent jurisdiction determines that the character, duration or geographical scope of the provisions of this Section
5.1 are unreasonable, it is the intention and the agreement of the parties that these provisions shall be construed by the court
in such a manner as to impose only those restrictions on Seller’s conduct that are reasonable in light of the circumstances
and as are necessary to assure to Buyer the benefits of this Agreement. If, in any judicial proceeding, a court shall refuse to
enforce all of the separate covenants of this Section 5.1 because taken together they are more extensive than necessary to assure
to Buyer the intended benefits of this Agreement, it is expressly understood and agreed by the parties that the provisions hereof
that, if eliminated, would permit the remaining separate provisions to be enforced in such proceeding, shall be deemed eliminated,
for the purposes of such proceeding, from this Agreement. The Restricted Period for a Seller shall be extended for a period equal
to any time period that Seller is in violation of Section 5.1(a).
5.2
Release of Obligations. Each of Seller, Erin Henderson and David Zarley, on or prior to the Closing, shall execute and
deliver to Buyer, for the benefit of the Company and Buyer, a general release and discharge, in form and substance satisfactory
to Buyer, releasing and discharging the Company and Buyer from any and all rights, claims, demands arising out, relating to, against,
or in any connected with, the Company in respect of any and all agreements, liabilities or obligations entered into or incurred
on or prior to the Closing Date, including any and all obligations to pay or indemnify Seller, guarantee or secure its obligations
or otherwise hold it harmless pursuant to any agreement or other arrangement entered into prior to the Closing. Additionally,
Seller hereby resigns from all positions held at the Company, including as an officer and director of the Company.
5.3
Transfer of Permits. Prior to the Closing, Seller will duly and validly transfer or cause to be transferred to the Company
without any consideration all Permits that are held in the name of Seller or any of their Affiliates (other than the Company)
on behalf of the Company and used in connection with the business of the Company, and the representations, covenants and agreements
contained herein shall apply to such Permits as if held by the Company on the date hereof.
5.4
Intercompany Arrangements. All intercompany and intracompany accounts or contracts between the Company, on the one hand,
and Seller or his Affiliates (other than the Company), on the other hand, are hereby cancelled without any consideration or further
liability to any party and without the need for any further documentation, immediately prior to the Closing.
5.5
Confidentiality.
(a)
For a period of three years following the Closing Date, Seller shall not, and he shall cause his Affiliates and their respective
Representatives not to, without the prior written consent of Buyer, use for its or their own benefit or divulge or convey to any
third party other than for Buyer’s benefit to Representatives and Affiliates of Buyer, any Confidential Information; provided,
however, that any Seller or its Affiliates may (X) disclose such information to their attorneys and accountants and other
professional advisors who owe a duty of confidentiality to their clients or have undertaken in writing not to disclose such Confidential
Information to a third party (including as required to enforce Seller’s rights under this Agreement or the Ancillary Agreements)
and (y) furnish such portion (and only such portion) of the Confidential Information as Seller or such Affiliate reasonably determines
it is legally obligated to disclose pursuant to applicable Law if: (i) Seller receives a request to disclose all or any part of
the Confidential Information under the terms of a subpoena, civil investigative demand or order issued by a Governmental Authority;
(ii) to the extent not inconsistent with such request or applicable Law, Seller notifies Buyer of the existence, terms and circumstances
surrounding such request and consults with Buyer on the advisability of taking steps available under applicable Law to resist
or narrow such request so that Buyer may seek, at its sole cost and expense, a protective order or other remedy to limit such
disclosure; and (iii) Seller exercises its commercially reasonable efforts to cooperate and provide reasonable assistance, at
Buyer’s sole cost and expense, to obtain an order or other reliable assurance that confidential treatment will be accorded
to the disclosed Confidential Information. For purposes of this Agreement, “Confidential Information” consists
of all information and data relating to the Company or the transactions contemplated hereby (other than data or information that
is or becomes available to the public other than as a result of a breach of this Section).
(b)
Effective as of the Closing, Seller hereby assigns to Buyer all of Seller’s right, title and interest in and to any confidentiality
agreements entered into by Seller (or their Affiliates or Representatives) and each Person (other than Buyer and its Affiliates
and Representatives) who entered into any such agreement or to whom Confidential Information was provided in connection with a
business combination involving the Company or its Affiliates. From and after the Closing, Seller will take all actions reasonably
requested by Buyer in order to assist in enforcing the rights so assigned. Seller shall use their commercially reasonable efforts
to cause any such Person to return to the Company any documents, files, data or other materials constituting Confidential Information
that were provided to such Person in connection with the consideration of any such business combination.
(c)
Seller shall not issue any such press releases nor otherwise make any public statement regarding this Agreement or the transactions
contemplated hereby without the prior consent of Buyer.
5.6
Consents and Filings; Further Assurances.
(a)
Seller and Buyer agree that, in the event that any consent, approval or authorization necessary or desirable to preserve for the
Company any right or benefit under any lease, license, commitment or other Contract to which the Company is a party is not obtained
prior to the Closing, Seller will, subsequent to the Closing, cooperate with Buyer and the Company in attempting to obtain such
consent, approval or authorization as promptly thereafter as practicable.
(b)
From time to time after the Closing, and for no further consideration, each of the parties shall, and shall cause its Subsidiaries
to, execute, acknowledge and deliver such assignments, transfers, consents, assumptions and other documents and instruments and
take such other actions as may be necessary or desirable to consummate and make effective the transactions contemplated by this
Agreement and the Ancillary Agreements.
(c)
Notwithstanding anything herein to the contrary, Buyer shall not be required by this Section to take or agree to undertake any
action, including entering into any consent decree, hold separate order or other arrangement, that would (A) require the divestiture
of any assets of Buyer, the Company or any of their respective Affiliates, (B) limit Buyer’s freedom of action with respect
to, or its ability to consolidate and control, the Company or any of its assets or businesses or any of Buyer’s or its Affiliates’
other assets or businesses or (C) limit Buyer’s ability to acquire or hold, or exercise full rights of ownership with respect
to, the Shares.
5.7
Registration Rights.
(a)
As soon as practicable after the Closing Date and, in any event (subject to Seller’s reasonable opportunity to review and
comment), within thirty (30) days after the Closing Date (but after Seller has had a reasonable opportunity to review and comment
on such Forms S-3), unless otherwise agreed between Buyer and Seller, Buyer shall file a registration statement on Form S-1 or
Form S-3 or such other form under the Securities Act then available to Buyer (each, a “Registration Statement”)
with respect to the resale of the Registrable Securities. Buyer shall use reasonable best efforts to ensure that each such Registration
Statement is declared effective under the Securities Act within ninety (90) days thereafter and promptly notify Seller that such
Registration Statement has been declared effective. After effectiveness of each Registration Statement, Buyer shall use reasonable
best efforts to prepare and file with the SEC such amendments and post-effective amendments to such Registration Statement, such
supplements to the prospectus in such Registration Statement, and such replacement registration statements on Registration Statement,
as may be reasonably requested by Seller or as may be required by the rules, regulations or instructions applicable to Registration
Statement or by the Securities Act or rules and regulations thereunder to keep such Registration Statement effective for the resale
of the Registrable Securities until all Registrable Securities registered thereunder have ceased to be Registrable Securities.
(b)
In connection with each Registration Statement, Buyer shall (i) pay all costs and expenses in connection with such registration
including all registration and filing fees, expenses of any audits incident to or required by any such registration, fees and
expenses of complying with securities and “blue sky” laws, printing expenses and fees and expenses of Buyer’s
counsel and accountants and Financial Industry Regulatory Authority, Inc. filing fees (if any) (other than underwriting discounts
and commissions and the costs of any counsel of a Seller), (ii) use reasonable best efforts to prepare and file with the SEC such
amendments and supplements to such registration statement and the prospectus used in connection with such registration statement
as may be necessary to comply with the provisions of the Securities Act in connection with resales of the Registrable Securities,
(iii) furnish to Seller such numbers of copies of a prospectus and any supplement thereto (in each case including all exhibits
and documents incorporated by reference therein) conforming to the requirements of the Securities Act, and such other documents
as Seller may reasonably request in order to facilitate the disposition of the Registrable Securities, (iv) notify Seller (A)
of any request by the SEC that Buyer amend or supplement such registration statement or prospectus or the issuance by the SEC
of any stop order suspending the effectiveness of such registration statement or the initiation or threatening of any proceeding
for such purpose (and promptly use its reasonable best efforts to prevent the issuance of any stop order or to obtain its withdrawal
at the earliest possible moment if such stop order should be issued), or (B) to cease distribution of the prospectus if the prospectus
included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state
a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances,
and, as soon as reasonably practicable, file with the SEC and furnish to Seller, a supplement or amendment to such prospectus
such that such prospectus will not contain an untrue statement of a material fact or omit to state any fact necessary to make
the statements therein not misleading in light of the circumstances under which they were made, (v) take such further action as
reasonably requested from time to time by Seller, to the extent required to enable Seller to sell the Registrable Securities under
each Registration Statement or pursuant to an exemption provided under the Securities Act (including using its reasonable efforts
to (X) register or qualify such Registrable Securities under such other securities or “blue sky” laws of such U.S.
state jurisdictions as Seller reasonably requests and do any and all other acts and things which may be reasonably necessary or
advisable to enable Seller to consummate the disposition in such U.S. state jurisdictions of the Registrable Securities; provided,
that Buyer shall not be required to qualify generally to do business, subject itself to general taxation or consent to general
service of process in any jurisdiction where it would not otherwise be required to do so but for this Section 5.7(b), and (Y)
cooperate with Seller to facilitate the timely preparation and delivery of certificates representing the Registrable Securities
to be sold pursuant to such Registration Statement or Rule 144 free of any restrictive legends and representing such number of
shares of Common Stock and registered in the names of Seller; provided, that the Company may satisfy its obligations hereunder
without issuing physical stock certificates through the use of The Depository Trust Company’s Direct Registration System);
provided, further, that Seller shall deliver to Buyer such officer certificates and opinions of counsel supporting the removal
of any restrictive legends as Buyer shall reasonably request, and (vi) indemnify and hold harmless Seller, each underwriter, broker
or any other Person acting on behalf of Seller and each other Person, if any, who controls any of the foregoing Persons within
the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, to the fullest extent permitted by Law, from
and against any and all Losses to which any of the foregoing Persons may become subject under the Securities Act or otherwise
caused by, arising from or relating to any untrue statement or alleged untrue statement of a material fact, or any omission or
alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not
misleading in light of the circumstances in which they were made, contained in any such registration statement, prospectus, preliminary
prospectus, free writing prospectus (as defined in Rule 405 promulgated under the Securities Act) or any amendment thereof or
supplement thereto relating to the Registrable Securities, except in each case insofar as such Losses are caused by or related
to any such untrue statement or omission or alleged untrue statement or omission so made based upon information furnished in writing
to Buyer by Seller expressly for use therein (provided, that the provisions set forth in Section 7.4 shall apply to any
indemnification under this Section 5.7(b) mutatis mutandis).
(c)
If, in the judgment of outside counsel to Buyer, the filing, initial effectiveness or continued use of a Registration Statement
would require disclosure of information not otherwise then required by Law to be publicly disclosed and, in the good faith judgment
of the board of directors of Buyer, such disclosure is reasonably likely to adversely affect any material financing, acquisition,
corporate reorganization or merger or other material transaction or event involving Buyer or otherwise have a material adverse
effect on Buyer (a “Valid Business Reason”), Buyer may postpone or withdraw a filing of such Registration Statement,
or delay use of an effective Registration Statement until such Valid Business Reason no longer exists, but in no event shall Buyer
avail itself of such right for more than 45 consecutive days at any one time or 90 days, in the aggregate, in any period of 365
consecutive days; and Buyer shall give notice to Seller of its determination to postpone or withdraw a registration statement
and of the fact that the Valid Business Reason for such postponement or withdrawal no longer exists, in each case, promptly after
the occurrence thereof. In the event Buyer exercises its rights under the preceding sentence, Seller agree to suspend, immediately
upon receipt of the notice referred to above by Seller, its use of the prospectus relating to such Registration Statement in connection
with any sale or offer to sell Registrable Securities.
5.8
NYSE American Required Shareholder Approval. Buyer shall take all action necessary to obtain the Shareholder Approval that
is required by the NYSE American rules in order to permit Seller to exercise its Warrants for Buyer Common Stock as soon as practicable
in accordance with the Warrants, which NYSE American required Shareholder Approval shall be obtained no later than one twenty
days (120) after the Closing Date. Seller covenants that until such time as the NYSE American required Shareholder Approval is
obtained, Seller shall not exercise its Warrants for Buyer Common Stock. Notwithstanding anything contained in this Agreement
to the contrary, unless and until the Shareholder Approval is obtained, in no event shall Buyer be required to issue an aggregate
number of shares of the Buyer Common Stock pursuant to this Agreement (including upon exercise of the Warrants) in excess of 19.99%
of the shares of the Buyer Common Stock as of the date hereof (the “Issuance Limit”).
5.9
Voting. Seller shall vote all of the shares comprising the Share Consideration in favor of any proposals presented to the
shareholders of Seller to approve the exercise of the Warrant for Buyer Common Stock as required by the Trading Market; provided
however, that Seller acknowledges and agrees that any subsequent vote by Seller with respect to the Share Consideration received
at Closing shall be disregarded and not counted by the Company for purposes of determining whether the Shareholder Approval referenced
in Section 5.8 has been obtained. This Agreement is given in consideration of, and as a condition to enter into this Agreement
and is not revocable by Seller.
5.10
Listing of Common Stock. Buyer hereby agrees to use best efforts to maintain the listing or quotation of the Buyer Common
Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, Buyer shall apply to list or quote
all of the Share Consideration on such Trading Market and promptly secure the listing of all of the Share Consideration on such
Trading Market, and, promptly after Shareholder Approval is obtained, Buyer shall apply to list or quote all of the Warrant Shares
on such Trading Market and promptly thereafter secure the listing of all of the Warrant Shares on such Trading Market. Buyer further
agrees, if Buyer applies to have the Buyer Common Stock traded on any other Trading Market, it will then include in such application
all of the Share Consideration and Warrant Shares, and will take such other action as is necessary to cause all of the Share Consideration
and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. Buyer will then take all action
reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects
with Buyer’s reporting, filing and other obligations under the bylaws or rules of the Trading Market. Buyer agrees to maintain
the eligibility of the Buyer Common Stock for electronic transfer through the Depository Trust Company or another established
clearing corporation, including by timely payment of fees to the Depository Trust Company or such other established clearing corporation
in connection with such electronic transfer.
5.11
Form D; Blue Sky Filings. Buyer agrees to timely file a Form D with respect to the Share Consideration, Warrant and Warrant
Shares as required under Regulation D and to provide a copy thereof, promptly upon request of Seller. Buyer shall take such action
as Buyer shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Share Consideration, Warrant
and Warrant Shares for, sale to Sellers at the Closing under applicable securities or “Blue Sky” laws of the states
of the United States, and shall provide evidence of such actions promptly upon request of Seller.
5.12
Board Appointment. Immediately after Closing, the Board of Directors will be expanded by one Person and the Board will
appoint Kim Murphy to fill such vacancy until her successor is duly elected or until her earlier resignation, removal or death.
5.13
Lock-Up. Notwithstanding anything to the contrary, Seller shall not effect any Transfer of any Securities, directly
or indirectly, or engage in any Hedging Activities until the earlier of (i) one-hundred eighty (180) days following the date hereof,
(ii) the public announcement by Buyer that the Company has received funding from BARDA, NIH or any other Governmental Authority
to fully fund the development program for SARS-CoV-2 vaccine, and (iii) such date, after the Registration Statement has been declared
effected by the SEC, that the closing price per share of Buyer Common Stock, as reported on the Trading Market, closes above $2.50.
Any Transfer or attempted Transfer in violation of this Section 5.12 shall, to the fullest extent permitted by applicable Law,
be null and void ab initio. Buyer may make a notation on its records and on any certificates representing the Securities
or give instructions to its Transfer Agents or other registrars for the Securities in order to implement the restrictions on Transfer
set forth in this Agreement. Additionally, from and after the Closing Date, Seller shall and hereby does authorize Buyer to notify
its Transfer Agent that there is a stop transfer order with respect to all Securities (and that this Agreement places limits on
the transfer of the Securities). Seller further agrees to permit Buyer, from and after the Closing, not to register the transfer
of any certificate representing any of the Securities unless such Transfer is made in accordance with the terms of this Agreement.
Article
VI
TAX MATTERS
6.1
Allocation of Taxes for a Straddle Period. For any Straddle Period, Taxes shall be attributable to the portion of such
period ending on the Closing Date in an amount equal to: (A) in the case of any gross receipts, income or similar Taxes, the portion
of such Taxes allocable to the portion of the Straddle Period ending on or before the Closing Date, as determined on the basis
of the deemed closing of the books and records of the Company at the end of the Closing Date (unless otherwise required by applicable
Tax Law) and (B) in the case of any Taxes other than gross receipts, income, or similar Taxes, the Taxes for the entire Straddle
Period multiplied by a fraction the numerator of which is the number of days in the Straddle Period from the beginning of the
Straddle Period through and including the Closing Date and the denominator of which is the number of days in the entire Straddle
Period.
6.2
Tax Returns for Pre-Closing Tax Periods and Straddle Periods.
(a)
Seller, at Seller’s sole cost and expense, shall prepare or cause to be prepared and file or cause to be filed all Tax Returns
of the Company for Pre-Closing Tax Periods that have not been filed as of the Closing Date, and all such Tax Returns shall be
prepared in a manner consistent with past practice with respect to the Company unless otherwise required by applicable Law or
this Agreement. The Parties acknowledge that pursuant to Code Section 1501 and the Treasury Regulations promulgated thereunder,
the Company’s tax year shall close on the Closing Date, and the Company will join the Buyer’s consolidated reporting
group effective the day immediately after the Closing Date. Seller shall provide drafts of each such Tax Return to Buyer for Buyer’s
review and comment at least 30 days prior to the due date for filing such Tax Return (including any applicable extensions), or,
in the case of Tax Returns filed on a more frequent than annual basis, as soon as reasonably practicable but at least five days
prior to the due date for filing such Tax Return. For the avoidance of doubt, any Tax Return that is normally filed on an annual
basis, but that is required to be filed for a period of less than one year due to a termination or other event (e.g., a “stub”
period income Tax Return of the Company for the period ending on the Closing Date) shall not be considered a Tax Return filed
on a more frequent than annual basis. Before filing such Tax Return, Seller shall consider in good faith all comments made in
writing by Buyer. Seller shall pay any Taxes shown to be due on all Tax Returns prepared by Seller.
(b)
Buyer, at Buyer’s sole cost and expense, shall prepare or cause to be prepared and file or cause to be filed all Tax Returns
of the Company for any Straddle Period. Buyer shall provide drafts of each such material Tax Return to Seller for Seller’s
review and comment at least 30 days prior to the due date for filing such Tax Return (including any applicable extensions) or,
in the case of a material Tax Return filed on a more frequent than annual basis, as soon as reasonably practicable but at least
five days prior to the due date for filing such Tax Return. Buyer shall consider in good faith all reasonable comments made by
Seller. Seller shall pay to Buyer the amount of the Taxes with respect to the pre-Closing portion of the Straddle Period for which
Seller is responsible under Section 6.1 within five days following any demand by Buyer for such payment. Buyer shall pay all Taxes
of the Company (other than Pre-Closing Taxes) for Tax periods beginning after the Closing Date and the portion of the Straddle
Period beginning after the Closing Date.
6.3
Other Tax Matters. Without the prior written consent of Seller (which shall not be unreasonably withheld, conditioned or
delayed), unless required by applicable Tax Law, Buyer and the Company shall not, and shall not direct any Person to, (i) make,
amend, revoke or terminate any Tax election or change any accounting practice or procedure of the Company with an effect to any
Pre-Closing Tax Period or the pre-Closing portion of any Straddle Period, (ii) voluntarily approach any Governmental Authority
regarding any Tax or Tax Return of the Company for any Pre-Closing Tax Period or the pre-Closing portion of any Straddle Period,
including entering into any “voluntary disclosure program” with any Governmental Authority, or (iii) consent to any
extension or waiver of the limitation period applicable to any Action regarding any Taxes or Tax Returns of the Company for any
Pre-Closing Tax Period or the pre-Closing portion of any Straddle Period. Subject to the foregoing and solely with respect to
tax periods beginning after the Closing Date, Buyer (and, after the Closing, the Company) shall be entitled to, and shall be in
full control of any decisions with respect to the Taxes or Tax-related affairs of the Company.
6.4
Cooperation on Tax Matters.
(a)
Buyer and the Company, on the one hand, and Seller on the other, shall cooperate fully, as and to the extent reasonably requested
by the other party, in connection with the preparation and filing of any Tax Returns pursuant to this Article VI and any audit
or other proceeding with respect to Taxes. Such cooperation shall include the retention and, upon the other party’s request,
the provision of records and information that are reasonably relevant to any such audit or other Action and making employees available
on a mutually convenient basis to provide additional information and explanation of any material provided hereunder; provided,
that Buyer and the Company shall not be required to provide Seller any affiliated group Tax Return or portion thereof (including
any work papers or related documentation) of Buyer or its Affiliates (other than the Company). Buyer and the Company, on the one
hand, and Seller, on the other hand, agree to retain all books and records with respect to Tax matters pertinent to the Company
relating to any taxable period beginning before the Closing Date for a period of seven years and to abide by all record retention
agreements entered into with any Taxing Authority; provided, that Buyer may dispose of such books and records that are
offered in writing to, but not accepted by, Seller.
(b)
Buyer and Seller further agree, upon request, to use their commercially reasonable efforts to obtain any certificate or other
document from any Governmental Authority or any other Person as may be necessary to mitigate, reduce or eliminate any Transfer
Tax that could be imposed with respect to the transactions contemplated by this Agreement.
6.5
Transfer Taxes. Transfer Taxes shall be paid by Seller when due, and Seller shall, at its own expense, file all necessary
Tax Returns and other documentation with respect to all such Transfer Taxes, and, if required by applicable Law, Buyer shall,
and shall cause the Company and their Affiliates to, join in the execution of any such Tax Returns and other documentation.
6.6
Tax Contests.
(a)
After the Closing, each of Buyer and Seller shall promptly notify the other in writing of the proposed assessment or the commencement
of any Tax audit or administrative or judicial proceeding or of any demand or claim with respect to Taxes relating to the Company,
of which such party has been informed in writing by any Governmental Authority, which, if determined adversely to the taxpayer
or after the lapse of time, could be grounds for indemnification under this Agreement. Such notice shall contain factual information
(to the extent known to Seller, Buyer, or the Company) describing the asserted liability for Taxes in reasonable detail and shall
include copies of any notice or other document received from any Governmental Authority in respect of any such asserted liability
for Taxes, provided, that failure to so notify Seller shall not relieve Seller of its obligations hereunder unless and
to the extent Seller is actually and materially prejudiced thereby or to the extent that Seller waives any claims or defenses.
In the case of a Tax audit or administrative or judicial proceeding with respect to the Company (a “Contest”)
that relates to a Pre-Closing Tax Period, Seller shall have the right, at its expense, to control the conduct of such Contest;
provided, that (i) Seller shall diligently prosecute such Contest in good faith, (ii) Seller shall keep Buyer reasonably
informed of the status of developments with respect to such Contest, (iii) Seller shall demonstrate to Buyer in writing Seller’s
financial ability to provide full indemnification to Buyer with respect to such Contest (including the ability to post any bond
required by the court or adjudicative body before which such Contest is taking place), (iv) Seller shall, subject to the limitations
set forth herein, agree in writing to be fully responsible for all losses relating to such Contest, (v) Seller shall not settle,
discharge, or otherwise dispose of any such Contest without the prior written consent of Buyer, which shall not be unreasonably
withheld, conditioned, or delayed, and (vi) Buyer, at its own expense, shall have the right to fully participate in any such Contest.
(b)
Buyer shall control and shall have the right to discharge, settle, or otherwise dispose of, at its own expense, all other Contests.
(c)
To the extent of any inconsistency between this Section 6.6 and any other provision of this Agreement, this Section 6.6 shall
control.
Article
VII
INDEMNIFICATION
7.1
Survival.
(a)
The representations and warranties of Seller and Buyer contained in this Agreement and the Ancillary Agreements and any schedule,
certificate or other document delivered pursuant hereto or thereto or in connection with the transactions contemplated hereby
or thereby shall survive the Closing for a period of two years following the Closing Date; provided, however, that:
(i)
the representations and warranties set forth in Sections 3.1 and 4.1 relating to organization and existence, Sections 3.2 and
4.2 relating to authority, Section 3.4 relating to the Shares, Section 3.5 relating to capitalization, Section 3.6 relating to
equity interest, Section 3.7 relating to financial statements and undisclosed liabilities, Section 3.13 relating to assets, Section
3.18 relating to Material Contracts and Sections 3.22 and 4.4 relating to broker’s fees and finder’s fees (Sections
3.1, 3.2, 3.4, 3.5, 3.6, 3.7, 3.13, 3.18, 3.22, 4.1, 4.2 and 4.4 are collectively referred to herein as the “Fundamental
Representations”), and any representation in the case of Fraud, shall survive indefinitely; and
(ii)
the representations and warranties set forth in Section 3.16 relating to Taxes shall survive until the end of the 60th day following
the expiration of the applicable statute of limitations with respect to the Tax liabilities in question (giving effect to any
waiver, mitigation or extension thereof).
(b)
The respective covenants and agreements of Seller and Buyer contained in this Agreement shall survive the Closing until fully
performed in accordance with their terms; provided, however, that (i) the indemnification obligations set forth
in this Article VIII with respect to a claim for indemnification in accordance with this Article VIII shall survive until the
date such claim has been finally resolved and (ii) the covenants and agreements set forth in Article VI shall survive until the
end of the 60th day following the expiration of the applicable statute of limitations with respect to the Tax liabilities in question
(giving effect to any waiver, mitigation or extension thereof).
(c)
None of Seller or Buyer shall have any liability with respect to any representations, warranties, covenants or agreements unless
an Indemnified Party provides notice in writing of an actual or threatened claim, or of discovery of any facts or circumstances
that the Indemnified Party reasonably believes may result in a claim hereunder, to the Indemnifying Party prior to the expiration
of the applicable survival period, if any, for such representation, warranty, covenant or agreement, in which case such representation,
warranty, covenant or agreement shall survive as to such claim until such claim has been finally resolved, without the requirement
of commencing any Action in order to extend such survival period or preserve such claim. For purposes of this Section 7.1, “applicable
statute of limitations” means, with respect to any particular representation, warranty, covenant or agreement, the longest
limitation period that may apply (under any Law) to any claim or action (asserted or brought by any Indemnified Party against
any Indemnifying Party, by any party against any Indemnifying Party or by or against any other Person) that relates in any way
to such representation, warranty, covenant or agreement or that constitutes, gives rise to or relates in any way to any actual
or alleged inaccuracy in or breach of such representation, warranty, covenant or agreement.
7.2
Indemnification by Seller. Seller shall save, defend, indemnify and hold harmless Buyer and its Affiliates (including the
Company) and the respective Representatives, successors and assigns of each of the foregoing from and against, and shall compensate
and reimburse each of the foregoing for, any and all losses, damages, liabilities, deficiencies, claims, interest, awards, judgments,
penalties, costs and expenses (including attorneys’ fees, costs and other out-of-pocket expenses incurred in investigating,
preparing or defending the foregoing) (hereinafter collectively, “Losses”), asserted against, incurred, sustained
or suffered by any of the foregoing as a result of, arising out of or relating to:
(a)
any breach of any representation or warranty made by Seller or Seller contained in this Agreement or any Ancillary Agreement or
any schedule, certificate or other document delivered pursuant hereto or thereto or in connection with the transactions contemplated
hereby or thereby (without giving effect to any limitations or qualifications thereto, including materiality, Material Adverse
Effect or subsequent supplements or updates to the Disclosure Schedules);
(b)
any breach of any covenant or agreement by Seller contained in this Agreement or any Ancillary Agreement or any schedule, certificate
or other document delivered pursuant hereto or thereto or in connection with the transactions contemplated hereby or thereby (including
as a result of the action or failure to act of the Company prior to the Closing); or
(c)
any Pre-Closing Taxes.
7.3
Indemnification by Buyer. Buyer shall save, defend, indemnify and hold harmless Seller and his Affiliates and their respective
Representatives, successors and assigns of each of the foregoing from and against, and shall compensate and reimburse each of
the foregoing for, any and all Losses asserted against, incurred, sustained or suffered by any of the foregoing as a result of,
arising out of or relating to:
(a)
any breach of any representation or warranty made by Buyer contained in this Agreement or any Ancillary Agreement or any schedule,
certificate or other document delivered pursuant hereto or thereto or in connection with the transactions contemplated hereby
or thereby (without giving effect to any limitations or qualifications as to materiality, Material Adverse Effect or other exception
set forth therein); or
(b)
any breach of any covenant or agreement by Buyer contained in this Agreement or any Ancillary Agreement or any schedule, certificate
or other document delivered pursuant hereto or thereto or in connection with the transactions contemplated hereby or thereby.
7.4
Procedures.
(a)
A party seeking indemnification (the “Indemnified Party”) in respect of, arising out of or involving a Loss
or a claim or demand made by any person against the Indemnified Party (a “Third Party Claim”) shall deliver
notice (a “Claim Notice”) in respect thereof to the party against whom indemnity is sought (the “Indemnifying
Party”) with reasonable promptness after receipt by such Indemnified Party of notice of the Third Party Claim, and shall
provide the Indemnifying Party with such information with respect thereto as the Indemnifying Party may reasonably request. The
failure to deliver a Claim Notice, however, shall not release the Indemnifying Party from any of its obligations under this Article
VIII except to the extent that the Indemnifying Party is materially prejudiced by such failure.
(b)
The Indemnifying Party shall have the right to participate in, or by giving written notice to the Indemnified Party within 20
days of receipt of a Claim Notice from the Indemnified Party in respect of such Third Party Claim, to assume the defense thereof
at the expense of the Indemnifying Party (which expenses shall not be applied against any indemnity limitation herein) with counsel
selected by the Indemnifying Party and satisfactory to the Indemnified Party. Notwithstanding the foregoing, the Indemnifying
Party shall not be entitled to assume the defense of (but may still participate in) any Third Party Claim (1) with respect to
Taxes (except to the extent specifically provided in Section 6.6) or (2) for equitable or injunctive relief, any claim that would
impose criminal liability or damages or any claim involving a material customer or supplier of the Indemnified Party, and the
Indemnified Party shall have the right to defend, at the expense of the Indemnifying Party, any such Third Party Claim. The Indemnifying
Party shall be liable for the fees and expenses of counsel employed by the Indemnified Party for any period during which the Indemnifying
Party has failed to assume the defense thereof. If the Indemnifying Party does not expressly elect to assume the defense of such
Third Party Claim within the time period and otherwise in accordance with the first sentence of this Section 7.4(b), the Indemnified
Party shall have the sole right to assume the defense of (although the Indemnifying Party may still participate in) and to settle
such Third Party Claim. If the Indemnifying Party assumes the defense of such Third Party Claim, the Indemnified Party shall have
the right to employ separate counsel and to participate in the defense thereof, subject to the Indemnifying Party’s right
to control the defense thereof in accordance with this Section 7.4, but the fees and expenses of such counsel shall be at the
expense of the Indemnified Party unless (i) the employment of such counsel shall have been specifically authorized in writing
by the Indemnifying Party or (ii) the named parties to the Third Party Claim (including any impleaded parties) include both the
Indemnified Party and the Indemnifying Party, and the Indemnified Party reasonably determines that representation by counsel to
the Indemnifying Party of both the Indemnifying Party and such Indemnified Party may present such counsel with a conflict of interest.
If the Indemnifying Party assumes the defense of any Third Party Claim, it shall have the right, subject to the other provisions
of this Section 7.4, to take such action as it deems necessary to avoid, dispute, defend, appeal or make counterclaims pertaining
to any such Third Party Claim in the name and on behalf of the Indemnified Party and the Indemnified Party shall, at the Indemnifying
Party’s expense, cooperate with the Indemnifying Party in such defense and make available to the Indemnifying Party all
witnesses, pertinent records, materials and information in the Indemnified Party’s possession or under the Indemnified Party’s
control relating thereto as is reasonably required by the Indemnifying Party. If the Indemnifying Party assumes the defense of
any Third Party Claim, the Indemnifying Party shall not, without the prior written consent of the Indemnified Party, enter into
any settlement or compromise or consent to the entry of any judgment with respect to such Third Party Claim if such settlement,
compromise or judgment (i) involves a finding or admission of wrongdoing, (ii) does not include an unconditional written release
by the claimant or plaintiff of the Indemnified Party from all liability in respect of such Third Party Claim, or (iii) imposes
equitable remedies or any obligation on the Indemnified Party other than solely the payment of money damages for which the Indemnified
Party will be indemnified hereunder.
(c)
An Indemnified Party seeking indemnification in respect of, arising out of or involving a Loss or a claim or demand hereunder
that does not involve a Third Party Claim being asserted against or sought to be collected from such Indemnified Party (a “Direct
Claim”) shall deliver a Claim Notice in respect thereof to the Indemnifying Party with reasonable promptness after becoming
aware of facts supporting such Direct Claim, and shall provide the Indemnifying Party with such information with respect thereto
as the Indemnifying Party may reasonably request. The failure to deliver a Claim Notice, however, shall not release the Indemnifying
Party from any of its obligations under this Article VIII except to the extent that the Indemnifying Party is materially prejudiced
by such failure and shall not relieve the Indemnifying Party from any other obligation or liability that it may have to the Indemnified
Party or otherwise than pursuant to this Article VIII. If the Indemnifying Party does not notify the Indemnified Party within
20 days following its receipt of a Claim Notice in respect of a Direct Claim that the Indemnifying Party disputes its liability
to the Indemnified Party hereunder, such Direct Claim specified by the Indemnified Party in such Claim Notice shall be conclusively
deemed a liability of the Indemnifying Party hereunder and the Indemnifying Party shall, subject to the other provisions of this
Article VIII, pay the amount of such liability to the Indemnified Party on demand. During such 20-day period, the Indemnified
Party shall use commercially reasonable efforts to allow the Indemnifying Party reasonable access, during normal business hours
and upon reasonable prior notice, to such information as may be reasonably requested by the Indemnifying Party for purposes of
investigating the Direct Claim (provided, however, that failure to provide such access shall not release the Indemnifying
Party from any of its obligations under this Article VIII).
(d)
The Indemnifying Party shall not be entitled to require that any action be made or brought against any other Person before action
is brought or claim is made against it hereunder by the Indemnified Party.
(e)
Subject to the other provisions of this Article VIII, including the limits on indemnification set forth in Section 7.5, the indemnification
required hereunder in respect of a Third Party Claim or a Direct Claim shall be made by prompt payment by the Indemnifying Party
of the amount of actual undisputed Losses in connection therewith within five Business Days after such Loss is agreed to by the
Indemnifying Party or finally adjudicated to be payable pursuant to this Article VIII.
(f)
Notwithstanding the provisions of Section 8.9, each Indemnifying Party hereby consents to the nonexclusive jurisdiction of any
court in which an Action in respect of a Third Party Claim is brought against any Indemnified Party for purposes of any claim
that an Indemnified Party may have under this Agreement with respect to such Action or the matters alleged therein and agrees
that process may be served on each Indemnifying Party with respect to such claim anywhere.
7.5
Limits on Indemnification. Notwithstanding anything to the contrary contained in this Agreement:
(a)
an Indemnifying Party shall not be liable for any claim for indemnification pursuant to Section 7.2(a) or Section 7.3(a), as the
case may be, unless and until the aggregate amount of indemnifiable Losses which may be recovered from the Indemnifying Party
equals or exceeds $5,000 (the “Basket”), in which case the Indemnifying Party shall be liable for the full
amount of such Losses from the first dollar thereof;
(b)
the maximum aggregate amount of indemnifiable Losses which may be recovered from an Indemnifying Party arising out of or relating
to the causes set forth in Section 7.2(a) or Section 7.3(a), as the case may be, shall be an amount equal to the Purchase Price
(the “General Cap”); provided, that the Basket and the General Cap shall not apply to Losses arising
out of, or relating to the inaccuracy or breach of, any Fundamental Representation or to any representation or warranty in the
event of Fraud;
7.6
Remedies Not Affected by Investigation, Disclosure or Knowledge. If the transactions contemplated hereby are consummated,
Buyer expressly reserves the right to seek indemnity or other remedy for any Losses arising out of or relating to any breach of
any representation, warranty or covenant contained herein, notwithstanding any investigation by, disclosure to, knowledge or imputed
knowledge of Buyer or any of its Representatives in respect of any fact or circumstance that reveals the occurrence of any such
breach, whether before or after the execution and delivery hereof.
7.7
Tax Matters. In the event of a conflict between the provisions of Article VI and this Article VIII, the provisions of Article
VI shall control. All indemnification payments made under this Agreement shall be treated as an adjustment to the purchase price
for Tax purposes, unless otherwise required by applicable Law.
7.8
Right of Set-off. Subject to the General Cap, the Basket and the other provisions of this Article VIII, Buyer shall have
the right to withhold and set-off against the Additional Cash Consideration the amount of any Losses (the “Set-off Amount”)
that Seller may be reasonably required to pay under Section 7.2 pursuant to any good faith claim for indemnification made by an
Indemnified Party; provided, that (i) Buyer shall deliver to Seller a notice (a “Set-off Notice”) specifying
in reasonable detail the nature and dollar amount of the Losses and the Set-off Amount and (ii) to the extent the claims set forth
in the Set-off Notice are finally resolved in the favor of Seller (whether by mutual agreement of Buyer and Seller or by final
non-appealable order of an arbitration panel or court of competent jurisdiction), Buyer shall within five Business Days thereafter
pay the portion of the Set-off Amount resolved in the favor of Seller to Seller. If any amounts otherwise payable under this Agreement
are so set-off, the amount of such set-off shall be treated as an adjustment to the Purchase Price once finally determined to
be required to be paid to an Indemnified Party under Section 7.2.
7.9
Exclusive Remedy. Following the Closing, the parties acknowledge and agree that their sole and exclusive remedy with respect
to any and all claims for any breach of any representation, warranty, covenant, agreement or obligation set forth herein or otherwise
relating to the subject matter of this Agreement, shall be pursuant to the indemnification provisions set forth in this Article
VIII, except for (a) claims for Fraud, in any which case the parties will have all rights and remedies available under this Agreement
and available under any Law or (b) actions for specific performance, injunctive relief of other equitable relief pursuant to Section
8.11. In furtherance of the foregoing, other than as set forth in this Section 7.9, following the Closing, each party hereby waives,
to the fullest extent permitted under Law, any and all rights, claims and causes of action for any breach of any representation,
warranty, covenant, agreement or obligation set forth herein or otherwise relating to the subject matter of this Agreement it
may have against the other parties hereto and their Affiliates and each of their respective Representatives arising under or based
upon any Law, except pursuant to the indemnification provisions set forth in this Article VIII. Notwithstanding anything contained
herein to the contrary, nothing in this Section 7.9 shall limit (a) claims for Fraud, in any which case the parties will have
all rights and remedies available under this Agreement and available under any Law or (b) actions for specific performance, injunctive
relief of other equitable relief pursuant to Section 8.11.
Article
VIII
GENERAL PROVISIONS
8.1
Fees and Expenses. Except as otherwise provided herein, all fees and expenses incurred in connection with or related to
this Agreement and the Ancillary Agreements and the transactions contemplated hereby and thereby shall be paid by the party incurring
such fees or expenses, whether or not such transactions are consummated; provided, that if the transactions contemplated
hereby are consummated, Transaction Expenses shall be borne and paid as provided in this Agreement. In the event of termination
of this Agreement, the obligation of each party to pay its own expenses will be subject to any rights of such party arising from
a breach of this Agreement by the other.
8.2
Amendment and Modification. This Agreement may not be amended, modified or supplemented in any manner, whether by course
of conduct or otherwise, except by an instrument in writing specifically designated as an amendment hereto, signed on behalf of
Buyer and Seller.
8.3
Waiver. No failure or delay of any party in exercising any right or remedy hereunder shall operate as a waiver thereof,
nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce
such right or power, or any course of conduct, preclude any other or further exercise thereof or the exercise of any other right
or power. The rights and remedies of the parties hereunder are cumulative and are not exclusive of any rights or remedies which
they would otherwise have hereunder. Any agreement on the part of any party to any such waiver shall be valid only if set forth
in a written instrument executed and delivered by a duly authorized officer on behalf of such party.
8.4
Notices. All notices and other communications hereunder shall be in writing and shall be deemed duly given (a) on the date
of delivery if delivered personally, or if by e-mail, upon written confirmation of receipt by e-mail or otherwise, (b) on the
first Business Day following the date of dispatch if delivered utilizing a next-day service by a recognized next-day courier or
(c) on the earlier of confirmed receipt or the fifth Business Day following the date of mailing if delivered by registered or
certified mail, return receipt requested, postage prepaid. All notices hereunder shall be delivered to the addresses set forth
below, or pursuant to such other instructions as may be designated in writing by the party to receive such notice:
|
if
to Seller, to:
|
Joseph
Hernandez
|
|
|
15
E. Putnam Avenue, Suite 363
Greenwich,
CT 06830
E-mail: Hernandez_Joe@yahoo.com
|
|
if
to Buyer, to:
|
Oragenics,
Inc.
4902
Eisenhower Blvd., Suite 125
|
|
|
Tampa,
FL 33634
Attention:
Dr. Alan Joslyn, Chief Executive Officer and President
E-mail:
ajoslyn@oragenics.com
|
|
|
|
|
|
with
a copy (which shall not constitute notice) to:
|
|
|
|
|
|
Shumaker,
Loop & Kendrick, LLP
101
East Kennedy Boulevard, Ste. 2800
Tampa,
FL 33602
Attention: Mark Catchur
E-mail:
mcatchur@shumaker.com
|
8.5
Interpretation. When a reference is made in this Agreement to a Section, Article, Exhibit or Schedule such reference shall
be to a Section, Article, Exhibit or Schedule of this Agreement unless otherwise indicated. The table of contents and headings
contained in this Agreement or in any Exhibit or Schedule are for convenience of reference purposes only and shall not affect
in any way the meaning or interpretation of this Agreement. All words used in this Agreement will be construed to be of such gender
or number as the circumstances require. Any capitalized terms used in any Exhibit or Schedule but not otherwise defined therein
shall have the meaning as defined in this Agreement. All Exhibits and Schedules annexed hereto or referred to herein are hereby
incorporated in and made a part of this Agreement as if set forth herein. The word “including” and words of similar
import when used in this Agreement will mean “including, without limitation,” unless otherwise specified. The words
“hereof,” “herein” and “hereunder” and words of similar import when used in this Agreement
shall refer to the Agreement as a whole and not to any particular provision in this Agreement. The term “or” is not
exclusive. The word “will” shall be construed to have the same meaning and effect as the word “shall.”
References to days mean calendar days unless otherwise specified.
8.6
Entire Agreement. This Agreement (including the Exhibits and Schedules hereto), the Ancillary Agreements and the Confidentiality
Agreement constitute the entire agreement, and supersede all prior written agreements, arrangements, communications, representations,
warranties and understandings and all prior and contemporaneous oral agreements, arrangements, communications, representations,
warranties and understandings between the parties with respect to the subject matter hereof and thereof. Notwithstanding any oral
agreement or course of conduct of the parties or their Representatives to the contrary, no party to this Agreement shall be under
any legal obligation to enter into or complete the transactions contemplated hereby unless and until this Agreement shall have
been executed and delivered by each of the parties.
8.7
No Third-Party Beneficiaries. Except as provided in Article VIII, nothing in this Agreement, express or implied, is intended
to or shall confer upon any Person other than the parties and their respective heirs, successors and permitted assigns any legal
or equitable right, benefit or remedy of any nature under or by reason of this Agreement.
8.8
Governing Law. This Agreement and all disputes or controversies arising out of or relating to this Agreement or the transactions
contemplated hereby shall be governed by, and construed in accordance with, the internal laws of the State of Florida, without
regard to the laws of any other jurisdiction that might be applied because of the conflicts of laws principles of the State of
Florida.
8.9
Submission to Jurisdiction. Each of the parties irrevocably agrees that any legal action or proceeding arising out of or
relating to this Agreement brought by any party or its successors or assigns against the other party shall be brought and determined
in the Federal courts of the United States of America or the courts of the State of Florida, in each case located in the City
of Tampa and County of Hillsborough, and each of the parties hereby irrevocably submits to the exclusive jurisdiction of the aforesaid
courts for itself and with respect to its property, generally and unconditionally, with regard to any such action or proceeding
arising out of or relating to this Agreement and the transactions contemplated hereby. Each of the parties agrees not to commence
any action, suit or proceeding relating thereto except in the courts described above in Florida, other than actions in any court
of competent jurisdiction to enforce any judgment, decree or award rendered by any such court in Florida as described herein.
Each of the parties further agrees that notice as provided herein shall constitute sufficient service of process and the parties
further waive any argument that such service is insufficient. Each of the parties hereby irrevocably and unconditionally waives,
and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any action or proceeding arising out
of or relating to this Agreement or the transactions contemplated hereby, (a) any claim that it is not personally subject to the
jurisdiction of the courts in Florida as described herein for any reason, (b) that it or its property is exempt or immune from
jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment
prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (c) that (i) the suit,
action or proceeding in any such court is brought in an inconvenient forum, (ii) the venue of such suit, action or proceeding
is improper or (iii) this Agreement, or the subject matter hereof, may not be enforced in or by such courts.
8.10
Assignment; Successors. Neither this Agreement nor any of the rights, interests or obligations under this Agreement may
be assigned or delegated, in whole or in part, by operation of law or otherwise, by (a) Buyer without the prior written consent
of Seller or (b) any Seller without the prior written consent of Buyer, and any such assignment without such prior written consent
shall be null and void; provided, however, that Buyer may assign this Agreement to any Affiliate of Buyer without
the prior consent of Seller; provided further, that no assignment shall limit the assignor’s obligations hereunder.
Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of, and be enforceable by, the parties
and their respective successors and assigns.
8.11
Enforcement. The parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement
were not performed in accordance with their specific terms or were otherwise breached. Accordingly, each of the parties shall
be entitled to specific performance of the terms hereof, including an injunction or injunctions to prevent breaches of this Agreement
and to enforce specifically the terms and provisions of this Agreement, this being in addition to any other remedy to which such
party is entitled at law or in equity. Each of the parties hereby further waives (a) any defense in any action for specific performance
that a remedy at law would be adequate and (b) any requirement under any law to post security as a prerequisite to obtaining equitable
relief.
8.12
Currency; Payments. All references to “dollars” or “$” or “US$” in this Agreement or
any Ancillary Agreement refer to United States dollars, which is the currency used for all purposes in this Agreement and any
Ancillary Agreement. All payments hereunder shall be made by wire transfer of immediately available funds in United States dollars
to such account as may be designated to the payor by the payee at least two Business Days prior to the applicable payment date.
8.13
Severability. Whenever possible, each provision or portion of any provision of this Agreement shall be interpreted in such
manner as to be effective and valid under applicable Law, but if any provision or portion of any provision of this Agreement is
held to be invalid, illegal or unenforceable in any respect under any applicable Law or rule in any jurisdiction, such invalidity,
illegality or unenforceability shall not affect any other provision or portion of any provision in such jurisdiction, and this
Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision
or portion of any provision had never been contained herein.
8.14
Waiver of Jury Trial. EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHT TO A TRIAL BY JURY IN ANY
ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.
8.15
Counterparts. This Agreement may be executed in two or more counterparts, all of which shall be considered one and the
same instrument and shall become effective when one or more counterparts have been signed by each of the parties and delivered
to the other party.
8.16
Facsimile or .pdf Signature. This Agreement may be executed by facsimile or .pdf signature and a facsimile or .pdf signature
shall constitute an original for all purposes.
8.17
Time of Essence. Time is of the essence with regard to all dates and time periods set forth or referred to in this Agreement.
8.18
No Presumption Against Drafting Party. Each of Buyer and Seller acknowledges that each party to this Agreement has been
represented by legal counsel in connection with this Agreement and the transactions contemplated by this Agreement. Accordingly,
any rule of law or any legal decision that would require interpretation of any claimed ambiguities in this Agreement against the
drafting party has no application and is expressly waived.
[The
remainder of this page is intentionally left blank.]
IN
WITNESS WHEREOF, Buyer and Seller have caused this Agreement to be executed as of the date first written above by their respective
officers thereunto duly authorized.
|
BUYER:
|
|
|
|
ORAGENICS,
INC.
|
|
|
|
|
By:
|
/s/
Alan Joslyn
|
|
Name:
|
Alan
Joslyn
|
|
Title:
|
President
and Chief Executive Officer
|
|
|
|
|
SELLER:
|
|
|
|
|
By:
|
/s/
Joseph Hernandez
|
|
|
Joseph
Hernandez, Individually
|
Signature
Page to Purchase Agreement
EXHIBIT
A
Form
of Warrant
EXHIBIT
B
List
Additional Cash Consideration Warrants
●
|
9,545,334
Series 1 Warrants with an exercise price of $0.75
|
|
|
●
|
9,583,334
Series 2 Warrants with an exercise price of $0.90
|
|
|
●
|
4,294,500
Warrants with an exercise price of $1.00
|
APPENDIX
B
THIS
WARRANT AND ANY SHARES ACQUIRED UPON THE EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SUCH ACT AND ANY
APPLICABLE STATE SECURITIES LAWS.
This
Warrant is issued pursuant to that certain Stock Purchase Agreement dated May 1, 2020 by and among the Company and the stockholder
(the “Purchase Agreement”).
No.
2020-1
|
CUSIP:
684023-30 2
|
Oragenics,
INC.
COMMON
STOCK PURCHASE WARRANT
Oragenics,
Inc., a Florida corporation (together with any corporation which shall succeed to or assume the obligations of Oragenics, Inc.
hereunder, the “Company”), hereby certifies that, for value received, Joseph Hernandez (the “Holder”),
or his assigns, is entitled, subject to the terms set forth below, to purchase from the Company at any time during the Exercise
Period (as defined in Section 12 hereof) up to 9,200,000 fully paid and non-assessable shares of Common Stock (as defined in Section
12 hereof), at a purchase price per share equal to the Exercise Price (as defined in Section 12 hereof). The number of shares
of Common Stock for which this Common Stock Purchase Warrant (the “Warrant”) is exercisable and the
Exercise Price are subject to adjustment as provided herein.
1.
DEFINITIONS. Terms defined in the Purchase Agreement and not otherwise defined herein are used herein with the meanings
so defined. Certain terms are used in this Warrant as specifically defined in Section 12 hereof.
2.
EXERCISE OF WARRANT.
2.1.
Exercise. This Warrant may be exercised prior to its expiration pursuant to Section 2.5 hereof by the Holder at any time
prior to the Exercise Period by submitting the form of subscription attached hereto (the “Exercise Notice”)
duly executed by the Holder, to the Company at its principal office, indicating whether the Holder is electing to purchase a specified
number of shares by paying the Aggregate Exercise Price as provided in Section 2.2 or is electing to exercise this Warrant as
to a specified number of shares pursuant to the net exercise provisions of Section 2.3. On or before the first Trading Day following
the date on which the Company has received the Exercise Notice, the Company shall transmit by facsimile an acknowledgement of
confirmation of receipt of the Exercise Notice. This Warrant shall be deemed exercised for all purposes as of the close of business
on the day on which the Holder has delivered the Exercise Notice to the Company. The Aggregate Purchase Price, if any, shall be
paid by wire transfer to the Company within two (2) Business Days of the date of exercise and prior to the time the Company issues
the certificates evidencing the shares issuable upon such exercise. In the event the Warrant is not exercised in full, the Company
may, at its expense, require the Holder, after such partial exercise, to promptly return this Warrant to the Company and the Company
will forthwith issue and deliver to or upon the order of the Holder a new Warrant or Warrants of like tenor, in the name of the
Holder or as the Holder (upon payment by the Holder of any applicable transfer taxes) may request, calling in the aggregate on
the face or faces thereof for the number of shares of Common Stock equal (without giving effect to any adjustment therein) to
the number of such shares called for on the face of this Warrant minus the number of such shares (without giving effect to any
adjustment therein) for which this Warrant shall have been exercised. Notwithstanding the foregoing, if shareholder approval of
the issuance of the Common Stock issuable upon exercise of this Warrant is required under NYSE listing rules, then, until such
shareholder approval is obtained, the Holder shall not be entitled to receive shares of Common Stock upon exercise of the Warrant
to the extent (but only to the extent) that such exercise or receipt would cause a violation of such listing rules.
2.2.
Payment of Exercise Price by Wire Transfer. If the Holder elects to purchase a specified number of shares by paying the
Aggregate Exercise Price, the Holder shall pay such amount by wire transfer of immediately available funds to an account designated
in advance by the Company.
2.3.
Net Exercise. If at any time after the date hereof, there is no effective registration statement registering, or no current
prospectus available for, the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised, in whole
or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number
of Warrant Shares, by receiving shares of Common Stock equal to the number of shares determined pursuant to the following formula:
X
= Y (A - B)
A
where,
|
X
=
|
the
number of shares of Common Stock to be issued to Holder;
|
|
|
|
|
Y
=
|
the
number of shares of Common Stock as to which this Warrant is to be exercised (as indicated on the Exercise Notice);
|
|
|
|
|
A
=
|
the
volume weighted average price of the Common Stock quoted on the NYSE or any other U.S. exchange on which the Common Stock
is listed, whichever is applicable, as posted by Bloomberg L.P. (or such other reference reasonably relied upon by the Company
if not so published) for the five (5) Trading Days ending on the Trading Day immediately preceding the date of exercise; and
|
|
|
|
|
B
=
|
the
Exercise Price.
|
2.4.
Antitrust Notification. If the Holder determines, in its sole judgment upon the advice of counsel, that an exercise of
this Warrant pursuant to the terms hereof would be subject to the provisions of the Hart-Scott-Rodino Antitrust Improvements Act
of 1976, as amended (the “HSR Act”), the Company shall file, within seven (7) Business Days after receiving
notice from the Holder of the applicability of the HSR Act and a request to so file, with the United States Federal Trade Commission
(the “FTC”) and the United States Department of Justice (the “DOJ”) the notification
and report form and any supplemental information required to be filed by it pursuant to the HSR Act in connection with the exercise
of this Warrant. Any such notification and report form and supplemental information will be in full compliance with the requirements
of the HSR Act. The Company will furnish to the Holder promptly (but in no event more than five (5) Business Days) such information
and assistance as the Holder may reasonably request in connection with the preparation of any filing or submission required to
be filed by the Holder under the HSR Act. The Company shall respond promptly after receiving any inquiries or requests for additional
information from the FTC or the DOJ (and in no event more than three (3) Business Days after receipt of such inquiry or request).
The Company shall keep the Holder apprised periodically and at the Holder’s request of the status of any communications
with, and any inquiries or requests for additional information from, the FTC or the DOJ. The Company shall bear all filing or
other fees required to be paid by the Company and the Holder (or the “ultimate parent entity” of the Holder, if any)
under the HSR Act or any other applicable law in connection with such filings and all costs and expenses (including, without limitation,
reasonable attorneys’ fees and expenses) incurred by the Company and the Holder in connection with the preparation of such
filings and responses to inquiries or requests. In the event that this Section 2.4 is applicable to any exercise of this Warrant,
the purchase by the Holder of the Exercise Shares subject to such exercise, and the payment by the Holder of the Exercise Price
therefor, shall be subject to the expiration or earlier termination of the waiting period under the HSR Act (with the exercise
date of this Warrant being deemed to be the date immediately following the date of such expiration or early termination).
2.5.
Termination. This Warrant shall terminate upon the earlier to occur of (i) exercise in full or (ii) the expiration of the
Exercise Period.
3.
REGISTRATION RIGHTS. The Holder of this Warrant has certain rights to require the Company to register its resale of the
Warrant Shares under the Securities Act and any blue sky or securities laws of any jurisdictions within the United States at the
time and in the manner specified in the Purchase Agreement, dated as of May 1, 2020, as amended and in effect from time to time.
4.
DELIVERY OF STOCK CERTIFICATES ON EXERCISE.
4.1.
Delivery of Exercise Shares. As soon as practicable after any exercise of this Warrant and in any event within three (3)
Trading Days thereafter (such date, the “Exercise Share Delivery Date”), the Company shall, at its expense
(including the payment by it of any applicable issue or stamp taxes), cause to be issued in the name of and delivered to the Holder,
or as the Holder may direct, a certificate or certificates evidencing the number of fully paid and nonassessable shares of Common
Stock (or Other Securities, as applicable) (which number shall be rounded up to the nearest whole share in the event any fractional
share may otherwise be issuable upon such exercise) to which the Holder shall be entitled on such exercise, in such denominations
as may be requested by the Holder, which certificate or certificates shall be free of restrictive and trading legends provided
that the shares subject to the Exercise Notice are included in an effective Registration Statement or all applicable requirements
of Rule 144, including the holding period thereof, are met. In lieu of delivering physical certificates for the shares of Common
Stock (or Other Securities) issuable upon any exercise of this Warrant, provided the Company’s transfer agent is participating
in the Depository Trust Company (“DTC”) Fast Automated Securities Transfer (“FAST”)
program or a similar program and either (A) there is an effective registration statement permitting the issuance of the shares
to or resale of the shares by the Holder or (B) the shares are eligible for resale without volume or manner-of-sale limitations
pursuant to Rule 144 (it being understood that if both (A) and (B) are not satisfied, then such shares of Common Stock (or Other
Securities) shall be kept in book entry form by the Company’s transfer agent), upon request of the Holder, the Company shall
cause its transfer agent to electronically transmit such shares of Common Stock (or Other Securities) issuable upon exercise of
this Warrant to the Holder (or its designee), by crediting the account of the Holder’s (or such designee’s) broker
with DTC through its Deposit Withdrawal Agent Commission system (provided that the same time periods herein as for stock certificates
shall apply) as instructed by the Holder (or its designee). The Company understands that a delay in the delivery of the Exercise
Shares after the Exercise Share Delivery Date could result in economic loss to the Holder. As compensation to the Holder for such
loss, the Company agrees to pay (as liquidated damages and not as a penalty) to the Holder for late issuance of Exercise Shares
upon exercise of this Warrant the proportionate amount of $10 per Trading Day (increasing to $20 per Trading Day after the fifth
(5th) Trading Day) after the Exercise Share Delivery Date for each $1,000 of Aggregate Exercise Price for which this Warrant is
exercised which are not timely delivered. The Company shall pay any payments incurred under this Section 4 in immediately available
funds upon demand. Furthermore, in addition to any other remedies which may be available to the Holder, in the event that the
Company fails for any reason to effect delivery of the Exercise Shares by the Exercise Share Delivery Date, the Holder may revoke
all or part of the relevant Warrant exercise by delivery of a notice to such effect to the Company, whereupon the Company and
the Holder shall each be restored to their respective positions immediately prior to the exercise of the relevant portion of this
Warrant, except that the liquidated damages described above shall be payable through the date notice of revocation or rescission
is given to the Company.
4.2.
Compensation for Buy-In on Failure to Timely Deliver Exercise Shares. In addition to any other rights available to the
Holder, if the Company fails to cause its transfer agent to transmit to the Holder Exercise Shares pursuant to an exercise on
or before the Exercise Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open
market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in
satisfaction of a sale by the Holder of the Exercise Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying
(1) the number of Exercise Shares that the Company was required to deliver to the Holder in connection with the exercise at issue
times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Exercise Shares for which such exercise was not honored
(in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would
have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder
purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice
indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount
of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law
or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s
failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.
4.3.
Charges, Taxes and Expenses. Issuance of Exercise Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Exercise Shares, all of which taxes and expenses shall be paid
by the Company, and such Exercise Shares shall be issued in the name of the Holder or in such name or names as may be directed
by the Holder; provided, however, that in the event Exercise Shares are to be issued in a name other than the name
of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed
by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer
tax incidental thereto. The Company shall pay all transfer agent fees required for same-day processing of any Exercise Notice.
5.
ADJUSTMENT FOR DIVIDENDS, DISTRIBUTIONS AND RECLASSIFICATIONS.
5.1.
Distribution of Assets; Spin-Off. If the Company shall declare or make any dividend or other distribution of its assets
(or rights to acquire its assets) to holders of Common Stock, by way of return of capital or otherwise (including, without limitation,
any distribution of cash, stock or other securities, property or options by way of a Spin-Off, dividend, reclassification, corporate
rearrangement or other similar transaction, but excluding cash dividends which are prohibited by Section 5.2 hereof and excluding
stock dividends or stock split adjustments in respect of which are provided for in Section 7 hereof) (a “Distribution”),
at any time on or after the Closing Date (as defined in the Purchase Agreement), then, in each such case:
(a)
(i) the Exercise Price in effect immediately prior to the close of business on the record date fixed for the determination of
holders of Common Stock entitled to receive the Distribution shall be reduced, effective as of the close of business on such record
date, to a price determined by multiplying such Exercise Price by a fraction of which:
(A)
the numerator shall be the Market Price of the Common Stock on the Trading Day immediately preceding such record date minus the
Fair Market Value of the Distribution applicable to one share of Common Stock, and
(B)
the denominator shall be the Market Price of the Common Stock on the Trading Day immediately preceding such record date; and (ii)
the number of Warrant Shares obtainable upon exercise of this Warrant shall be increased to a number of shares equal to the number
of shares of Common Stock obtainable immediately prior to the close of business on the record date fixed for the determination
of holders of Common Stock entitled to receive the Distribution multiplied by the reciprocal of the fraction set forth
in the immediately preceding clause (i) of this Section 5.1(a); and
(b)
Notwithstanding the provisions of the foregoing clause (a), in the event of a Spin-Off in which the Distribution is of common
stock of a subsidiary of the Company, then (i) the Exercise Price in effect immediately prior to the close of business on the
record date fixed for the determination of holders of Common Stock entitled to receive such Distribution shall be reduced, effective
as of the close of business on such record date, to a price determined by multiplying such Exercise Price by a fraction of which:
(A)
the numerator shall be the Market Price of the Common Stock on the Trading Day immediately preceding such record date minus the
Fair Market Value of the Distribution applicable to one share of Common Stock, and
(B)
the denominator shall be the Market Price of the Common Stock on the Trading Day immediately preceding such record date; and (ii)
the Holder shall receive an additional warrant to purchase common stock of such company, the terms of which shall be identical
to those of this Warrant, except that such warrant shall be exercisable into the number of shares of common stock of such company
that would have been issuable or distributed to the Holder of this Warrant pursuant to the Distribution had the Holder exercised
this Warrant for cash for the full number of shares of Common Stock on the face of this Warrant (notwithstanding the requirement
that this Warrant be exercised pursuant to the net exercise provisions of Section 2.3) immediately prior to such record date and
with an exercise price equal to the amount by which the Exercise Price of this Warrant was decreased with respect to the Distribution
pursuant to the terms of the preceding clause (i) of this Section 5.1(b).
5.2.
Cash Dividends. For so long as any Warrants are outstanding, no cash dividend shall be declared or paid or set aside for
payment on any shares of the Company’s Common Stock or any parity or junior stock thereto.
5.3.
Other Events. If any event occurs of the type contemplated by the provisions of this Section 5 but not expressly provided
for by such provisions, then the Company’s board of directors (the “Board of Directors”), acting
in good faith and consistent with their fiduciary duties, shall make an appropriate adjustment in the Exercise Price and the number
of shares of Common Stock obtainable upon exercise of this Warrant so as to protect the rights of the Holder.
6.
ADJUSTMENT FOR REORGANIZATION, CONSOLIDATION, MERGER, ETC.
6.1.
Certain Adjustments. In case at any time or from time to time on or after the Closing Date (as defined in the Purchase
Agreement), the Company shall (i) effect a capital reorganization, reclassification or recapitalization, (ii) consolidate with
or merge into any other Person, or (iii) transfer all or substantially all of its properties or assets to any other Person under
any plan or arrangement contemplating the dissolution of the Company, then in each such case, this Warrant shall thereafter be
exercisable for the same kind and amounts of securities (including shares of stock) or other assets, or both, which were issuable
or distributable to the holders of outstanding Common Stock upon such reorganization, reclassification, recapitalization, consolidation,
merger or transfer, in respect of that number of shares of Common Stock for which this Warrant could have been exercised immediately
prior to such reorganization, reclassification, recapitalization, consolidation, merger or transfer; and, in any such case, appropriate
adjustments (as determined in good faith by the Board of Directors of the Company) shall be made to assure that the provisions
set forth herein shall thereafter be applicable, as nearly as reasonably may be practicable, in relation to any securities or
other assets thereafter deliverable upon the exercise of this Warrant.
6.2.
Continuation of Terms. Upon any reorganization, consolidation, merger or transfer (and any dissolution following any transfer)
referred to in this Section 6, this Warrant shall continue in full force and effect and the terms hereof shall be applicable to
the shares of stock and other securities and property receivable on the exercise of this Warrant after the consummation of such
reorganization, consolidation or merger or the effective date of dissolution following any such transfer, as the case may be,
and shall be binding upon the issuer of any such stock or other securities, including, in the case of any such transfer, the Person
acquiring all or substantially all of the properties or assets of the Company, whether or not such Person shall have expressly
assumed the terms of this Warrant as provided in Section 8 hereof.
7.
ADJUSTMENTS FOR STOCK EVENTS AND ISSUANCE OF OTHER SECURITIES.
7.1.
General. If at any time on or after the Closing Date (as defined in the Purchase Agreement) there shall occur any
stock split, stock dividend, reverse stock split or other subdivision of the Company’s Common Stock (“Stock
Event”), then the number of shares of Common Stock to be received by the Holder shall be appropriately adjusted
such that the proportion of the number of shares issuable hereunder to the total number of shares of the Company (on a fully diluted
basis) prior to such Stock Event is equal to the proportion of the number of shares issuable hereunder after such Stock Event
to the total number of shares of the Company (on a fully-diluted basis) after such Stock Event. The Exercise Price shall be proportionately
decreased or increased upon the occurrence of any Stock Event; provided that in no event will the Exercise Price be less
than the par value of the Common Stock.
7.2.
Other Securities. In case any Other Securities shall have been issued, or shall then be subject to issue upon the conversion
or exchange of any stock (or Other Securities) of the Company (or any other issuer of Other Securities or any other entity referred
to in Section 6 hereof) or to subscription, purchase or other acquisition pursuant to any rights or options granted by the Company
(or such other issuer or entity), the Holder shall be entitled to receive upon exercise hereof such amount of Other Securities
(in lieu of or in addition to Common Stock) as is determined in accordance with the terms hereof, treating all references to Common
Stock herein as references to Other Securities to the extent applicable, and the computations, adjustments and readjustments provided
for in this Section 7 with respect to the number of shares of Common Stock issuable upon exercise of this Warrant shall be made
as nearly as possible in the manner so provided and applied to determine the amount of Other Securities from time to time receivable
on the exercise of the Warrant, so as to provide the Holder with the benefits intended by this Section 7 and the other provisions
of this Warrant.
8.
NO DILUTION OR IMPAIRMENT. The Company will not, by amendment of its Certificate of Incorporation or through any reorganization,
transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek
to avoid the observance or performance of any of the terms of the Warrant, but will at all times in good faith assist in the carrying
out of all such terms and in taking all such action as may be necessary or appropriate in order to protect the rights of the Holder
against dilution. Without limiting the generality of the foregoing, the Company (i) will not increase the par value of any shares
of stock receivable on the exercise of the Warrant above the amount payable therefor on such exercise, (ii) will take all such
action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable
shares of stock on the exercise of the Warrant from time to time outstanding, and (iii) subject to Section 14, will not transfer
all or substantially all of its properties and assets to any other entity (corporate or otherwise), or consolidate with or merge
into any other entity or permit any such entity to consolidate with or merge with the Company (if the Company is not the surviving
entity), unless such other entity shall expressly assume in writing and will be bound by all the terms of this Warrant.
9.
CERTIFICATE AS TO ADJUSTMENTS. In each case of any event that may require any adjustment or readjustment in the shares
of Common Stock issuable on the exercise of this Warrant, the Company at its expense will promptly prepare a certificate setting
forth such adjustment or readjustment, or stating the reasons why no adjustment or readjustment is being made, and showing, in
detail, the facts upon which any such adjustment or readjustment is based, including a statement of (i) the number of shares of
Common Stock then issued and outstanding, and (ii) the number of shares of Common Stock to be received upon exercise of this Warrant,
in effect immediately prior to such adjustment or readjustment and as adjusted and readjusted (if required by Section 7) on account
thereof. The Company will forthwith mail a copy of each such certificate to the Holder, and will, on the written request at any
time of the Holder, furnish to the Holder a like certificate setting forth the calculations used to determine such adjustment
or readjustment.
10.
NOTICES OF RECORD DATE. In the event of:
(a)
any taking by the Company of a record of the holders of any class of securities for the purpose of determining the holders thereof
who are entitled to receive any dividend or other distribution, or any right to subscribe for, purchase or otherwise acquire any
shares of stock of any class or any other securities or property, or to receive any other right; or
(b)
any capital reorganization of the Company, any reclassification or recapitalization of the capital stock of the Company or any
transfer of all or substantially all the assets of the Company to or any consolidation or merger of the Company with or into any
other Person; or
(c)
any voluntary or involuntary dissolution, liquidation or winding-up of the Company. then, and in each such event, the Company
will mail or cause to be mailed to the Holder a notice specifying (i) the date on which any such record is to be taken for the
purpose of such dividend, distribution or right, and stating the amount and character of such dividend, distribution or right,
or (ii) the date on which any such reorganization, reclassification, recapitalization, transfer, consolidation, merger, dissolution,
liquidation or winding-up is anticipated to take place, and the time, if any is to be fixed, as of which the holders of record
of Common Stock (or Other Securities) shall be entitled to exchange their shares of Common Stock (or Other Securities) for securities
or other property deliverable on such reorganization, reclassification, recapitalization, transfer, consolidation, merger, dissolution,
liquidation or winding-up. Such notice shall be mailed at least thirty (30) days prior to the date specified in such notice on
which any such action is to be taken.
11.
RESERVATION OF STOCK ISSUABLE ON EXERCISE OF WARRANT; REGULATORY COMPLIANCE.
11.1.
Reservation of Stock Issuable on Exercise of Warrant. The Company shall at all times while this Warrant shall be outstanding,
reserve and keep available out of its authorized but unissued Common Stock, such number of shares of Common Stock as shall from
time to time be sufficient to effect the exercise of all or any portion of the Warrant Shares (disregarding for this purpose any
and all limitations of any kind on such exercise). The Company shall, from time to time in accordance with the Florida Business
Corporation Act, increase the authorized number of shares of Common Stock or take other effective action if at any time the unissued
number of authorized shares shall not be sufficient to satisfy the Company’s obligations under this Section 11.
11.2
Regulatory Compliance. If any shares of Common Stock to be reserved for the purpose of exercise of the Warrant Shares require
registration or listing with or approval of any Governmental Authority, stock exchange or other regulatory body under any federal
or state law or regulation or otherwise before such shares may be validly issued or delivered upon exercise, the Company shall,
at its sole cost and expense, in good faith and as expeditiously as possible, secure such registration, listing or approval, as
the case may be.
12.
DEFINITIONS. As used herein the following terms, unless the context otherwise requires, have the following respective meanings:
Aggregate
Exercise Price means, in connection with the exercise of this Warrant at any time, an amount equal to the product obtained
by multiplying (i) the Exercise Price times (ii) the number of shares of Common Stock for which this Warrant is being exercised
at such time.
Common
Stock means (i) the Company’s Common Stock, $0.001 par value per share, (ii) any other capital stock of any class or
classes (however designated) of the Company, the holders of which shall have the right, without limitation as to amount, either
to all or to a share of the balance of current dividends and liquidating dividends after the payment of dividends and distributions
on any shares entitled to preference, and (iii) any other securities into which or for which any of the securities described in
clauses (i), or (ii) above have been converted or exchanged pursuant to a plan of recapitalization, reorganization, merger, sale
of assets or otherwise.
Common
Stock Deemed Outstanding means, at any given time, the number of shares of Common Stock actually outstanding at such time,
plus the number of shares of Common Stock issuable at such time upon conversion of any Convertible Securities and Options (other
than this Warrant and any other warrants issued under the Purchase Agreement) then outstanding to the extent such Convertible
Security or Option is (i) convertible, exercisable or exchangeable at such time and (ii) convertible, exercisable or exchangeable
at a price that is less than the Fair Market Value of a share of Common Stock issuable upon such conversion, exercise or exchange
at such time.
Convertible
Securities means any evidences of indebtedness, shares (other than Common Stock) or other securities directly or indirectly
convertible into or exchangeable for Common Stock.
Exchange
Act shall mean the Securities Exchange Act of 1934, as amended from time to time, and the rules and regulations promulgated
thereunder from time to time in effect.
Exercise
Period means the period commencing on the earlier of the following: (i) receipt of notification that the Biomedical
Advanced Research and Development Authority (BARDA) is willing to fund the development program for COVID-19 vaccine, (ii) phase
1 clinical data demonstrating activity (by definition this requires evidence of SARS-COV-2 antibody appearance in blood/serum
in phase 1 subjects who had tested negative for SARS-Cov-2 antibodies prior to receipt of the vaccine), or (iii) one year from
the date of issuance and ending on the fifth (5th) anniversary of the Issue Date.
Exercise
Price means $1.25 per share of Common Stock.
Exercise
Shares means the shares of Common Stock for which this Warrant is then being exercised.
Fair
Market Value means, with respect to any security or other property, the fair market value of such security or other property
as determined unanimously by the Board of Directors, acting in good faith. If the Board of Directors is unable to unanimously
agree to the fair market value, it will have an independent third-party appraisal conducted by a nationally-recognized valuation
company and the determination of such company shall be final.
Governmental
Authority means the government of the United States or any other nation, or of any political subdivision thereof, whether
state or local, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive,
legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including any
supra-national bodies such as the European Union or the European Central Bank).
Issue
Date means May 1, 2020.
Market
Price means, with respect to the Common Stock, on any given day, the closing sale price or, if no closing sale price is reported,
the last reported sale price of the shares of the Common Stock on the New York Stock Exchange on such date. If the Common Stock
is not traded on the New York Stock Exchange on any date of determination, the Market Price of the Common Stock on such date of
determination means the closing sale price as reported in the composite transactions for the principal U.S. national or regional
securities exchange on which the Common Stock is so listed or quoted, or, if no closing sale price is reported, the last reported
sale price on the principal U.S. national or regional securities exchange on which the Common Stock is so listed or quoted, or
if the Common Stock is not so listed or quoted on a U.S. national or regional securities exchange, the last quoted bid price for
the Common Stock in the over-the-counter market as reported by the OTC Markets Group or similar organization, or, if that bid
price is not available, the market price of the Common Stock on that date as determined by a nationally recognized independent
investment banking firm retained by the Company for this purpose.
Option
means any rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or Convertible Securities.
Other
Securities refers to any stock (other than Common Stock) and other securities of the Company or any other entity (corporate
or otherwise) (i) which the Holder at any time shall be entitled to receive, or shall have received, on the exercise of this Warrant,
in lieu of or in addition to Common Stock, or (ii) which at any time shall be issuable or shall have been issued in exchange for
or in replacement of Common Stock or Other Securities, in each case pursuant to Section 5 or 6 hereof.
Person
shall mean and include an individual, a partnership, a joint venture, a corporation, a limited liability company, a trust, an
unincorporated organization and a government or any department or agency thereof.
Principal
Market means, at any time, the securities exchange, quotation system or over-the-counter trading facility on which the Common
Stock is then principally traded or quoted at such time.
Reference
Price means, on any date of determination, the greater of (i) the Market Price per share as of such date and (ii) the Exercise
Price.
Securities
Act means the Securities Act of 1933, as amended from time to time, and the rules and regulations promulgated thereunder from
time to time in effect.
Spin-Off
means a transaction in which the Company spins off or otherwise divests itself of a part of its business or operations or
disposes all or a part of its assets in a transaction in which the Company does not receive compensation for such business,
operations or assets, but causes securities of a subsidiary of the Company or another entity to be distributed or otherwise
issued to security holders of the Company.
Trading
Day means, at any time, a day on which the Principal Market is open for the general trading or quotation of securities and
the Common Stock is traded or quoted thereon without suspension or interruption.
13.
LIMITATION ON BENEFICIAL OWNERSHIP. Notwithstanding anything to the contrary contained herein, the Holder shall not be
entitled to receive shares of Common Stock or Other Securities (together with Common Stock, “Equity Interests”)
upon exercise of the Warrant to the extent (but only to the extent) that such exercise or receipt would cause the Holder Group
to become, directly or indirectly, a “beneficial owner” (within the meaning of Section 13(d) of the Exchange Act and
the rules and regulations promulgated thereunder) of a number of Equity Interests of a class that is registered under the Exchange
Act which exceeds the Maximum Percentage (as defined below) of the Equity Interests of such class that are outstanding at such
time. This limitation on beneficial ownership (a) may be increased, decreased or terminated, in the Holder’s sole discretion,
upon 61 days’ written notice to the Company by the Holder and (b) shall terminate automatically on the date that is 15 days
prior to expiration of the Exercise Period. Any purported delivery of Equity Interests in connection with the exercise of the
Warrant prior to the termination of this restriction in accordance herewith shall be void and have no effect to the extent (but
only to the extent) that such delivery would result in the Holder Group becoming the beneficial owner of more than the Maximum
Percentage of the Equity Interests of a class that is registered under the Exchange Act that is outstanding at such time. If any
delivery of Equity Interests owed to the Holder following exercise of the Warrant is not made, in whole or in part, as a result
of this limitation, the Company’s obligation to make such delivery shall not be extinguished and the Company shall deliver
such Equity Interests as promptly as practicable after the Holder gives notice to the Company that such delivery would not result
in such limitation being triggered or upon termination of the restriction in accordance with the terms hereof. For purposes of
this Section 13, (i) unless modified by the Holder pursuant to the second sentence of this Section 13, the term “Maximum
Percentage” shall mean 19.99%; provided, that if at any time after the date hereof the Holder Group beneficially
owns in excess of 19.99% of any class of Equity Interests in the Company that is registered under the Exchange Act (excluding
any Equity Interests deemed beneficially; and (ii) the term “Holder Group” shall mean the Holder plus
any other Person with which the Holder is considered to be part of a group under Section 13 of the Exchange Act or with which
the Holder otherwise files reports under Sections 13 and/or 16 of the Exchange Act. In determining the number of Equity Interests
of a particular class outstanding at any point in time, the Holder may rely on the number of outstanding Equity Interests of such
class as reflected in (x) the Company’s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q filed with
the Securities and Exchange Commission, as the case may be, (y) a more recent public announcement by the Company or (z) a more
recent notice by the Company or its transfer agent to the Holder setting forth the number of Equity Interests of such class then
outstanding. For any reason at any time, upon written or oral request of the Holder, the Company shall, within two Trading Days
of such request, confirm orally and in writing to the Holder the number of Equity Interests of any class then outstanding. The
provisions of this Section 13 shall be construed, corrected and implemented in a manner so as to effectuate the intended beneficial
ownership limitation herein contained.
14.
TRANSFER OF WARRANT.
14.1.
Transferability. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, subject to compliance with any applicable securities laws, upon surrender of this Warrant at the principal
office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form of
assignment (the “Assignment Notice”) attached hereto duly executed by the Holder or its agent or attorney.
Upon such surrender, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees,
as applicable, and in the denomination or denominations specified in such Assignment Notice, and shall issue to the assignor a
new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. The Warrant,
if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Exercise Shares without having
a new Warrant issued.
14.2.
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 14.1, as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated
the original Issue Date and shall be identical with this Warrant except as to the number of Exercise Shares issuable pursuant
thereto.
15.
LOSS, THEFT, DESTRUCTION OR MUTILATION OF WARRANT. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Exercise
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of this Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.
16.
REMEDIES. The Company stipulates that the remedies at law of the Holder in the event of any default or threatened default
by the Company in the performance of or compliance with any of the terms of this Warrant are not and will not be adequate, and
that such terms may be specifically enforced by a decree for the specific performance of any agreement contained herein or by
an injunction against a violation of any of the terms hereof or otherwise.
17.
NOTICES. All notices and other communications from the Company to the Holder shall be sent by overnight courier (or sent
in the form of a facsimile) at such address as may have been furnished to the Company in writing by the Holder or, until the Holder
furnishes to the Company an address, then to, and at the address of, the last Holder of this Warrant who has so furnished an address
to the Company.
18.
CONSENT TO AMENDMENTS. Any term of this Warrant may be amended, and the Company may take any action herein prohibited,
or compliance therewith may be waived, only if the Company shall have obtained the written consent (and not without such written
consent) to such amendment, action or waiver from the Holder; provided, that if any other holder of Warrants receives any remuneration
or compensation as consideration for any consent, amendment or waiver to its Warrant, then such remuneration or compensation shall
be concurrently delivered, on the same equivalent terms, ratably to the Holder. No course of dealing between the Company and the
Holder nor any delay in exercising any rights hereunder shall operate as a waiver of any rights of the Holder.
19.
MISCELLANEOUS. In case any provision of this Warrant shall be invalid, illegal or unenforceable, or partially invalid,
illegal or unenforceable, the provision shall be enforced to the extent, if any, that it may legally be enforced and the validity,
legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. If any provision
of this Warrant is found to conflict with the Purchase Agreement, the provisions of this Warrant shall prevail. THIS WARRANT SHALL
BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, AND THE RIGHTS OF THE PARTIES SHALL BE GOVERNED BY, THE INTERNAL LAW OF THE STATE
OF FLORIDA, EXCLUDING CHOICE-OF-LAW PRINCIPLES OF THE LAW OF SUCH STATE THAT WOULD PERMIT THE APPLICATION OF THE LAWS OF A JURISDICTION
OTHER THAN SUCH STATE. The headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect
any of the terms hereof.
[Remainder
of Page Intentionally Left Blank]
IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its duly authorized officer.
Dated
as of May 1, 2020
|
ORAGENICS,
INC.
|
|
|
|
|
By:
|
/s/
Alan Joslyn
|
|
|
Alan
Joslyn, Chief Executive Officer and President
|
[Signature
Page to Warrant]
EXERCISE
NOTICE
(To
be signed only on exercise
of
Common Stock Purchase Warrant)
1.
The undersigned Holder of the attached Warrant hereby elects to exercise its purchase right under such Warrant to purchase shares
of Common Stock of Oragenics, Inc., a Florida corporation (the “Company”), as follows (check one or
more, as applicable):
|
[ ]
|
to
exercise the Warrant to purchase __________ shares of Common Stock and to pay the Aggregate Exercise Price therefor by wire
transfer of United States funds to the account of the Company, which transfer has been made prior to or as of the date of
delivery of this Form of Subscription pursuant to the instructions of the Company;
|
|
[ ]
|
to
exercise the Warrant with respect to ____________ shares of Common Stock pursuant to the net exercise provisions specified
in Section 2.3 of the Warrant.
|
2.
Please issue a stock certificate or certificates representing the appropriate number of shares of Common Stock in the name of
the undersigned or in such other name(s) as is specified below:
|
|
Dated:
|
|
(Signature
must conform exactly to name of Holder
as
specified on the face of the Warrant)
|
|
|
|
FORM
OF ASSIGNMENT
(To
be signed only on transfer of Warrant)
For
value received, the undersigned hereby sells, assigns, and transfers unto ____________ the right represented by the within Warrant
to purchase shares of Common Stock of Oragenics, Inc., a Florida corporation, to which the within Warrant relates, and appoints
_______________ attorney to transfer such right on the books of Oragenics, Inc., with full power of substitution in the premises.
|
|
|
[insert name of Holder]
|
|
|
|
|
|
Dated:
|
|
|
By:
|
|
|
|
|
Title:
|
|
|
|
|
|
|
|
|
|
[insert address of Holder]
|
Signed
in the presence of:
|
|
|
|
|
|
COMPOSITE
EXHIBIT C
NOACHIS
TERRA INC.
AUDITED
FINANCIAL STATEMENTS
MARCH
31, 2020
AND
UNAUDITED PRO FORMA
NOACHIS
TERRA INC.
Table
of Contents
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To
the Board of Directors and Stockholders of
Noachis
Terra, Inc.:
We
have audited the accompanying financial statements of Noachis Terra, Inc. (a Delaware corporation), which comprise the balance
sheet as of March 31, 2020, and the related statement of operations, stockholder’s deficit, and cash flows for the years
then ended, and the related notes to the financial statements.
Management’s
Responsibility for the Financial Statements
Management
is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles
generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control
relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due
to fraud or error.
Auditors’
Responsibility
Our
responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance
with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the
audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.
An
audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The
procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of
the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control
relevant to the entity’s preparation and fair presentation of the financial statements in order to design audit procedures
that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s
internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting
policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall
presentation of the financial statements.
We
believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
Opinion
In
our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Noachis
Terra, Inc. as of March 31, 2020, and the results of its operations and its cash flows for the years then ended in accordance
with accounting principles generally accepted in the United States of America.
/s/
Mayer Hoffman McCann P.C.
|
|
Mayer
Hoffman McCann P.C.
|
|
May
26, 2020
Clearwater,
FL
NOACHIS
TERRA INC.
BALANCE
SHEET
|
|
March 31, 2020
|
|
LIABILITIES AND STOCKHOLDER’S DEFICIT:
|
|
|
|
|
Current liabilities
|
|
|
|
|
Accounts payable
|
|
$
|
54,635
|
|
Accounts payable to related party
|
|
|
191,456
|
|
Total current liabilities
|
|
|
246,091
|
|
Total liabilities
|
|
|
246,091
|
|
|
|
|
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
|
Stockholder’s Deficit:
|
|
|
|
|
Common stock, $0.01 par value; 10,000,000 shares authorized; 10,000 shares issued and outstanding as of March 31, 2020
|
|
|
100
|
|
Additional paid-in capital
|
|
|
-
|
|
Accumulated deficit
|
|
|
(246,191
|
)
|
Total stockholder’s deficit
|
|
|
(246,191
|
)
|
TOTAL LIABILITIES AND STOCKHOLDER’S DEFICIT
|
|
$
|
-
|
|
The
accompanying notes are an integral part of these financial statements.
NOACHIS
TERRA INC.
STATEMENT
OF OPERATIONS
|
|
For the period
from March 9, 2020
(inception) through
March 31, 2020
|
|
Operating expenses:
|
|
|
|
|
Research and development
|
|
$
|
41,739
|
|
General and administrative
|
|
|
204,452
|
|
Total operating expenses
|
|
|
246,191
|
|
Loss from operations
|
|
|
(246,191
|
)
|
|
|
|
|
|
Net loss
|
|
$
|
(246,191
|
)
|
|
|
|
|
|
Weighted average common shares outstanding, basic and diluted
|
|
|
10,000
|
|
Net loss per share, basic and diluted
|
|
$
|
(24.62
|
)
|
The
accompanying notes are an integral part of these financial statements.
NOACHIS
TERRA INC.
STATEMENT
OF STOCKHOLDER’S DEFICIT
|
|
For
the period from March 9, 2020 (inception) through March 31, 2020
|
|
|
|
Common
stock
|
|
|
Additional
paid-in
|
|
|
Accumulated
|
|
|
Total
stockholder’s
|
|
|
|
Shares
|
|
|
Amount
|
|
|
capital
|
|
|
Deficit
|
|
|
Deficit
|
|
Balance as of March 9, 2020 (inception)
|
|
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
Issuance of common stock
in exchange for formation costs paid for by stockholder
|
|
|
10,000
|
|
|
|
100
|
|
|
|
-
|
|
|
|
-
|
|
|
|
100
|
|
Net loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(246,191
|
)
|
|
|
(246,191
|
)
|
Balance as of
March 31, 2020
|
|
|
10,000
|
|
|
$
|
100
|
|
|
$
|
-
|
|
|
$
|
(246,191
|
)
|
|
$
|
(246,191
|
)
|
The
accompanying notes are an integral part of these financial statements.
NOACHIS
TERRA INC.
STATEMENT
OF CASH FLOWS
|
|
For the period
from March 9, 2020
(inception) through
March 31, 2020
|
|
Cash flows from operating activities
|
|
|
|
|
Net loss
|
|
$
|
(246,191
|
)
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
|
Issuance of common stock in exchange for formation costs paid for by stockholder
|
|
|
100
|
|
Changes in assets and liabilities:
|
|
|
|
|
Accounts payable
|
|
|
54,635
|
|
Accounts payable to related party
|
|
|
191,456
|
|
Net cash used in operating activities
|
|
|
-
|
|
|
|
|
|
|
Net change in cash and cash equivalents,
|
|
|
-
|
|
Cash and cash equivalents, at the beginning of the period
|
|
|
-
|
|
Cash and cash equivalents, at the end of the period
|
|
$
|
-
|
|
The
accompanying notes are an integral part of these financial statements.
NOACHIS
TERRA INC.
NOTES
TO FINANCIAL STATEMENTS
Note
1—Organization, Plan of Business Operations
Noachis
Terra, Inc. (the “Company”) was formed on March 9, 2020, to focus on the development of a vaccine for the SARS-CoV-2
virus and other strains of coronavirus using patented and patent-pending technology. The Company obtained a nonexclusive license
from National Institutes of Health (“NIH”) for the use of certain patents and tangible materials to be used in the
development and commercialization of a vaccine for the SARS-CoV-2 virus.
The
Company may seek to obtain additional capital through the sale of debt or equity financings or other arrangements to fund its
research and development activities as well as its operations; however, there can be no assurance that the Company will be able
to raise needed capital under acceptable terms, if at all. The sale of additional equity may dilute existing stockholders and
newly issued shares may contain senior rights and preferences compared to currently outstanding shares of common stock. Issued
debt securities may contain covenants and limit the Company’s ability to pay dividends or make other distributions to stockholders.
If the Company is unable to obtain such additional financing, future operations would need to be scaled back or discontinued.
On
May 1, 2020, Oragenics, Inc. a Florida corporation (“Oragenics”), acquired the Company in accordance with the terms
of a Stock Purchase Agreement, dated as of May 1, 2020 (the “Stock Purchase Agreement”), by and among Oragenics, and
Mr. Joseph Hernandez, the sole shareholder of the Company. On May 1, 2020, pursuant to the Stock Purchase Agreement, Oragenics
acquired from Mr. Hernandez one hundred percent (100%) of the issued and outstanding common stock of the Company, and the Company
became a wholly-owned subsidiary of Oragenics.
Note
2—Liquidity, Financial Condition and Management’s Plans
The
Company has had limited operating activities to date, substantially all of which have been devoted to seeking the license with
NIH and start-up activities. The Company has financed its operations since inception using proceeds received from cash advances
from its stockholder.
Notwithstanding,
the Company has no revenues, limited capital resources and is subject to all of the risks and uncertainties that are typical of
an early stage enterprise. Significant uncertainties include, among others, whether the Company will be able to raise the capital
it needs to finance its longer-term operations and whether such operations, if launched, will enable the Company to sustain operations
as a profitable enterprise.
The
Company’s working capital needs are influenced by the level of operations, and generally decrease with higher levels of
revenue. The Company had a working capital deficit of approximately $246,000 at March 31, 2020. The Company expects to incur losses
into the foreseeable future as it undertakes its efforts to execute its business plans.
The
Company will require significant additional capital to sustain its short-term operations and make the investments it needs to
execute its longer-term business plan. The Company’s existing liquidity is not sufficient to fund its operations and anticipated
capital expenditures for the foreseeable future. The Company is currently seeking to obtain additional debt or equity financing,
however there are currently no commitments in place for further financing nor is there any assurance that such financing will
be available to the Company on favorable terms, if at all.
Because
of operating losses, a net operating cash flow deficit, and an accumulated deficit, there is substantial doubt about the Company’s
ability to continue as a going concern for one year from the issuance of the financial statements. The financial statements have
been prepared assuming the Company will continue as a going concern. The Company has not made adjustments to the accompanying
financial statements to reflect the potential effects on the recoverability and classification of assets or liabilities should
the Company be unable to continue as a going concern.
Note
3—Summary of Significant Accounting Policies
Basis
of Presentation
The
Company maintains its books of account and prepares financial statements in accordance with accounting principles generally accepted
in the United States of America (“U.S. GAAP”). The Company’s fiscal year ends on December 31st. The
accompanying financial statements have been prepared in accordance with U.S. GAAP for interim financial information. Accordingly,
since they are interim statements, the accompanying financial statements do not include all of the information and notes required
by U.S. GAAP for annual financial statements, but in the opinion of the Company’s management, reflect all adjustments consisting
of normal, recurring adjustments, that are necessary for a fair presentation of the financial position, results of operations
and cash flows for the interim periods presented. Interim results are not necessarily indicative of results for a full year.
Use
of Estimates
In
preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making
estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company
evaluates its estimates and assumptions.
Income
Taxes
Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax
consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and
their respective tax bases and operating loss and tax credit carryforwards.
Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those
temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in
tax rate is recognized in operations in the period that includes the enactment date. Deferred tax assets are reduced to estimated
amounts expected to be realized by the use of a valuation allowance.
Under
U.S. GAAP, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that
is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not
be recognized if it has less than a 50% likelihood of being sustained. Additionally, U.S. GAAP provides guidance on derecognition,
classification, interest and penalties, accounting for interim periods, disclosure and transition.
Net
loss Per Share
Net
loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the
period. The Company had no securities outstanding during the period presented that could potentially dilute basic loss per share
in the future but were excluded from the computation of diluted net loss per share. Basic and diluted net loss per share amounts
are the same for the period presented.
New
Accounting Pronouncements
The
Company’s management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently
adopted, would have a material effect on the Company’s financial statements.
Note
4—License Acquired
On
March 23, 2020, the Company entered into a worldwide nonexclusive License Agreement (the “Agreement”) with NIH for
the use of certain patents and tangible materials to be used in the development and commercialization of a vaccine for the SARS-CoV-2
virus. Under the terms of the Agreement, the Company was required to pay NIH an upfront nonrefundable fee of $30,000 and reimbursement
of past patent prosecution costs totaling $11,739.
Under
the terms of the Agreement, the Company agreed to pay NIH a fee of $30,000 for each year prior the first commercial sale and $75,000
annually for each year after the first commercial sale. The Company also agrees to pay NIH certain payments ranging from $75,000
to $200,000 for reaching certain milestones identified in planned future clinical trials and approvals. Lastly, the Company agrees
to pay NIH earned royalties of on net sales of the licensed products equal to a range of 0% to 5% of net sales, depending on the
territory of the sale, and significant payments upon achieving cumulative net sales milestones.
In
accordance with ASC 730-10-25-1, Research and Development, costs incurred in obtaining technology licenses are charged
to research and development expense if the technology licensed has not reached technological feasibility and has no alternative
future use. The license purchased by the Company requires substantial completion of research and development, regulatory and marketing
approval efforts in order to reach technological feasibility. As such, the purchase price of the license acquired from NIH was
classified as research and development expenses in the Statements of Operations. This purchase of the license was accounted for
as an asset acquisition pursuant to ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business,
as the majority of the fair value of the assets acquired is concentrated in a group of similar assets, and the acquired assets
did not have outputs or employees.
Note
5—Stockholder’s Deficit
Common
Stock
The
Company has authorized 10,000,000 shares of common stock, $0.01 par value per share, for issuance. Each share of common stock
is entitled to one vote. Common stock owners are entitled to dividends when funds are legally available and declared by the Board.
As of March 31, 2020, the Company had 10,000 shares of common stock issued and outstanding.
Common
Stock Transactions
On
March 10, 2020, the Company issued 10,000 shares of common stock, for $0.01 per share, to its founder in exchange for the founder
incurring $100 of the Company’s formation costs.
Note
6—Commitments and Contingencies
Litigation
The
Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time,
the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.
Note
7—Related Party Transactions
The
Company has engaged the Chairman and sole stockholder of the Company pursuant to a consulting agreement through December 31, 2020,
which calls for the Company to pay the consultant an hourly fee for services performed. During the period from March 9, 2020 (inception)
to March 31, 2020, the Company incurred $160,000 in fees under the consulting agreement, which are recognized in general and administrative
expenses in the Statement of Operations.
During
the period from March 9, 2020 (inception) to March 31, 2020, the sole stockholder of the Company paid for the Company’s
research and development expenses totaling $30,000 and for certain of the Company’s general and administrative expenses
totaling $1,456.
As
of March 31, 2020, the Company has outstanding payables to the Chairman and sole stockholder of the Company totaling $191,456.
Note
8—Income Taxes
As
of March 31, 2020, the Company has no net operating loss carryforwards available to reduce future taxable income, if any, for
Federal and state income tax purposes, but has other deferred tax assets as presented below. The Company has no income tax affect
resulting from the deferred tax assets due to the recognition of a full valuation allowance on the expected tax benefits of future
loss carry forwards based on uncertainty surrounding realization of such assets.
The
tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following:
|
|
March 31, 2020
|
|
Deferred tax assets
|
|
|
|
|
In-process research and development
|
|
$
|
10,234
|
|
Startup/Organizational Costs
|
|
|
50,132
|
|
Total deferred tax assets
|
|
|
60,366
|
|
Valuation allowance
|
|
|
(60,366
|
)
|
Deferred tax assets, net of allowance
|
|
$
|
—
|
|
A
reconciliation of the statutory income tax rates and the Company’s effective tax rate is as follows:
|
|
March 31, 2020
|
|
Statutory federal income tax rate
|
|
|
21.0
|
%
|
State taxes, net of federal tax benefit
|
|
|
3.5
|
%
|
Federal tax rate change
|
|
|
0.0
|
%
|
Valuation allowance
|
|
|
-24.5
|
%
|
Income tax provision expense
|
|
|
0.0
|
%
|
The
Company’s major tax jurisdictions are the United States and Florida. The Company does not have any tax audits pending.
Note
9—Subsequent Events
Subsequent
events have been evaluated through May 26, 2020, which is the date the financial statements were available to be issued. All appropriate
subsequent event disclosures, if any, have been made in the notes to the financial statements.
UNAUDITED
PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
The
following unaudited pro forma condensed combined financial information is presented to illustrate the estimated effects of the
acquisition by Oragenics, Inc. (the “Company” or “Oragenics”) of Noachis Terra Inc. (“Noachis Terra”)
pursuant to a Stock Purchase Agreement, dated as of May 1, 2020, (the “Acquisition”) by and among the Company, and
Mr. Joseph Hernandez, the sole shareholder of Noachis Terra (the “Seller”) (the “Stock Purchase Agreement”).
Pursuant to the Stock Purchase Agreement, the Company acquired one hundred percent (100%) of the total issued and outstanding
common stock of Noachis Terra. In exchange, the Seller received the following: (i) cash consideration equal to $1,925,000, of
which approximately $500,000 has been applied to extinguish Noachis Terra’s pre-Transaction liabilities (a portion of which
were due to the Seller); (ii) 9,200,000 restricted shares of the Company’s common stock, and (iii) warrants to purchase
9,200,000 shares of the Company’s common stock, which warrants carry an exercise price of $1.25 per share, a five-year term,
and subject to additional exercise restrictions as defined in the Stock Purchase Agreement. In addition to the above consideration,
the Seller is entitled to receive contingent consideration based upon the exercise of certain of the Company’s outstanding
warrants, for so long as the warrants remain outstanding.
The
following pro forma condensed combined balance sheet information as of March 31, 2020 is based upon and derived from the historical
financial information of the Company and Noachis Terra and gives effect to the Acquisition as if such transaction had occurred
on March 31, 2020. The unaudited pro forma condensed combined statements of operations for the three months ended March 31, 2020
and for the year ended December 31, 2019 are also based upon and derived from the historical financial information of the Company
and Noachis Terra and gives effect to the Acquisition as if it occurred on January 1, 2019. The historical financial information
reflects adjustments that are (i) directly attributable to the Acquisition, (ii) factually supportable, and (iii) with respect
to the unaudited pro forma condensed combined statements of operations, are expected to have a continuing impact on the results
of operations. The pro forma adjustments are preliminary and are based upon available information and certain assumptions, as
described in the accompanying notes to the unaudited pro forma condensed combined financial information, that the Company believes
are reasonable under the circumstances and which are described in the accompanying notes to the unaudited pro forma condensed
combined financial information. Actual results and valuations may differ materially from the assumptions within the accompanying
unaudited pro forma condensed combined financial information.
The
Acquisition will be accounted for as a business combination using the acquisition method of accounting under the provisions of
Accounting Standards Codification (“ASC”) 805, Business Combinations, (“ASC 805”). Under ASC 805,
assets acquired and liabilities assumed are generally recorded at their acquisition date fair value. The fair value of identifiable
tangible and intangible assets acquired and liabilities assumed from the Acquisition are based on preliminary estimates of fair
value utilizing currently available information. Any excess of the purchase price over the fair value of identified assets acquired
and liabilities assumed is recognized as goodwill. Significant judgment is required in determining the estimated fair values of
the net assets acquired, including in-process research and development intangible assets (“IPR&D”). Such a valuation
requires estimates and assumptions including, but not limited to, estimating future cash flows and direct costs in addition to
developing the appropriate discount rates and current market profit margins.
The
unaudited pro forma condensed combined financial information has been prepared in accordance with SEC Regulation S-X Article 11
and is not necessarily indicative of the combined financial position or results of operations that would have been realized had
the transactions been completed as of the dates indicated, nor is it meant to be indicative of any anticipated combined financial
position or future results of operations that the Company will experience. In addition, the accompanying unaudited pro forma condensed
combined statement of operations do not include any pro forma adjustments to reflect expected cost savings or restructuring actions
which may be achievable or the impact of any non-recurring expenses and one-time transaction related costs that may be incurred
as a result of the Acquisition.
The
unaudited pro forma condensed combined financial statements, including the notes thereto, should be read in conjunction with the
historical financial statements of the Company included in its Annual Report on Form 10-K for the year ended December 31, 2019
and in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, as well as the historical financial statements
of Noachis Terra included in Exhibit 99.1 to the Company’s Form 8-K/A.
Unaudited
Pro Forma Condensed Combined Balance Sheet as of March 31, 2020
|
|
|
|
|
Noachis
|
|
|
Pro
Forma
|
|
|
|
|
Pro
Forma
|
|
|
|
Oragenics(1)
|
|
|
Terra(2)
|
|
|
Adjustments
|
|
|
Note
3
|
|
Combined
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current
assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents
|
|
$
|
14,372,105
|
|
|
$
|
-
|
|
|
$
|
(1,925,000
|
)
|
|
(a)
|
|
$
|
12,447,105
|
|
Prepaid
expense and other current assets
|
|
|
328,674
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
328,674
|
|
Total
current assets
|
|
|
14,700,779
|
|
|
|
-
|
|
|
|
(1,925,000
|
)
|
|
|
|
|
12,775,779
|
|
Property
and equipment, net
|
|
|
79,654
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
79,654
|
|
Operating
lease right-of-use assets
|
|
|
781,674
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
781,674
|
|
Goodwill
|
|
|
-
|
|
|
|
-
|
|
|
|
3,651,617
|
|
|
(c)
|
|
|
3,651,617
|
|
Intangible
assets
|
|
|
-
|
|
|
|
-
|
|
|
|
8,200,000
|
|
|
(c)
|
|
|
8,200,000
|
|
Total
assets
|
|
$
|
15,562,107
|
|
|
$
|
-
|
|
|
$
|
9,926,617
|
|
|
|
|
$
|
25,488,724
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities
and Shareholders’ Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts
payable and accrued expenses
|
|
$
|
1,786,671
|
|
|
$
|
54,635
|
|
|
$
|
(54,635
|
)
|
|
(a)
|
|
$
|
1,986,671
|
|
|
|
|
|
|
|
|
|
|
|
|
200,000
|
|
|
(d)
|
|
|
|
|
Accounts
payable to related party
|
|
|
-
|
|
|
|
191,456
|
|
|
|
(191,456
|
)
|
|
(a)
|
|
|
-
|
|
Short-term
notes payable
|
|
|
70,847
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
70,847
|
|
Operating
lease liabilities
|
|
|
167,864
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
167,864
|
|
Contingent
consideration
|
|
|
-
|
|
|
|
-
|
|
|
|
173,918
|
|
|
(a)
|
|
|
173,918
|
|
Total
current liabilities
|
|
|
2,025,382
|
|
|
|
246,091
|
|
|
|
127,827
|
|
|
|
|
|
2,399,300
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term
liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
lease liabilities
|
|
|
627,723
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
627,723
|
|
Deferred
tax liabilities
|
|
|
-
|
|
|
|
-
|
|
|
|
1,722,000
|
|
|
(c)
|
|
|
1,722,000
|
|
Total
long-term liabilities
|
|
|
627,723
|
|
|
|
-
|
|
|
|
1,722,000
|
|
|
|
|
|
2,349,723
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commitments
and contingencies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders’
equity (deficit)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred
stock
|
|
|
7,174,854
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
7,174,854
|
|
Common
Stock
|
|
|
46,125
|
|
|
|
100
|
|
|
|
9,200
|
|
|
(a)
|
|
|
55,325
|
|
|
|
|
|
|
|
|
|
|
|
|
(100
|
)
|
|
(b)
|
|
|
|
|
Additional
paid-in capital
|
|
|
138,890,067
|
|
|
|
-
|
|
|
|
8,021,499
|
|
|
(a)
|
|
|
146,911,566
|
|
Accumulated
deficit
|
|
|
(133,202,044
|
)
|
|
|
(246,191
|
)
|
|
|
246,191
|
|
|
(b)
|
|
|
(133,402,044
|
)
|
|
|
|
|
|
|
|
|
|
|
|
(200,000
|
)
|
|
(d)
|
|
|
|
|
Total
shareholders’ equity (deficit)
|
|
|
12,909,002
|
|
|
|
(246,091
|
)
|
|
|
8,076,790
|
|
|
|
|
|
20,739,701
|
|
Total
liabilities and shareholders’ equity (deficit)
|
|
$
|
15,562,107
|
|
|
$
|
-
|
|
|
$
|
9,926,617
|
|
|
|
|
$
|
25,488,724
|
|
(1)
Derived from the Oragenics unaudited balance sheet as of March 31, 2020.
(2)
Derived from the Noachis Terra audited balance sheet as of March 31, 2020.
See
the accompanying notes to the unaudited pro forma condensed combined financial statements.
Unaudited
Pro Forma Condensed Combined Statement of Operations for the Three Months Ended March 31, 2020
|
|
|
|
|
Noachis
|
|
|
Pro
Forma
|
|
|
|
|
Pro
Forma
|
|
|
|
Oragenics(1)
|
|
|
Terra(2)
|
|
|
Adjustments
|
|
|
Note
3
|
|
Combined
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research
and development
|
|
$
|
3,712,679
|
|
|
$
|
41,739
|
|
|
$
|
-
|
|
|
|
|
$
|
3,754,418
|
|
General
and administrative
|
|
|
1,519,083
|
|
|
|
204,452
|
|
|
|
-
|
|
|
|
|
|
1,723,535
|
|
Total
operating expenses
|
|
|
5,231,762
|
|
|
|
246,191
|
|
|
|
-
|
|
|
|
|
|
5,477,953
|
|
Loss
from operations
|
|
|
(5,231,762
|
)
|
|
|
(246,191
|
)
|
|
|
-
|
|
|
|
|
|
(5,477,953
|
)
|
Other
income (expense)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
income
|
|
|
44,515
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
44,515
|
|
Interest
expense
|
|
|
(1,708
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
(1,708
|
)
|
Local
business tax
|
|
|
(600
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
(600
|
)
|
Miscellaneous
income
|
|
|
1,795
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
1,795
|
|
Total
other income, net
|
|
|
44,002
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
44,002
|
|
Loss
before income taxes
|
|
|
(5,187,760
|
)
|
|
|
(246,191
|
)
|
|
|
-
|
|
|
|
|
|
(5,433,951
|
)
|
Income
tax benefit
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
-
|
|
Net
loss
|
|
$
|
(5,187,760
|
)
|
|
$
|
(246,191
|
)
|
|
$
|
-
|
|
|
|
|
|
(5,433,951
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
and diluted
|
|
$
|
(0.11
|
)
|
|
$
|
(24.62
|
)
|
|
|
-
|
|
|
|
|
$
|
(0.10
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number of shares
|
|
|
46,124,803
|
|
|
|
10,000
|
|
|
|
|
|
|
(e)
|
|
|
55,324,803
|
|
(1)
Derived from the Oragenics unaudited statement of operations for the three months ended March 31, 2020.
(2)
Derived from the Noachis Terra audited statement of operations for the period from March 9, 2020 (inception) through March
31, 2020.
See
the accompanying notes to the unaudited pro forma condensed combined financial statements.
Unaudited
Pro Forma Condensed Combined Statement of Operations for the Year Ended December 31, 2019
|
|
|
|
|
Noachis
|
|
|
Pro
Forma
|
|
|
|
|
Pro
Forma
|
|
|
|
Oragenics(1)
|
|
|
Terra(2)
|
|
|
Adjustments
|
|
|
Note
3
|
|
Combined
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research
and development
|
|
$
|
12,120,318
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
|
|
$
|
12,120,318
|
|
General
and administrative
|
|
|
3,757,251
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
3,757,251
|
|
Total
operating expenses
|
|
|
15,877,569
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
15,877,569
|
|
Loss
from operations
|
|
|
(15,877,569
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
(15,877,569
|
)
|
Other
income (expense)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
income
|
|
|
320,011
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
320,011
|
|
Interest
expense
|
|
|
(7,300
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
(7,300
|
)
|
Local
business tax
|
|
|
(1,601
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
(1,601
|
)
|
Miscellaneous
income
|
|
|
456
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
456
|
|
Total
other income, net
|
|
|
311,566
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
311,566
|
|
Loss
before income taxes
|
|
|
(15,566,003
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
(15,566,003
|
)
|
Income
tax benefit
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
-
|
|
Net
loss
|
|
$
|
(15,566,003
|
)
|
|
$
|
-
|
|
|
$
|
-
|
|
|
|
|
|
(15,566,003
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
and diluted
|
|
$
|
(0.37
|
)
|
|
$
|
-
|
|
|
|
-
|
|
|
|
|
$
|
(0.30
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number of shares
|
|
|
42,283,947
|
|
|
|
-
|
|
|
|
9,200,000
|
|
|
(e)
|
|
|
51,483,947
|
|
(1)
Derived from the Oragenics unaudited statement of operations for the three months ended March 31, 2020.
(2)
Noachis Terra was formed on March 9, 2020 and therefore historical information for the year ended December 31, 2019 is not
applicable.
See
the accompanying notes to the unaudited pro forma condensed combined financial statements.
Notes
to the Unaudited Pro Forma Condensed Combined Financial Information
Note
1—Description of Transaction and Basis of Presentation
Description
of Transaction
On
May 1, 2020, the Company completed its acquisition of Noachis Terra pursuant to the Stock Purchase Agreement. The Company acquired
one hundred percent (100%) of the total issued and outstanding common stock of Noachis Terra for, (i) cash consideration equal
to $1,925,000, (ii) 9,200,000 restricted shares of the Company’s common stock, and (iii) warrants to purchase 9,200,000
shares of the Company’s common stock. In addition the Seller is entitled to receive contingent consideration based upon
the exercise of certain of the Company’s outstanding warrants.
Basis
of Presentation
The
unaudited pro forma condensed combined financial statements are based on the Company’s and Noachis Terra’s historical
financial statements as adjusted to give effect to the Acquisition. The unaudited pro forma condensed combined balance sheet as
of March 31, 2020 gives effect to the Acquisition as if it had occurred on March 31, 2020. The unaudited pro forma condensed combined
statements of operations for the three months ended March 31, 2020 and the year ended December 31, 2019 give effect to the Acquisition
as if it had occurred on January 1, 2019, however, Noachis Terra was formed on March 9, 2020 and therefore historical information
for the year ended December 31, 2019 is not applicable.
The
historical financial information of the Company has been adjusted in the accompanying unaudited pro forma condensed combined financial
information to give effect to pro forma events that are (i) directly attributable to the Acquisition, (ii) factually supportable,
and (iii) with respect to the unaudited pro forma condensed combined statements of operations, are expected to have a continuing
impact on the results of operations. The Acquisition will be accounted for as a business combination using the acquisition method
of accounting under the provisions ASC 805. The unaudited pro forma condensed combined financial information was prepared using
the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed in a business
combination be recognized at their fair values as of the acquisition date. The adjustments to reflect the acquisition method of
accounting are preliminary and are based upon available information and certain assumptions which management believes are reasonable
under the circumstances.
Note
2—Preliminary consideration and purchase price allocation
The
following table summarizes the components of the total estimated consideration:
Cash consideration(i)
|
|
$
|
1,925,000
|
|
|
|
|
|
|
Number of Oragenics restricted shares issued
|
|
|
9,200,000
|
|
Multiplied by the fair value per share of Oragenics common stock(ii)
|
|
$
|
0.5030
|
|
Common stock consideration
|
|
|
4,627,600
|
|
|
|
|
|
|
Number of Oragenics warrants issued
|
|
|
9,200,000
|
|
Multiplied by the fair value of Oragenics warrants(iii)
|
|
$
|
0.3699
|
|
Estimated fair value of warrant consideration
|
|
|
3,403,099
|
|
|
|
|
|
|
Estimated fair value of contingent consideration(iv)
|
|
|
173,918
|
|
Total estimated consideration
|
|
$
|
10,129,617
|
|
|
(i)
|
Represents
the cash consideration, of which a portion was applied to extinguish Noachis Terra’s pre-acquisition liabilities.
|
|
(ii)
|
Represents
the closing price of the Company’s common stock as reported on the NYSE on May 1, 2020.
|
|
(iii)
|
Represents
the estimated fair value of warrants issued as consideration. The fair value was calculated under the Black-Scholes option
pricing model, with the following assumptions: strike price of $1.25, risk free interest rate of 0.36%; expected volatility
of 121%, effective life of 5.0 years and dividend yield of zero. The Company has preliminary determined the exercise features
of these warrants would be afforded equity treatment.
|
|
(iv)
|
Represents
the estimated fair value of contingent consideration. Pursuant to the terms of the Stock Purchase Agreement, the Seller is
entitled to receive contingent consideration based upon the exercise of certain of the Company’s outstanding warrants
as follows: (i) twenty percent (20%) of the cash proceeds received by the Company upon exercise of the Company’s warrants
carrying an exercise price of $0.75 and $0.90 and (ii) forty-five percent (45%) of the cash proceeds received by the Company
upon exercise of the Company’s warrants carrying an exercise price of $1.00, in each case, for so long as the warrants
remain outstanding. The fair value of the contingent consideration was calculated based on the estimated present value of
probable exercise of the outstanding warrants.
|
The
preliminary purchase price is as follows:
Indefinite-lived intangible assets (IPR&D)
|
|
$
|
8,200,000
|
|
Goodwill
|
|
|
3,651,617
|
|
Deferred income taxes
|
|
|
(1,722,000
|
)
|
Net assets acquired
|
|
$
|
10,129,617
|
|
The
fair value estimates are preliminary as the valuations have not yet been finalized. The final total consideration and amounts
allocated to the acquired assets and liabilities could differ materially from the preliminary amounts presented in these unaudited
pro forma condensed combined financial statements. A decrease in the fair value of assets or an increase in the fair value of
liabilities from the preliminary valuations presented would result in a dollar-for-dollar corresponding increase in the amount
of goodwill that will result from the Acquisition.
Note
3—Pro forma adjustments
(a)
Represents the estimated fair value of consideration transferred in the Acquisition and settlement of Noachis Terra’s outstanding
liabilities.
|
|
Cash and cash equivalents
|
|
|
Contingent consideration
|
|
|
Common stock, $0.001 par value
|
|
|
Additional paid-in capital
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash consideration
|
|
$
|
1,925,000
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
Common stock consideration
|
|
|
-
|
|
|
|
-
|
|
|
|
9,200
|
|
|
|
4,618,400
|
|
Estimated fair value of warrant consideration
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
3,403,099
|
|
Estimated fair value of contingent consideration
|
|
|
-
|
|
|
|
173,918
|
|
|
|
-
|
|
|
|
-
|
|
Total estimated consideration
|
|
$
|
1,925,000
|
|
|
$
|
173,918
|
|
|
$
|
9,200
|
|
|
$
|
8,021,499
|
|
As
of March 31, 2020, Noachis Terra’s outstanding liabilities to be settled with the proceeds from the consideration transferred
was $246,091.
(b)
Represents the elimination of Noachis Terra’s historical common stock and accumulated deficit.
(c)
Represents the preliminary purchase price allocation of the Acquisition, based on the estimated fair values of the acquired assets.
Indefinite-lived
intangible assets (IPR&D): IPR&D represents incomplete research and development projects at Noachis Terra. Management
estimated that $8.2 million of the acquisition consideration represents the fair value of acquired IPR&D. The fair value of
IPR&D was determined using the income approach that took into consideration information and certain program-related documents
and forecasts prepared by management. The fair value of IPR&D will be capitalized as of the acquisition date and subsequently
accounted for as an indefinite-lived intangible asset until completion or abandonment of the associated research and development
efforts. Accordingly, during the development period after the completion of the acquisition, these assets will not be amortized
into earnings; instead, these assets will be subject to periodic impairment testing. Upon successful completion of the development
process for an acquired IPR&D project, determination as to the useful life of the asset will be made. The asset would then
be considered a finite-lived intangible asset and amortization of the asset into earnings would begin over the estimated useful
life of the asset.
Goodwill:
Goodwill represents the excess of the preliminary estimated acquisition consideration over the preliminary fair value of the underlying
net tangible and intangible assets. Goodwill will not be amortized, but instead will be tested for impairment at least annually
and whenever events or circumstances have occurred that may indicate a possible impairment. In the event management determines
that the value of goodwill has become impaired, the combined company will incur an accounting charge for the amount of the impairment
during the period in which the determination is made.
Deferred
tax liabilities: Deferred tax assets and liabilities arise from acquisition accounting adjustments where book values of certain
assets and liabilities differ from their tax bases. The deferred tax liability represents the estimated deferred tax liability
associated with the fair value of intangible assets using an estimated federal and state statutory rate of 21%.
(d)
Represents $200,000 of estimated acquisition-related costs for the Company. Such costs have not been reflected in the pro forma
statements of operations as they are nonrecurring.
(e)
Represents the increase in the weighted average shares outstanding due to the issuance of 9,200,000 shares common stock in connection
with the Acquisition.
|
|
Three Months ended
March 31, 2020
|
|
|
Year ended
December 31, 2019
|
|
Historical Oragenics—Basic and diluted weighted average number of shares
|
|
|
46,124,803
|
|
|
|
42,283,947
|
|
Shares issued in Acquisition
|
|
|
9,200,000
|
|
|
|
9,200,000
|
|
Pro forma—Basic and diluted weighted average number of shares
|
|
|
55,324,803
|
|
|
|
51,483,947
|
|
APPENDIX
D
REQUEST FOR INTERIM FINANCIAL STATEMENTS
Oragenics,
Inc.
Request
for Interim Financial Statements
In
accordance with National Instrument 54-102 of the Canadian Securities Administrators, registered and beneficial shareholders of
the subject Corporation may elect annually to receive interim corporate mailings, including interim financial statements of the
Corporation, if they so request. If you wish to receive such mailings, please complete and return this form to:
Oragenics,
Inc.
Investor
Relations
4902
Eisenhower Blvd., Suite 125
Tampa,
Florida 33634
POSTAL
CODE:
|
|
|
|
I
confirm that I am an owner of common stock of the Corporation.
|
|
|
|
SIGNATURE
OF
|
|
SHAREHOLDER: DATE:
|
|
|
|
CUSIP:
684023203
|
|
|
|
SCRIP
COMPANY CODE: ORGQ
|
|